

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : A61K 27/00	A2	(11) International Publication Number: WO 94/06420 (43) International Publication Date: 31 March 1994 (31.03.94)
(21) International Application Number: PCT/US93/08885 (22) International Filing Date: 15 September 1993 (15.09.93) (30) Priority data: 945,286 15 September 1992 (15.09.92) US 029,335 4 March 1993 (04.03.93) US 040,510 31 March 1993 (31.03.93) US (71) Applicant: CREATIVE BIOMOLECULES, INC. [US/ US]; 45 South Street, Hopkinton, MA 01748 (US). (72) Inventors: COHEN, Charles, M. ; 98 Winthrop Street, Medway, MA 02053 (US). CHARETTE, Marc, F. ; 18 Ellicott Street, Needham, MA 02192 (US). KUBERA- SAMPATH, Thangavel ; Six Spring Street, Medway, MA 02053 (US). RUEGER, David, C. ; 19 Downey Street, Hopkinton, MA 01748 (US). OPPERMANN, Hermann ; 25 Summer Hill Road, Medway, MA 02053 (US). PANG, Roy, H., L. ; 15 Partridge Road, Etna, NH 03750 (US). OZKAYNAK, Engin ; 44 Purdue Drive, Milford, MA 01757 (US). SMART, John, E. ; 50 Mead- owbrook Road, Weston, MA 02193 (US).		(74) Agent: KELLEY, Robin, D.; Testa, Hurwitz & Thibault, Exchange Place, 53 State Street, Boston, MA 02109 (US). (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: MORPHOGEN TREATMENT OF GASTROINTESTINAL ULCERS (57) Abstract <p>Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mam- mal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation nor- mally associated with ulcerative diseases, and/or (4) stimulating the repair of ulcerative lesions and the regeneration of the lumi- nal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TO	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

MORPHOGEN TREATMENT OF GASTROINTESTINAL ULCERS

Field of the Invention

The invention relates generally to the treatment of
5 gastrointestinal (GI) disorders and the tissue damage
associated therewith. In particular, the invention
relates to the treatment of ulcerative diseases within
the gastrointestinal tract of a mammal.

10 Background of the Invention

The luminal lining of the mammalian
gastrointestinal tract (GI tract), which extends from
the mouth cavity to the rectum, includes a protective
15 layer of continually proliferating basal epithelial
cells overlying a mucosal layer. Together, the basal
epithelium and mucosa create the protective
"gastrointestinal barrier." Disruption of this barrier
results in lesions that can become infected and/or
20 expose underlying tissue to the corrosive effect of
gastric juices. Gastrointestinal ulcerations can cause
oral mucositis, gastric ulcers, necrotizing
enterocolitis, regional ileitis, ulcerative colitis,
regional enteritis (Crohn's disease), proctitis, and
25 other forms of inflammatory bowel disease (IBD).

Ulcerative oral mucositis is a serious and dose-
limiting toxic side effect of many forms of cancer
therapies, including chemotherapy and radiation
30 therapy. Oral mucositis accounts for significant pain
and discomfort for these patients, and ranges in

- 2 -

severity from redness and swelling to frank ulcerative lesions. Chemotherapeutic agents and radiation can kill or damage the epithelial cells lining the oral cavity. Such damage includes the inhibitory effect
5 that chemotherapeutic agents may have on mitoses of the rapidly dividing cells of the oral basal epithelium. The severity of damage is related to the type and dose of chemotherapeutic agent(s) and concomitant therapy such as radiotherapy. Further, ulceration is hastened
10 if sources of chronic irritation such as defective dental restorations, fractured teeth or ill-fitting dental prostheses are present. Oral mucositis most often affects the nonkeratinized mucosa of the cheeks, lips, soft palate, ventral surface of the tongue and
15 floor of the mouth, approximately one to two weeks after cancer therapy. The lesions often become secondarily infected and become much harder to heal. The disruption in the oral mucosa results in a systemic portal of entry for the numerous microorganisms found
20 in the mouth. Consequently, the oral cavity is the most frequently identifiable source of sepsis in the granulocytopenic cancer patient. Of primary concern are those patients undergoing: chemotherapy for cancer such as leukemia, breast cancer or as an adjuvant to
25 tumor removal; radiotherapy for head and neck cancer; and combined chemotherapy and radiotherapy for bone marrow transplants.

One source of oral mucositis can result from
30 xerostomia, or chronic mouth dryness, which typically results from diminished or arrested salivary secretion or asialism. Salivary gland dysfunction or atrophy may result from tissue senescence in aged individuals, or from an organic disorder. Most frequently, xerostomia
35 is an undesired side effect of a clinical or

- 3 -

pharmaceutical therapy. Normally, saliva moistens the oral mucosal membrane, allowing for the dissolution and limited absorption of exogenous substances introduced into the oral cavity. In xerostomaic individuals
5 irritating exogenous substances, including foods and medications, remain exposed to the mucosa and can cause inflammation and ulceration. A description of xerostomia-causing medications is described in
10 1:777-782.

Current therapy for mucositis is limited to either local or systemic palliation or topical antibacterial therapy. At present there is no effective treatment
15 for mucositis. Therapy typically is limited to pain medications and treatment of secondary infection. In particular, recommendations have included treatment with topical anesthetics such as xylocaine, benzocaine and cocaine, treatment with solutions which coat the
20 ulcerative lesions with a polysaccharide gel and use of antiseptic solutions such as Chlorhexadine. While all these treatments do provide some relief, none are directed to the actual healing of oral mucositis, which entails directly healing the mucosal epithelium cells.

25 Recently, certain local-acting growth factors, such as TGF- α have been shown to have some effect on ulcerative mucositis lesions at low concentrations, but less effect at higher concentrations (see US Pat.
30 No. 5,102,870, issued April 7, 1992 to Florine et al.) The biphasic effect exhibited by such factors may limit their clinical utility. There remains a need for a therapy that inhibits ulcerative mucositis lesion
35 formation and significantly enhances healing of lesions following th ir f rmation.

- 4 -

Gastrointestinal ulcer disease, in particular, peptic ulcers, affect 5-15% of the United States population. Peptic ulcers include gastric ulcers, which occur as lesions in the wall of the stomach, and
5 duodenal ulcers, which are deep lesions that occur in the wall of the duodenum, i.e., the upper portion of the small intestine. Another ulcer disease, particularly worrisome to pediatricians, occurs in the premature infants. This condition, known as
10 necrotizing enterocolitis, affects 10-15% of newborns having a birth weight of under 1.5 kg and results in severe ulceration of the small intestine, which frequently requires surgery. Gastric ulcers can result from an imbalance in factors which maintain the natural
15 gasatointestinal barrier, including factors which neutralize corrosive gastric juices, such as the mucous bicarbonate, and other factors which protect the body from luminal damaging agents. Although current antiulcer therapeutics, including antisecretory
20 products such as cimetidine and ranitidine, appear to be effective in healing duodenal ulcers, it is generally believed that they are effective because they reduce normal gastric acid secretion. While the reduction in acidity aids in the closure of the ulcer,
25 it also interferes with normal digestion. Accordingly, a high percentage of ulcers healed with current therapies recur within one year of therapy. The high rate of ulcer recurrence is thought to be at least partially attributable to the reduced number of mucus-
30 producing cells in the scar tissue which is left at the site of the healed ulcer, rendering the area more vulnerable to rupture when the gastrointestinal acidity returns to normal.

- 5 -

PCT Application No. PCT/US89/03467 discloses the use of an acid-resistant local-acting fibroblast growth factor to treat GI ulcers. US Pat. No. 5,043,329 discloses the use of phospholipids to treat ulcers of
5 the gastrointestinal tract.

Severe ulceration of the gastrointestinal mucosa also can spontaneously occur in the lower bowel (distal ileum and colon) in a spectrum of clinical disorders
10 called inflammatory bowel disease (IBD). The two major diseases in this classification are ulcerative colitis and regional enteritis (Crohn's Disease) which are associated with severe mucosal ulceration (frequently penetrating the wall of the bowel and forming
15 strictures and fistulas), severe mucosal and submucosal inflammation and edema, and fibrosis. Other forms of IBD include regional ileitis and proctitis. Clinically, patients with fulminant IBD can be severely ill with massive diarrhea, blood loss, dehydration,
20 weight loss and fever. The prognosis of the disease is not good and frequently requires resection of the diseased tissue.

It is an object of this invention to provide
25 methods and compositions for maintaining the integrity of the gastrointestinal luminal lining in a mammal. Another object is to provide methods and compositions for regenerating basal epithelium and mucosa in ulcerated gastrointestinal tract barrier tissue,
30 including the oral mucosa. Another object of the invention is to provide tissue protective methods and compositions that allow extension or enhancement of a chemical or radiotherapy. Another object is to provide methods and compositions capable of limiting the
35 proliferation of epithelial cells, particularly the

- 6 -

basal epithelial cells of the gastrointestinal tract. Still another object is to provide methods and compositions for substantially inhibiting inflammation normally associated with ulcerative diseases. Another
5 object is to provide methods and compositions for protecting mucosal tissue from the tissue destructive effects associated with xerostomia. Yet another object is to provide methods and compositions for the treatment of oral mucositis, peptic ulcers, ulcerative
10 colitis, regional enteritis, necrotizing enterocolitis, proctitis and other ulcerative diseases of the gastrointestinal tract.

These and other objects and features of the
15 invention will be apparent from the description, drawings, and claims which follow.

- 7 -

Summary of the Invention

It now has been discovered that morphogenic proteins ("morphogen"), as defined herein, are useful
5 as therapeutic methods and compositions for protecting the luminal lining of the gastrointestinal tract from ulceration, particularly in individuals at risk for ulcer formation. Specifically, the morphogens described herein can limit the proliferation of epithelial cells,
10 inhibit the inflammation normally associated with ulcerative disease, inhibit scar tissue formation, and/or induce repair and regeneration of the ulcerated tissue.

15 In one aspect, the invention features compositions and therapeutic treatment methods that comprise the step of administering to a mammal a therapeutically effective amount of a morphogenic protein ("morphogen"), as defined herein, upon injury to all or
20 a portion of the GI tract luminal lining, or in anticipation of such injury, for a time and at a concentration sufficient to maintain the integrity of the GI tract luminal lining, including repairing ulcerated tissue, and/or inhibiting damage thereto.

25 In another aspect, the invention features compositions and therapeutic treatment methods for maintaining the integrity of the GI tract luminal lining in a mammal which include administering to the
30 mammal, upon injury to all or a portion of the GI tract luminal lining, or in anticipation of such injury, a compound that stimulates in vivo a therapeutically effective concentration of an endogenous morphogen within the body of the mammal sufficient to maintain
35 the integrity of the luminal lining, including regenerating ulcerated tissue and/or inhibiting damage

- 8 -

thereto. These compounds are referred to herein as morphogen-stimulating agents, and are understood to include substances which, when administered to a mammal, act on cells in tissue(s) or organ(s) that normally are responsible for, or capable of, producing a morphogen and/or secreting a morphogen, and which cause the endogenous level of the morphogen to be altered. The agent may act, for example, by stimulating expression and/or secretion of an endogenous morphogen.

As used herein, "gastrointestinal tract" means the entire gastrointestinal tract of a mammal, from the mouth to the rectum, inclusive, including the mouth cavity, esophagus, stomach, upper and lower intestines, and colon. As used herein, "ulcer" refers to an open lesion or break of the integrity of the epithelial lining of the gastrointestinal tract, resulting in erosion of the underlying mucosa. "Maintaining the integrity of the luminal lining" means providing an effective morphogen concentration to the cells of the gastrointestinal tract luminal lining, the concentration being sufficient to substantially inhibit lesion formation in the basal epithelium of the gastrointestinal barrier, including stimulating the regeneration of damaged tissue and/or inhibiting additional damage thereto. "Protecting" mucosal tissue means providing a therapeutically effective morphogen concentration to the cells of the gastrointestinal tract luminal lining sufficient to inhibit the tissue damage associated with tissue ulceration, including stimulating regeneration of damaged tissue and/or inhibiting additional damage thereto. "Symptom-alleviating cofactor" refers to one or more pharmaceuticals which may be administered together with

- 9 -

the therapeutic agents of this invention and which alleviate or mitigate one or more of the symptoms typically associated with periodontal tissue loss. Exemplary cofactors include antibiotics, antiseptics, 5 anti-viral and anti-fungal agents, non-steroidal antiinflammatory agents, anesthetics and analgesics, and antisecretory agents.

In preferred embodiments of the invention, the 10 mammal is a human and ulcers treatable according to the invention include those found in the ileum which cause regional ileitis, those found in the colon which cause ulcerative colitis, regional enteritis (Crohn's disease), proctitis and other forms of inflammatory 15 bowel disease (IBD), gastric ulcers such as those found in the stomach, small intestines, duodenum and esophagus; and ulcers found in the mouth. The compositions and methods described herein are particularly useful in treating mucositis lesions 20 caused by chemotherapy or radiation therapy.

Because the morphogens described herein inhibit ulceration of the oral mucosa that typically results from cancer therapies, in another aspect, the invention 25 provides cancer treatment methods and compositions that significantly reduce or inhibit the onset of oral mucositis in a patient. In addition, the morphogens described herein may be used in conjunction with existing chemical or radiation therapies to enhance 30 their efficacy. Cancer chemical and radiation therapies currently in use often are limited in dose or duration by the onset of severe oral mucositis and/or the sepsis which often follows lesion formation. The morphogens described herein can inhibit lesion 35 formation and, accordingly, their administration to a

- 10 -

patient as part of a cancer therapy may allow significant enhancement of current therapy doses and/or treatment times.

5 The morphogens described herein can limit cell proliferation in a proliferating epithelial cell population, thereby protecting these cells from the cytotoxic effects of chemotherapeutic and
10 radiotherapeutic treatments. Accordingly, in another aspect, the invention provides methods and compositions for limiting the mitogenic activity of epithelial cells. This activity of the morphogens also has
15 application for other diseases associated with proliferating epithelial cells, including psoriasis and other such skin tissue disorders. In addition, this
activity of morphogens also may be useful to limit hair loss typically associated with cancer therapies.

20 The morphogens described also herein inhibit inflammation. Accordingly, in another aspect, the invention provides methods and compositions for inhibiting the inflammation associated with ulcerative disease.

25 The morphogens described herein also stimulate tissue morphogenesis at a site of tissue damage, inhibiting scar tissue formation at a lesion site. Accordingly, another aspect of the invention includes
30 methods and compositions for inhibiting scar tissue formation at a lesion site.

35 In another aspect of the invention, the morphogens described herein are useful in protecting the mucosal membrane from the tissue destructive effects associated with xer stomia. The xerostomaic condition may b

- 11 -

induced by a clinical therapy, including a cancer therapy, medication, diet or result from tissue senescence or an organic disorder of the salivary glands.

5

In one preferred embodiment, the morphogen or morphogen-stimulating agent is administered directly to the individual by topical administration, e.g., by coating the desired surface to be treated with the morphogen or morphogen-stimulating agent. For example, the therapeutic agent may be provided to the desired site by consuming a formulation containing the therapeutic agent in association with a compound capable of coating or adhering to the luminal lining surface. Such compounds include pectin-containing or sucralfate solutions such as are used in Milk of Magnesia and Kaopectate. For oral mucositis treatments, the agent may be provided in an oral rinse similar to a mouth wash that is swished around the mouth to coat the affected tissue, or disposed in a slow-dissolving lozenge or troche. Alternatively, the therapeutic agent may be provided to the site by physically applying or painting a formulation containing the morphogen or morphogen-stimulating agent to the site. Compositions for topical administration also may include a liquid adhesive to adhere the morphogen or morphogen-stimulating agent to the tissue surface. Useful adhesives include Zilactin, as is used in Orabase, hydroxypropylcellulose, and fibrinogen/thrombin solutions. Another potentially useful adhesive is the bioadhesive described in U.S. Patent No. 5,197,973. The liquid adhesive may be painted onto the tissue surface, or formulated into an aerosol that is sprayed onto the affected tissue. For treatment of the lower bowel, the therapeutic agent

- 12 -

also may be provided rectally, e.g., by suppository, foam, liquid ointment or cream, particularly for the treatment of ulcerations of the ileum and colon. In another embodiment of the invention, the morphogen or
5 morphogen-stimulating agent is provided systemically, e.g., by parenteral administration.

In any treatment method of the invention, "administration of morphogen" refers to the
10 administration of the morphogen, either alone or in combination with other molecules. For example, the mature form of the morphogen may be provided in association with its precursor "pro" domain, which is known to enhance the solubility of the protein in
15 physiological solutions. Other useful molecules known to enhance protein solubility include casein and other milk components, as well as various serum proteins. Additional useful molecules which may be associated with the morphogen or morphogen-stimulating agent
20 include tissue targeting molecules capable of directing the morphogen or morphogen-stimulating agent to epithelial mucosa tissue. Tissue targeting molecules envisioned to be useful in the treatment protocols of this invention include antibodies, antibody fragments
25 or other binding proteins which interact specifically with surface molecules on GI barrier tissue cells. Non-steroidal anti-inflammatory agents which typically are targeted to inflamed tissue also may be used.

30 Still another useful tissue targeting molecule may comprise part or all of the morphogen precursor "pro" domain. Under naturally occurring conditions, the endogenous morphogens described herein may be synthesized in other tissues and transported to target
35 tissue after secretion from the synth sizing tissu .

- 13 -

For example, while the protein has been shown to be active in bone tissue, the primary source of OP-1 synthesis appears to be the tissue of the urogenic system (e.g., renal and bladder tissue), with secondary
5 expression levels occurring in the brain, heart and lungs (see below.) Moreover, the protein has been identified in serum, saliva and various milk forms. In addition, the secreted form of the protein comprises the mature dimer in association with the pro domain of
10 the intact morphogen sequence. Accordingly, the associated morphogen pro domains may act to target specific morphogens to different tissues in vivo.

Associated tissue targeting or solubility-enhancing
15 molecules also may be covalently linked to the morphogen using standard chemical means, including acid-labile linkages, which likely will be preferentially cleaved in the acidic environment of the GI tract.

20 Finally, the morphogens or morphogen-stimulating agents provided herein also may be administered in combination with other molecules ("cofactors"), known to be beneficial in ulcer treatments, particularly
25 cofactors capable of mitigating or alleviating symptoms typically associated with ulcerated tissue damage and/or loss. Examples of such cofactors include, analgesics/anesthetics such as xylocaine, and benzocaine; antiseptics such as chlorohexidine; anti-
30 bacterial, anti-viral and anti-fungal agents, including aminoglycosides, macrolides, penicillins, and cephalosporins; and antacids or antisecretory agents such as cimetidine or ranitidine.

- 14 -

Among the morphogens useful in this invention are proteins originally identified as osteogenic proteins, such as the OP-1, OP-2 and CBMP2 proteins, as well as amino acid sequence-related proteins such as DPP (from Drosophila), Vgl (from Xenopus), Vgr-1 (from mouse, see U.S. 5,011,691 to Oppermann et al.), GDF-1 (from mouse, see Lee (1991) PNAS 88:4250-4254), all of which are presented in Table II and Seq. ID Nos.5-14), and the recently identified 60A protein (from Drosophila, Seq. ID No. 24, see Wharton et al. (1991) PNAS 88:9214-9218.) The members of this family, which include members of the TGF- β super-family of proteins, share substantial amino acid sequence homology in their C-terminal regions. The proteins are translated as a precursor, having an N-terminal signal peptide sequence, typically less than about 30 residues, followed by a "pro" domain that is cleaved to yield the mature sequence. The "pro" form of the protein includes the pro domain and the mature domain, and forms a soluble species that appears to be the primary form secreted from cultured mammalian cells. The signal peptide is cleaved rapidly upon translation, at a cleavage site that can be predicted in a given sequence using the method of Von Heijne ((1986) Nucleic Acids Research 14:4683-4691.) Table I, below, describes the various morphogens identified to date, including their nomenclature as used herein, their Seq. ID references, and publication sources for the amino acid sequences for the full length proteins not included in the Seq. Listing. The disclosure of these publications is incorporated herein by reference.

- 15 -

TABLE I

5	"OP-1"	Refers generically to the group of morphogenically active proteins expressed from part or all of a DNA sequence encoding OP-1 protein, including allelic and species variants thereof, e.g., human OP-1 ("hOP-1", Seq. ID No. 5, mature protein amino acid sequence), or mouse
10		OP-1 ("mOP-1", Seq. ID No. 6, mature protein amino acid sequence.) The conserved seven cysteine skeleton is defined by residues 38 to 139 of Seq. ID
15		Nos. 5 and 6. The cDNA sequences and the amino acids encoding the full length proteins are provided in Seq. ID Nos. 16 and 17 (hOP1) and Seq. ID Nos. 18 and 19 (mOP1.) The mature proteins are defined by residues 293-431 (hOP1) and 292-430
20		(mOP1). The "pro" regions of the proteins, cleaved to yield the mature, morphogenically active proteins are defined essentially by residues 30-292 (hOP1) and residues 30-291 (mOP1).
25		
30	"OP-2"	refers generically to the group of active proteins expressed from part or all of a DNA sequence encoding OP-2 protein, including allelic and species variants thereof, e.g., human OP-2 ("hOP-2", Seq. ID No. 7, mature protein amino acid
35		sequence) or mouse OP-2 ("mOP-2", Seq. ID No. 8, mature protein amino acid sequence). The conserved seven cysteine skeleton is defined by residues 38 to 139

- 16 -

of Seq. ID Nos. 7 and 8. The cDNA sequences and the amino acids encoding the full length proteins are provided in Seq. ID Nos. 20 and 21 (hOP2) and Seq. ID Nos. 22 and 23 (mOP2.) The mature proteins are defined essentially by residues 264-402 (hOP2) and 261-399 (mOP2). The "pro" regions of the proteins, cleaved to yield the mature, morphogenically active proteins likely are defined essentially by residues 18-263 (hOP2) and residues 18-260 (mOP2). (Another cleavage site also occurs 21 residues upstream for hOP-2 protein.)

"CBMP2" refers generically to the morphogenically active proteins expressed from a DNA sequence encoding the CBMP2 proteins, including allelic and species variants thereof, e.g., human CBMP2A ("CBMP2A(fx)", Seq ID No. 9) or human CBMP2B DNA ("CBMP2B(fx)", Seq. ID No. 10). The amino acid sequence for the full length proteins, referred to in the literature as BMP2A and BMP2B, or BMP2 and BMP4, appear in Wozney, et al. (1988) Science 242:1528-1534. The pro domain for BMP2 (BMP2A) likely includes residues 25-248 or 25-282; the mature protein, residues 249-396 or 283-396. The pro domain for BMP4 (BMP2B) likely includes residues 25-256 or 25-292; the mature protein, residues 257-408 or 293-408.

- 17. -

- 5 "DPP(fx)" refers to protein sequences encoded by the
Drosophila DPP gene and defining the
conserved seven cysteine skeleton (Seq. ID
No. 11). The amino acid sequence for the
full length protein appears in Padgett, et
al (1987) Nature 325: 81-84. The pro
domain likely extends from the signal
peptide cleavage site to residue 456; the
mature protein likely is defined by
residues 457-588.
- 15 "Vgl(fx)" refers to protein sequences encoded by the
Xenopus Vgl gene and defining the
conserved seven cysteine skeleton (Seq. ID
No. 12). The amino acid sequence for the
full length protein appears in
Weeks (1987) Cell 51: 861-867. The pro
domain likely extends from the signal
peptide cleavage site to residue 246; the
mature protein likely is defined by
residues 247-360.
- 25 "Vgr-1(fx)" refers to protein sequences encoded by the
murine Vgr-1 gene and defining the
conserved seven cysteine skeleton (Seq. ID
No. 13). The amino acid sequence for the
full length protein appears in Lyons, et
al, (1989) PNAS 86: 4554-4558. The pro
domain likely extends from the signal
peptide cleavage site to residue 299; the
mature protein likely is defined by
residues 300-438.
- 35 "GDF-1(fx)" refers to protein sequences encoded by the
human GDF-1 gene and defining the

- 18 -

- conserved seven cysteine skeleton (Seq. ID No. 14). The cDNA and encoded amino sequence for the full length protein is provided in Seq. ID. No. 32. The pro domain likely extends from the signal peptide cleavage site to residue 214; the mature protein likely is defined by residues 215-372.
- 10 "60A" refers generically to the morphogenically active proteins expressed from part or all of a DNA sequence (from the Drosophila 60A gene) encoding the 60A proteins (see Seq. ID No. 24 wherein the cDNA and encoded amino acid sequence for the full length protein is provided). "60A(fx)" refers to the protein sequences defining the conserved seven cysteine skeleton (residues 354 to 455 of Seq. ID No. 24.)
- 20 The pro domain likely extends from the signal peptide cleavage site to residue 324; the mature protein likely is defined by residues 325-455.
- 25 "BMP3(fx)" refers to protein sequences encoded by the human BMP3 gene and defining the conserved seven cysteine skeleton (Seq. ID No. 26). The amino acid sequence for the full length protein appears in Wozney et al. (1988) Science 242: 1528-1534. The pro domain likely extends from the signal peptide cleavage site to residue 290; the mature protein likely is defined by residues 291-472.

35

- 19 -

"BMP5(fx)" refers to protein sequences encoded by the human BMP5 gene and defining the conserved seven cysteine skeleton (Seq. ID No. 27). The amino acid sequence for the full length protein appears in Celeste, et al. (1991) PNAS 87: 9843-9847. The pro domain likely extends from the signal peptide cleavage site to residue 316; the mature protein likely is defined by residues 317-454.

"BMP6(fx)" refers to protein sequences encoded by the human BMP6 gene and defining the conserved seven cysteine skeleton (Seq. ID No. 28). The amino acid sequence for the full length protein appears in Celeste, et al. (1990) PNAS 87: 9843-5847. The pro domain likely extends from the signal peptide cleavage site to residue 374; the mature sequence likely includes residues 375-513.

The OP-2 proteins have an additional cysteine residue in this region (e.g., see residue 41 of Seq. ID Nos. 7 and 8), in addition to the conserved cysteine skeleton in common with the other proteins in this family. The GDF-1 protein has a four amino acid insert within the conserved skeleton (residues 44-47 of Seq. ID No. 14) but this insert likely does not interfere with the relationship of the cysteines in the folded structure. In addition, the CBMP2 proteins are missing one amino acid residue within the cysteine skeleton.

The morphogens are inactive when reduced, but are active as oxidized homodimers and when oxidized in combination with other morphogens of this invention.

- 20 -

Thus, as defined herein, a morphogen is a dimeric protein comprising a pair of polypeptide chains, wherein each polypeptide chain comprises at least the C-terminal six cysteine skeleton defined by residues 5 43-139 of Seq. ID No. 5, including functionally equivalent arrangements of these cysteines (e.g., amino acid insertions or deletions which alter the linear arrangement of the cysteines in the sequence but not their relationship in the folded structure), such that, 10 when the polypeptide chains are folded, the dimeric protein species comprising the pair of polypeptide chains has the appropriate three-dimensional structure, including the appropriate intra- or inter-chain disulfide bonds such that the protein is capable of 15 acting as a morphogen as defined herein. Specifically, the morphogens generally are capable of all of the following biological functions in a morphogenically permissive environment: stimulating proliferation of progenitor cells; stimulating the differentiation of 20 progenitor cells; stimulating the proliferation of differentiated cells; and supporting the growth and maintenance of differentiated cells. In addition, it is also anticipated that these morphogens are capable of inducing redifferentiation of committed cells under 25 appropriate environmental conditions.

In one preferred aspect, the morphogens, of this invention comprise one of two species of generic amino acid sequences: Generic Sequence 1 (Seq. ID No. 1) or 30 Generic Sequence 2 (Seq. ID No. 2); where each Xaa indicates one of the 20 naturally-occurring L-isomer, α -amino acids or a derivative thereof. Generic Sequence 1 comprises the conserved six cysteine skeleton and Generic Sequence 2 comprises the conserved 35 six cysteine skeleton plus the additional cystein

- 21. -

identified in OP-2 (see residue 36, Seq. ID No. 2). In another preferred aspect, these sequences further comprise the following additional sequence at their N-terminus:

5

Cys Xaa Xaa Xaa Xaa (Seq. ID No. 15)

1

5

Preferred amino acid sequences within the foregoing generic sequences include: Generic Sequence 3 (Seq. ID No. 3), Generic Sequence 4 (Seq. ID No. 4), Generic Sequence 5 (Seq. ID No. 30) and Generic Sequence 6 (Seq. ID No. 31), listed below. These Generic Sequences accommodate the homologies shared among the various preferred members of this morphogen family identified in Table II, as well as the amino acid sequence variation among them. Specifically, Generic Sequences 3 and 4 are composite amino acid sequences of the following proteins presented in Table II and identified in Seq. ID Nos. 5-14: human OP-1 (hOP-1, Seq. ID Nos. 5 and 16-17), mouse OP-1 (mOP-1, Seq. ID Nos. 6 and 18-19), human and mouse OP-2 (Seq. ID Nos. 7, 8, and 20-22), CBMP2A (Seq. ID No. 9), CBMP2B (Seq. ID No. 10), DPP (from Drosophila, Seq. ID No. 11), Vgl, (from Xenopus, Seq. ID No. 12), Vgr-1 (from mouse, Seq. ID No. 13), and GDF-1 (from mouse, Seq. ID No. 14.) The generic sequences include both the amino acid identity shared by the sequences in Table II, as well as alternative residues for the variable positions within the sequence. Note that these generic sequences allow for an additional cysteine at position 41 or 46 in Generic Sequences 3 or 4, respectively, providing an appropriate cysteine skeleton where inter- or intramolecular disulfide bonds can form, and contain critical amino acids which influence the tertiary structure of the proteins.

- 22. -

Generic Sequence 3

```

          Leu Tyr Val Xaa Phe
            1             5
5      Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa
            10
          Xaa Ala Pro Xaa Gly Xaa Xaa Ala
            15             20
          Xaa Tyr Cys Xaa Gly Xaa Cys Xaa
10             25             30
          Xaa Pro Xaa Xaa Xaa Xaa Xaa
            35
          Xaa Xaa Xaa Asn His Ala Xaa Xaa
            40             45
15      Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa
            50
          Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
            55             60
          Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa
20             65
          Xaa Xaa Xaa Leu Xaa Xaa Xaa
            70             75
          Xaa Xaa Xaa Xaa Val Xaa Leu Xaa
            80
25  A   Xaa Xaa Xaa Xaa Met Xaa Val Xaa
            85             90
          Xaa Cys Gly Cys Xaa
            95

```

30 wherein each Xaa is independently selected from a group of one or more specified amino acids defined as follows: "Res." means "residue" and Xaa at res.4 = (Ser, Asp or Glu); Xaa at res.6 = (Arg, Gln, Ser or Lys); Xaa at res.7 = (Asp or Glu); Xaa at res.8 = (Leu

35 r Val); Xaa at res.11 = (Gln, L u, Asp, His r Asn);

- 23 -

Xaa at res.12 = (Asp, Arg or Asn); Xaa at res.14 = (Ile or Val); Xaa at res.15 = (Ile or Val); Xaa at res.18 = (Glu, Gln, Leu, Lys, Pro or Arg); Xaa at res.20 = (Tyr or Phe); Xaa at res.21 = (Ala, Ser, Asp, Met, His, Leu or Gln); Xaa at res.23 = (Tyr, Asn or Phe); Xaa at res.26 = (Glu, His, Tyr, Asp or Gln); Xaa at res.28 = (Glu, Lys, Asp or Gln); Xaa at res.30 = (Ala, Ser, Pro or Gln); Xaa at res.31 = (Phe, Leu or Tyr); Xaa at res.33 = (Leu or Val); Xaa at res.34 = (Asn, Asp, Ala or Thr); Xaa at res.35 = (Ser, Asp, Glu, Leu or Ala); Xaa at res.36 = (Tyr, Cys, His, Ser or Ile); Xaa at res.37 = (Met, Phe, Gly or Leu); Xaa at res.38 = (Asn or Ser); Xaa at res.39 = (Ala, Ser or Gly); Xaa at res.40 = (Thr, Leu or Ser); Xaa at res.44 = (Ile or Val); Xaa at res.45 = (Val or Leu); Xaa at res.46 = (Gln or Arg); Xaa at res.47 = (Thr, Ala or Ser); Xaa at res.49 = (Val or Met); Xaa at res.50 = (His or Asn); Xaa at res.51 = (Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.52 = (Ile, Met, Asn, Ala or Val); Xaa at res.53 = (Asn, Lys, Ala or Glu); Xaa at res.54 = (Pro or Ser); Xaa at res.55 = (Glu, Asp, Asn, or Gly); Xaa at res.56 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser or Ala); Xaa at res.57 = (Val, Ala or Ile); Xaa at res.58 = (Pro or Asp); Xaa at res.59 = (Lys or Leu); Xaa at res.60 = (Pro or Ala); Xaa at res.63 = (Ala or Val); Xaa at res.65 = (Thr or Ala); Xaa at res.66 = (Gln, Lys, Arg or Glu); Xaa at res.67 = (Leu, Met or Val); Xaa at res.68 = (Asn, Ser or Asp); Xaa at res.69 = (Ala, Pro or Ser); Xaa at res.70 = (Ile, Thr or Val); Xaa at res.71 = (Ser or Ala); Xaa at res.72 = (Val or Met); Xaa at res.74 = (Tyr or Phe); Xaa at res.75 = (Phe, Tyr or Leu); Xaa at res.76 = (Asp or Asn); Xaa at res.77 = (Asp, Glu, Asn or Ser); Xaa at res.78 = (Ser, Gln, Asn or Tyr); Xaa at res.79 = (Ser, Asn, Asp or Glu); Xaa at res.80 = (Asn, Thr or Lys); Xaa at res.82 = (Ile r

- 24 -

Val); Xaa at res.84 = (Lys or Arg); Xaa at res.85 =
 (Lys, Asn, Gln or His); Xaa at res.86 = (Tyr or His);
 Xaa at res.87 = (Arg, Gln or Glu); Xaa at res.88 =
 (Asn, Glu or Asp); Xaa at res.90 = (Val, Thr or Ala);
 5 Xaa at res.92 = (Arg, Lys, Val, Asp or Glu); Xaa at
 res.93 = (Ala, Gly or Glu); and Xaa at res.97 = (His or
 Arg);

Generic Sequence 4

10	Cys Xaa Xaa Xaa Xaa Leu Tyr Val Xaa Phe	
	1	5 10
	Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa	
		15
15	Xaa Ala Pro Xaa Gly Xaa Xaa Ala	
	20	25
	Xaa Tyr Cys Xaa Gly Xaa Cys Xaa	
	30	35
	Xaa Pro Xaa Xaa Xaa Xaa Xaa	
20		40
	Xaa Xaa Xaa Asn His Ala Xaa Xaa	
	45	50
	Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa	
		55
25	Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys	
	60	65
	Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa	
		70
	Xaa Xaa Xaa Leu Xaa Xaa Xaa	
30	75	80
	Xaa Xaa Xaa Xaa Val Xaa Leu Xaa	
		85
	Xaa Xaa Xaa Xaa Met Xaa Val Xaa	
	90	95
35	Xaa Cys Gly Cys Xaa	
		100

- 25 -

wherein each Xaa is independently selected from a group of one or more specified amino acids as defined by the following: "Res." means "residue" and Xaa at res.2 = (Lys or Arg); Xaa at res.3 = (Lys or Arg); Xaa at
5 res.4 = (His or Arg); Xaa at res.5 = (Glu, Ser, His, Gly, Arg or Pro); Xaa at res.9 = (Ser, Asp or Glu); Xaa at res.11 = (Arg, Gln, Ser or Lys); Xaa at res.12 = (Asp or Glu); Xaa at res.13 = (Leu or Val); Xaa at res.16 = (Gln, Leu, Asp, His or Asn); Xaa at res.17 =
10 (Asp, Arg, or Asn); Xaa at res.19 = (Ile or Val); Xaa at res.20 = (Ile or Val); Xaa at res.23 = (Glu, Gln, Leu, Lys, Pro or Arg); Xaa at res.25 = (Tyr or Phe); Xaa at res.26 = (Ala, Ser, Asp, Met, His, Leu, or Gln); Xaa at res.28 = (Tyr, Asn or Phe); Xaa at res.31 =
15 (Glu, His, Tyr, Asp or Gln); Xaa at res.33 = Glu, Lys, Asp or Gln); Xaa at res.35 = (Ala, Ser or Pro); Xaa at res.36 = (Phe, Leu or Tyr); Xaa at res.38 = (Leu or Val); Xaa at res.39 = (Asn, Asp, Ala or Thr); Xaa at res.40 = (Ser, Asp, Glu, Leu or Ala); Xaa at res.41 =
20 (Tyr, Cys, His, Ser or Ile); Xaa at res.42 = (Met, Phe, Gly or Leu); Xaa at res.44 = (Ala, Ser or Gly); Xaa at res.45 = (Thr, Leu or Ser); Xaa at res.49 = (Ile or Val); Xaa at res.50 = (Val or Leu); Xaa at res.51 = (Gln or Arg); Xaa at res.52 = (Thr, Ala or Ser); Xaa at
25 res.54 = (Val or Met); Xaa at res.55 = (His or Asn); Xaa at res.56 = (Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.57 = (Ile, Met, Asn, Ala or Val); Xaa at res.58 = (Asn, Lys, Ala or Glu); Xaa at res.59 = (Pro or Ser); Xaa at res.60 = (Glu, Asp, or Gly); Xaa at
30 res.61 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser or Ala); Xaa at res.62 = (Val, Ala or Ile); Xaa at res.63 = (Pro or Asp); Xaa at res.64 = (Lys or Leu); Xaa at res.65 = (Pro or Ala); Xaa at res.68 = (Ala or Val); Xaa at res.70 = (Thr or Ala); Xaa at res.71 = (Gln, Lys, Arg
35 or Glu); Xaa at res.72 = (Leu, Met or Val); Xaa at

- 26 -

res.73 = (Asn, Ser or Asp); Xaa at res.74 = (Ala, Pro or Ser); Xaa at res.75 = (Ile, Thr or Val); Xaa at res.76 = (Ser or Ala); Xaa at res.77 = (Val or Met); Xaa at res.79 = (Tyr or Phe); Xaa at res.80 = (Phe, Tyr or Leu); Xaa at res.81 = (Asp or Asn); Xaa at res.82 = (Asp, Glu, Asn or Ser); Xaa at res.83 = (Ser, Gln, Asn or Tyr); Xaa at res.84 = (Ser, Asn, Asp or Glu); Xaa at res.85 = (Asn, Thr or Lys); Xaa at res.87 = (Ile or Val); Xaa at res.89 = (Lys or Arg); Xaa at res.90 = (Lys, Asn, Gln or His); Xaa at res.91 = (Tyr or His); Xaa at res.92 = (Arg, Gln or Glu); Xaa at res.93 = (Asn, Glu or Asp); Xaa at res.95 = (Val, Thr or Ala); Xaa at res.97 = (Arg, Lys, Val, Asp or Glu); Xaa at res.98 = (Ala, Gly or Glu); and Xaa at res.102 = (His or Arg).

Similarly, Generic Sequence 5 (Seq. ID No. 30) and Generic Sequence 6 (Seq. ID No. 31) accommodate the homologies shared among all the morphogen protein family members identified in Table II. Specifically, Generic Sequences 5 and 6 are composite amino acid sequences of human OP-1 (hOP-1, Seq. ID Nos. 5 and 16-17), mouse OP-1 (mOP-1, Seq. ID Nos. 6 and 18-19), human and mouse OP-2 (Seq. ID Nos. 7, 8, and 20-22), CBMP2A (Seq. ID No. 9), CBMP2B (Seq. ID No. 10), DPP (from Drosophila, Seq. ID No. 11), Vgl, (from Xenopus, Seq. ID No. 12), Vgr-1 (from mouse, Seq. ID No. 13), and GDF-1 (from mouse, Seq. ID No. 14), human BMP3 (Seq. ID No. 26), human BMP5 (Seq. ID No. 27), human BMP6 (Seq. ID No. 28) and 60(A) (from Drosophila, Seq. ID Nos. 24-25). The generic sequences include both the amino acid identity shared by these sequences in the C-terminal domain, defined by the six and seven cysteine skeletons (Generic Sequences 5 and 6, respectively), as well as alternative residues for the

- 27 -

variable positions within the sequence. As for Generic Sequences 3 and 4, Generic Sequences 5 and 6 allow for an additional cysteine at position 41 (Generic Sequence 5) or position 46 (Generic Sequence 6), providing an appropriate cysteine skeleton where inter- or intramolecular disulfide bonds can form, and containing certain critical amino acids which influence the tertiary structure of the proteins.

10 **Generic Sequence 5**

		Leu	Xaa	Xaa	Xaa	Phe	
		1				5	
15		Xaa	Xaa	Xaa	Gly	Trp	Xaa Xaa Trp Xaa
					10		
		Xaa	Xaa	Pro	Xaa	Xaa	Xaa Ala
		15				20	
		Xaa	Tyr	Cys	Xaa	Gly	Xaa Cys Xaa
			25				30
20		Xaa	Pro	Xaa	Xaa	Xaa	Xaa
					35		
		Xaa	Xaa	Xaa	Asn	His	Ala Xaa Xaa
			40				45
		Xaa	Xaa	Xaa	Xaa	Xaa	Xaa Xaa
25					50		
		Xaa	Xaa	Xaa	Xaa	Xaa	Xaa Cys
			55				60
		Cys	Xaa	Pro	Xaa	Xaa	Xaa Xaa
					65		
30		Xaa	Xaa	Xaa	Leu	Xaa	Xaa
			70				75
		Xaa	Xaa	Xaa	Xaa	Val	Xaa Leu Xaa
					80		
		Xaa	Xaa	Xaa	Xaa	Met	Xaa Val Xaa
35			85				90
		Xaa	Cys	Xaa	Cys	Xaa	
					95		

- 28 -

wherein each Xaa is independently selected from a group of one or more specified amino acids defined as follows: "Res." means "residue" and Xaa at res.2 = (Tyr or Lys); Xaa at res.3 = Val or Ile); Xaa at res.4 = (Ser, Asp or Glu); Xaa at res.6 = (Arg, Gln, Ser, Lys or Ala); Xaa at res.7 = (Asp, Glu or Lys); Xaa at res.8 = (Leu, Val or Ile); Xaa at res.11 = (Gln, Leu, Asp, His, Asn or Ser); Xaa at res.12 = (Asp, Arg, Asn or Glu); Xaa at res.14 = (Ile or Val); Xaa at res.15 = (Ile or Val); Xaa at res.16 = (Ala or Ser); Xaa at res.18 = (Glu, Gln, Leu, Lys, Pro or Arg); Xaa at res.19 = (Gly or Ser); Xaa at res.20 = (Tyr or Phe); Xaa at res.21 = (Ala, Ser, Asp, Met, His, Gln, Leu or Gly); Xaa at res.23 = (Tyr, Asn or Phe); Xaa at res.26 = (Glu, His, Tyr, Asp, Gln or Ser); Xaa at res.28 = (Glu, Lys, Asp, Gln or Ala); Xaa at res.30 = (Ala, Ser, Pro, Gln or Asn); Xaa at res.31 = (Phe, Leu or Tyr); Xaa at res.33 = (Leu, Val or Met); Xaa at res.34 = (Asn, Asp, Ala, Thr or Pro); Xaa at res.35 = (Ser, Asp, Glu, Leu, Ala or Lys); Xaa at res.36 = (Tyr, Cys, His, Ser or Ile); Xaa at res.37 = (Met, Phe, Gly or Leu); Xaa at res.38 = (Asn, Ser or Lys); Xaa at res.39 = (Ala, Ser, Gly or Pro); Xaa at res.40 = (Thr, Leu or Ser); Xaa at res.44 = (Ile, Val or Thr); Xaa at res.45 = (Val, Leu or Ile); Xaa at res.46 = (Gln or Arg); Xaa at res.47 = (Thr, Ala or Ser); Xaa at res.48 = (Leu or Ile); Xaa at res.49 = (Val or Met); Xaa at res.50 = (His, Asn or Arg); Xaa at res.51 = (Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.52 = (Ile, Met, Asn, Ala, Val or Leu); Xaa at res.53 = (Asn, Lys, Ala, Glu, Gly or Phe); Xaa at res.54 = (Pro, Ser or Val); Xaa at res.55 = (Glu, Asp, Asn, Gly, Val or Lys); Xaa at res.56 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser, Ala, Pro or His); Xaa at res.57 = (Val, Ala or Ile);

- 29 -

Xaa at res.58 = (Pro or Asp); Xaa at res.59 = (Lys, Leu or Glu); Xaa at res.60 = (Pro or Ala); Xaa at res.63 = (Ala or Val); Xaa at res.65 = (Thr, Ala or Glu); Xaa at res.66 = (Gln, Lys, Arg or Glu); Xaa at res.67 = (Leu, Met or Val); Xaa at res.68 = (Asn, Ser, Asp or Gly); Xaa at res.69 = (Ala, Pro or Ser); Xaa at res.70 = (Ile, Thr, Val or Leu); Xaa at res.71 = (Ser, Ala or Pro); Xaa at res.72 = (Val, Met or Ile); Xaa at res.74 = (Tyr or Phe); Xaa at res.75 = (Phe, Tyr, Leu or His); Xaa at res.76 = (Asp, Asn or Leu); Xaa at res.77 = (Asp, Glu, Asn or Ser); Xaa at res.78 = (Ser, Gln, Asn, Tyr or Asp); Xaa at res.79 = (Ser, Asn, Asp, Glu or Lys); Xaa at res.80 = (Asn, Thr or Lys); Xaa at res.82 = (Ile, Val or Asn); Xaa at res.84 = (Lys or Arg); Xaa at res.85 = (Lys, Asn, Gln, His or Val); Xaa at res.86 = (Tyr or His); Xaa at res.87 = (Arg, Gln, Glu or Pro); Xaa at res.88 = (Asn, Glu or Asp); Xaa at res.90 = (Val, Thr, Ala or Ile); Xaa at res.92 = (Arg, Lys, Val, Asp or Glu); Xaa at res.93 = (Ala, Gly, Glu or Ser); Xaa at res.95 = (Gly or Ala) and Xaa at res.97 = (His or Arg).

Generic Sequence 6

25	Cys Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Phe	
	1	10
	Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa	
	15	
	Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala	
30	20	25
	Xaa Tyr Cys Xaa Gly Xaa Cys Xaa	
	30	35
	Xaa Pro Xaa Xaa Xaa Xaa Xaa	
	40	
35	Xaa Xaa Xaa Asn His Ala Xaa Xaa	
	45	50

- 30 -

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 55
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
 60 65
 5 Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa
 70
 Xaa Xaa Xaa Leu Xaa Xaa Xaa
 75 80
 Xaa Xaa Xaa Xaa Val Xaa Leu Xaa
 10 85
 Xaa Xaa Xaa Xaa Met Xaa Val Xaa
 90 95
 Xaa Cys Xaa Cys Xaa
 100
 15

wherein each Xaa is independently selected from a group
 of one or more specified amino acids as defined by the
 following: "Res." means "residue" and Xaa at res.2 =
 (Lys, Arg, Ala or Gln); Xaa at res.3 = (Lys, Arg or
 20 Met); Xaa at res.4 = (His, Arg or Gln); Xaa at res.5 =
 (Glu, Ser, His, Gly, Arg, Pro, Thr, or Tyr); Xaa at
 res.7 = (Tyr or Lys); Xaa at res.8 = (Val or Ile); Xaa
 at res.9 = (Ser, Asp or Glu); Xaa at res.11 = (Arg,
 Gln, Ser, Lys or Ala); Xaa at res.12 = (Asp, Glu, or
 25 Lys); Xaa at res.13 = (Leu, Val or Ile); Xaa at
 res.16 = (Gln, Leu, Asp, His, Asn or Ser); Xaa at
 res.17 = (Asp, Arg, Asn or Glu); Xaa at res.19 = (Ile
 or Val); Xaa at res.20 = (Ile or Val); Xaa at res.21 =
 (Ala or Ser); Xaa at res.23 = (Glu, Gln, Leu, Lys, Pro
 30 or Arg); Xaa at res.24 = (Gly or Ser); Xaa at res.25 =
 (Tyr or Phe); Xaa at res.26 = (Ala, Ser, Asp, Met, His,
 Gln, Leu, or Gly); Xaa at res.28 = (Tyr, Asn or Phe);
 Xaa at res.31 = (Glu, His, Tyr, Asp, Gln or Ser); Xaa
 at res.33 = Glu, Lys, Asp, Gln or Ala); Xaa at res.35 =
 35 (Ala, Ser, Pro, Gln or Asn); Xaa at r s.36 = (Phe, L u

- 31 -

or Tyr); Xaa at res.38 = (Leu, Val or Met); Xaa at
res.39 = (Asn, Asp, Ala, Thr or Pro); Xaa at res.40 =
(Ser, Asp, Glu, Leu, Ala or Lys); Xaa at res.41 = (Tyr,
Cys, His, Ser or Ile); Xaa at res.42 = (Met, Phe, Gly
5 or Leu); Xaa at res.43 = (Asn, Ser or Lys); Xaa at
res.44 = (Ala, Ser, Gly or Pro); Xaa at res.45 = (Thr,
Leu or Ser); Xaa at res.49 = (Ile, Val or Thr); Xaa at
res.50 = (Val, Leu or Ile); Xaa at res.51 = (Gln or
Arg); Xaa at res.52 = (Thr, Ala or Ser); Xaa at
10 res.53 = (Leu or Ile); Xaa at res.54 = (Val or Met);
Xaa at res.55 = (His, Asn or Arg); Xaa at res.56 =
(Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.57 = (Ile,
Met, Asn, Ala, Val or Leu); Xaa at res.58 = (Asn, Lys,
Ala, Glu, Gly or Phe); Xaa at res.59 = (Pro, Ser or
15 Val); Xaa at res.60 = (Glu, Asp, Gly, Val or Lys); Xaa
at res.61 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser, Ala,
Pro or His); Xaa at res.62 = (Val, Ala or Ile); Xaa at
res.63 = (Pro or Asp); Xaa at res.64 = (Lys, Leu or
Glu); Xaa at res.65 = (Pro or Ala); Xaa at res.68 =
20 (Ala or Val); Xaa at res.70 = (Thr, Ala or Glu); Xaa at
res.71 = (Gln, Lys, Arg or Glu); Xaa at res.72 = (Leu,
Met or Val); Xaa at res.73 = (Asn, Ser, Asp or Gly);
Xaa at res.74 = (Ala, Pro or Ser); Xaa at res.75 =
(Ile, Thr, Val or Leu); Xaa at res.76 = (Ser, Ala or
25 Pro); Xaa at res.77 = (Val, Met or Ile); Xaa at
res.79 = (Tyr or Phe); Xaa at res.80 = (Phe, Tyr, Leu
or His); Xaa at res.81 = (Asp, Asn or Leu); Xaa at
res.82 = (Asp, Glu, Asn or Ser); Xaa at res.83 = (Ser,
Gln, Asn, Tyr or Asp); Xaa at res.84 = (Ser, Asn, Asp,
30 Glu or Lys); Xaa at res.85 = (Asn, Thr or Lys); Xaa at
res.87 = (Ile, Val or Asn); Xaa at res.89 = (Lys or
Arg); Xaa at res.90 = (Lys, Asn, Gln, His or Val); Xaa
at res.91 = (Tyr or His); Xaa at res.92 = (Arg, Gln,
Glu or Pro); Xaa at res.93 = (Asn, Glu or Asp); Xaa at
35 res.95 = (Val, Thr, Ala or Ile); Xaa at res.97 = (Arg,

- 32 -

Lys, Val, Asp or Glu); Xaa at res.98 = (Ala, Gly, Glu or Ser); Xaa at res.100 = (Gly or Ala); and Xaa at res.102 = (His or Arg).

5 Particularly useful sequences for use as morphogens in this invention include the C-terminal domains, e.g., the C-terminal 96-102 amino acid residues of Vgl, Vgr-1, DPP, OP-1, OP-2, CBMP-2A, CBMP-2B, GDF-1 (see Table II, below, and Seq. ID Nos. 5-14), as well as
10 proteins comprising the C-terminal domains of 60A, BMP3, BMP5 and BMP6 (see Seq. ID Nos. 24-28), all of which include at least the conserved six or seven cysteine skeleton. In addition, biosynthetic constructs designed from the generic sequences, such as
15 COP-1, 3-5, 7, 16, disclosed in U.S. Pat. No. 5,011,691, also are useful. Other sequences include the inhibins/activin proteins (see, for example, U.S. Pat. Nos. 4,968,590 and 5,011,691). Accordingly, other useful sequences are those sharing at least 70% amino
20 acid sequence homology or "similarity", and preferably 80% homology or similarity with any of the sequences above. These are anticipated to include allelic, species variants and other sequence variants (e.g., including "muteins" or "mutant proteins"), whether
25 naturally-occurring or biosynthetically produced, as well as novel members of this morphogenic family of proteins. As used herein, "amino acid sequence homology" is understood to mean amino acid sequence similarity, and homologous sequences share identical or
30 similar amino acids, where similar amino acids are conserved amino acids as defined by Dayoff et al., Atlas of Protein Sequence and Structure; vol.5, Suppl.3, pp.345-362 (M.O. Dayoff, ed., Nat'l BioMed. Research Fdn., Washington D.C. 1978.) Thus, a
35 candidate s qu nc sharing 70% amino acid homol gy with

- 33 -

- a reference sequence requires that, following alignment of the candidate sequence with the reference sequence, 70% of the amino acids in the candidate sequence are identical to the corresponding amino acid in the
- 5 reference sequence, or constitute a conserved amino acid change thereto. "Amino acid sequence identity" is understood to require identical amino acids between two aligned sequences. Thus, a candidate sequence sharing 60% amino acid identity with a reference sequence
- 10 requires that, following alignment of the candidate sequence with the reference sequence, 60% of the amino acids in the candidate sequence are identical to the corresponding amino acid in the reference sequence.
- 15 As used herein, all homologies and identities calculated use OP-1 as the reference sequence. Also as used herein, sequences are aligned for homology and identity calculations using the method of Needleman et al. (1970) J.Mol. Biol. 48:443-453 and identities
- 20 calculated by the Align program (DNASTar, Inc.) In all cases, internal gaps and amino acid insertions in the candidate sequence as aligned are ignored when making the homology/identity calculation.
- 25 The currently most preferred protein sequences useful as morphogens in this invention include those having greater than 60% identity, preferably greater than 65% identity, with the amino acid sequence defining the conserved six cysteine skeleton of hOP1
- 30 (e.g., residues 43-139 of Seq. ID No. 5). These most preferred sequences include both allelic and species variants of the OP-1 and OP-2 proteins, including the *Drosophila* 60A protein. Accordingly, in another preferred aspect of the invention, useful morphogens
- 35 include active proteins comprising species f

- 34 -

polypeptide chains having the generic amino acid sequence herein referred to as "OPX", which accommodates the homologies between the various identified species of OP1 and OP2 (Seq. ID No. 29).

5

In still another preferred aspect of the invention, useful morphogens include dimeric proteins comprising amino acid sequences encoded by nucleic acids that hybridize to DNA or RNA sequences encoding the C-terminal sequences defining the conserved seven cysteine domain of OP1 or OP2, e.g., nucleotides 1036-1341 and nucleotides 1390-1695 of Seq. ID No. 16 and 20, respectively, under stringent hybridization conditions. As used herein, stringent hybridization conditions are defined as hybridization in 40% formamide, 5 X SSPE, 5 X Denhardt's Solution, and 0.1% SDS at 37°C overnight, and washing in 0.1 X SSPE, 0.1% SDS at 50°C.

20 The morphogens useful in the methods, composition and devices of this invention include proteins comprising any of the polypeptide chains described above, whether isolated from naturally-occurring sources, or produced by recombinant DNA or other
25 synthetic techniques, and includes allelic and species variants of these proteins, naturally-occurring or biosynthetic mutants thereof, as well as various truncated and fusion constructs. Deletion or addition mutants also are envisioned to be active, including
30 those which may alter the conserved C-terminal cysteine skeleton, provided that the alteration does not functionally disrupt the relationship of these cysteines in the folded structure. Accordingly, such active forms are considered the equivalent of the
35 specifically described constructs disclosed herein.

- 35 -

The proteins may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of
5 native or biosynthetic proteins, produced by expression of recombinant DNA in host cells.

The morphogenic proteins can be expressed from intact or truncated cDNA or from synthetic DNAs in
10 procaryotic or eucaryotic host cells, and purified, cleaved, refolded, and dimerized to form morphogenically active compositions. Currently preferred host cells include E. coli or mammalian cells, such as CHO, COS or BSC cells. A detailed
15 description of the morphogens useful in the methods, compositions and devices of this invention is disclosed in international application US92/01908 (WO92/15323). A method for their recombinant production is provided in Sampath et al. (1992) J. Biol. Chem. 267: 20352-
20 20362.

Thus, in view of this disclosure, skilled genetic engineers can isolate genes from cDNA or genomic libraries of various different species which encode
25 appropriate amino acid sequences, or construct DNAs from oligonucleotides, and then can express them in various types of host cells, including both procaryotes and eucaryotes, to produce large quantities of active proteins capable of maintaining the integrity of the
30 gastrointestinal tract luminal lining in individuals at risk for ulcer formation.

The foregoing and other objects, features and advantages of the present invention will be made more
35 apparent from the following detailed description of the invention.

- 36 -

Brief Description of the Drawings

The foregoing and other objects and features of
5 this invention, as well as the invention itself, may be
more fully understood from the following description,
when read together with the accompanying drawings, in
which:

10 Fig. 1 graphs the effect of a morphogen (e.g., OP-
1) and a placebo control on mucositis lesion formation;

Fig. 2(A and B) are photomicrographs illustrating
the ability of morphogens to inhibit lesion formation
15 in an oral mucositis animal model, where (2A) shows
lesion formation in untreated hamster cheek pouches;
and (2B) shows the significantly reduced effect on
morphogen treated cheek pouches;

20 Fig. 3(A and B) graphs the antiproliferative effect of
morphogens on mink lung cells; and

Fig. 4(A-D) graphs the effects of a morphogen (eg.,
OP-1, Figs. 4A and 4C) and TGF- β (Fig. 4B and 4D) on
25 collagen (4A and 4B) and hyaluronic acid (4C and 4D)
production in primary fibroblast cultures.

- 37. -

Detailed Description of the Invention

It now has been discovered that the proteins described herein are effective agents for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal. As described herein, these proteins ("morphogens") are capable of substantially inhibiting lesion formation or associated tissue damage in the basal epithelium, and/or stimulating the repair and regeneration the barrier tissue following ulceration. The proteins are capable of inhibiting epithelial cell proliferation and/or protecting the barrier tissue from damage. The proteins also are capable of inhibiting scar tissue formation that typically follows lesion formation in a mammal. In addition, the morphogens also can inhibit the inflammation normally associated with ulcerative diseases. The proteins may be used to treat ulcerative diseases of the gastrointestinal tract, including oral mucositis, peptic ulcers, ulcerative colitis, proctitis, and regional enteritis. The proteins also may be used to protect and/or treat GI tissue subject to damage in a xerostomatic individual. Finally, the morphogens may be administered as part of a chemical or radiotherapy to inhibit lesion formation in a patient undergoing cancer therapy and enhance the efficacy of the therapy thereby.

Provided below are detailed descriptions of suitable morphogens useful in the methods and compositions of this invention, as well as methods for their administration and application, and numerous, nonlimiting examples which demonstrate (1) the suitability of the morphogens described herein as therapeutic agents for maintaining the integrity of the gastrointestinal tract luminal lining, and (2) provide

- 38 -

assays with which to test candidate morphogens and morphogen-stimulating agents for their efficacy. Specifically, the examples provide models for demonstrating the utility of morphogens in the treatment of oral mucositis, duodenal ulcers, peptic ulcers, and ulcerative colitis (Examples 3-6); and demonstrate the ability of morphogens to inhibit epithelial cell proliferation (Example 7), inhibit inflammation (Example 8) and inhibit scar tissue formation (Example 9.) The Examples also describe methods for identifying morphogen-expressing tissue and screening for candidate morphogen stimulating agents (Examples 1, 2 and 10.)

I. Useful Morphogens

As defined herein a protein is morphogenic if it is capable of inducing the developmental cascade of cellular and molecular events that culminate in the formation of new, organ-specific tissue and comprises at least the conserved C-terminal six cysteine skeleton or its functional equivalent (see supra). Specifically, the morphogens generally are capable of all of the following biological functions in a morphogenically permissive environment: stimulating proliferation of progenitor cells; stimulating the differentiation of progenitor cells; stimulating the proliferation of differentiated cells; and supporting the growth and maintenance of differentiated cells. Details of how the morphogens useful in the method of this invention first were identified, as well as a description on how to make, use and test them for morphogenic activity, are disclosed in international application US92/01968 (WO 92/15323). As disclosed therein, the morphogens may be purified from naturally-sourced material or recombinantly produced from prokaryotic or eukaryotic host cells, using the genetic

- 39 -

sequences disclosed therein. Alternatively, novel morphogenic sequences may be identified following the procedures disclosed therein.

5 Particularly useful proteins include those which comprise the naturally derived sequences disclosed in Table II. Other useful sequences include 60A, BMP5, BMP6, BMP3, and biosynthetic constructs such as those disclosed in U.S. Pat. 5,011,691, the disclosure of
10 which is incorporated herein by reference (e.g., COP-1, COP-3, COP-4, COP-5, COP-7, and COP-16).

 Accordingly, the morphogens useful in the methods and compositions of this invention also may be
15 described by morphogenically active proteins having amino acid sequences sharing 70% or, preferably, 80% homology (similarity) with any of the sequences described above, where "homology" is as defined herein above.

20 The morphogens useful in the method of this invention also can be described by any of the 6 generic sequences described herein (Generic Sequences 1, 2, 3, 4, 5 and 6). Generic sequences 1 and 2 also may
25 include, at their N-terminus, the sequence

Cys Xaa Xaa Xaa Xaa (Seq. ID No. 15)

1

5

30 Table II, set forth below, compares the amino acid sequences of the active regions of native proteins that have been identified as morphogens, including human OP-1 (hOP-1, Seq. ID Nos. 5 and 16-17), mouse OP-1 (mOP-1, Seq. ID Nos. 6 and 18-19), human and mouse OP-2
35 (Seq. ID Nos. 7, 8, and 20-23), CBMP2A (Seq. ID No. 9),

CBMP2B (Seq. ID No. 10), DPP (from Drosophila, Seq. ID No. 11), Vgl, (from Xenopus, Seq. ID No. 12), Vgr-1 (from mouse, Seq. ID No. 13), and GDF-1 (from mouse, Seq. ID No. 14.) The sequences are aligned essentially following the method of Needleman et al. (1970) J. Mol. Biol., 48:443-453, calculated using the Align Program (DNASTAR, Inc.) In the table, three dots indicates that the amino acid in that position is the same as the amino acid in hOP-1. Three dashes indicates that no amino acid is present in that position, and are included for purposes of illustrating homologies. For example, amino acid residue 60 of CBMP-2A and CBMP-2B is "missing". Of course, both these amino acid sequences in this region comprise Asn-Ser (residues 58, 59), with CBMP-2A then comprising Lys and Ile, whereas CBMP-2B comprises Ser and Ile.

TABLE II

[illegible]

- 41 -

5	hOP-2	Gln	Leu	...
	mOP-2	Ser	Leu	...
	DPP	Asp	...	Ser	...	Val	Asp	...
	Vgl	Glu	...	Lys	...	Val	Asn
	Vgr-1	Gln	...	Val
	CBMP-2A	Asp	...	Ser	...	Val	Asn	...
	CBMP-2B	Asp	...	Ser	...	Val	Asn	...
	GDF-1	Glu	Val	His	Arg
			10				15			
10	hOP-1	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala
	mOP-1
	hOP-2	...	Val	Gln	Ser
	mOP-2	...	Val	Gln	Ser
	DPP	Val	Leu	Asp
	Vgl	...	Val	Gln	Met
	Vgr-1	Lys
	CBMP-2A	Val	Pro	His
15	CBMP-2B	Val	Pro	Gln
	GDF-1	...	Val	Arg	...	Phe	Leu
			20				25			
20	hOP-1	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala
	mOP-1
	hOP-2	Ser
	mOP-2
	DPP	His	...	Lys	...	Pro
	Vgl	...	Asn	Tyr	Pro
	Vgr-1	...	Asn	Asp	Ser
	CBMP-2A	...	Phe	His	...	Glu	...	Pro
30	CBMP-2B	...	Phe	His	...	Asp	...	Pro
	GDF-1	...	Asn	Gln	...	Gln
			30				35			
35	hOP-1
	mOP-1
	hOP-2
	mOP-2
	DPP	His	...	Lys	...	Pro
	Vgl	...	Asn	Tyr	Pro
	Vgr-1	...	Asn	Asp	Ser
	CBMP-2A	...	Phe	His	...	Glu	...	Pro

- 42 -

	hOP-1	Phe	Pro	Leu	Asn	Ser	Tyr	Met	Asn	Ala
	mOP-1
	hOP-2	Asp	...	Cys
	mOP-2	Asp	...	Cys
5	DPP	Ala	Asp	His	Phe	...	Ser
	Vgl	Tyr	Thr	Glu	Ile	Leu	...	Gly
	Vgr-1	Ala	His
	CBMP-2A	Ala	Asp	His	Leu	...	Ser
	CBMP-2B	Ala	Asp	His	Leu	...	Ser
10	GDF-1	Leu	...	Val	Ala	Leu	Ser	Gly	Ser**	...
						40				
	hOP-1	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu
	mOP-1
15	hOP-2	Leu	...	Ser	...
	mOP-2	Leu	...	Ser	...
	DPP	Val
	Vgl	Ser	Leu
	Vgr-1
20	CBMP-2A
	CBMP-2B
	GDF-1	Leu	Val	Leu	Arg	Ala	...
		45					50			
25	hOP-1	Val	His	Phe	Ile	Asn	Pro	Glu	Thr	Val
	mOP-1	Asp
	hOP-2	...	His	Leu	Met	Lys	...	Asn	Ala	...
	mOP-2	...	His	Leu	Met	Lys	...	Asp	Val	...
	DPP	...	Asn	Asn	Asn	Gly	Lys	...
30	Vgl	Ser	...	Glu	Asp	Ile
	Vgr-1	Val	Met	Tyr	...
	CBMP-2A	...	Asn	Ser	Val	...	Ser	---	Lys	Ile
	CBMP-2B	...	Asn	Ser	Val	...	Ser	---	Ser	Ile
	GDF-1	Met	...	Ala	Ala	Ala	...	Gly	Ala	Ala
35			55					60		

- 43 -

	hOP-1	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
	mOP-1
	hOP-2	Ala	Lys
	mOP-2	Ala	Lys
5	DPP	Ala	Val
	Vgl	...	Leu	Val	Lys
	Vgr-1	Lys
	CBMP-2A	Ala	Val	Glu
	CBMP-2B	Ala	Val	Glu
10	GDF-1	Asp	Leu	Val	...	Ala	Arg
				65					70	
	hOP-1	Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe
15	mOP-1
	hOP-2	...	Ser	...	Thr	Tyr
	mOP-2	...	Ser	...	Thr	Tyr
	Vgl	Met	Ser	Pro	Met	...	Phe	Tyr
	Vgr-1	Val
20	DPP	...	Asp	Ser	Val	Ala	Met	Leu
	CBMP-2A	...	Ser	Met	Leu
	CBMP-2B	...	Ser	Met	Leu
	GDF-1	...	Ser	Pro	Phe	...
				75						80
25	hOP-1	Asp	Asp	Ser	Ser	Asn	Val	Ile	Leu	Lys
	mOP-1
	hOP-2	...	Ser	...	Asn	Arg
	mOP-2	...	Ser	...	Asn	Arg
	DPP	Asn	...	Gln	...	Thr	...	Val
30	Vgl	...	Asn	Asn	Asp	Val	...	Arg
	Vgr-1	Asn
	CBMP-2A	...	Glu	Asn	Glu	Lys	...	Val
	CBMP-2B	...	Glu	Tyr	Asp	Lys	...	Val
	GDF-1	...	Asn	...	Asp	Val	...	Arg
35					85					

- 44 -

	hOP-1	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg
	mOP-1
	hOP-2	...	His	Lys
	mOP-2	...	His	Lys
5	DPP	Asn	...	Gln	Glu	...	Thr	...	Val
	Vgl	His	...	Glu	Ala	...	Asp
	Vgr-1
	CBMP-2A	Asn	...	Gln	Asp	Glu
	CBMP-2B	Asn	...	Gln	Glu	Glu
10	GDF-1	Gln	...	Glu	Asp	Asp
		90					95		

	hOP-1	Ala	Cys	Gly	Cys	His
15	mOP-1
	hOP-2
	mOP-2
	DPP	Gly	Arg
	Vgl	Glu	Arg
20	Vgr-1
	CBMP-2A	Gly	Arg
	CBMP-2B	Gly	Arg
	GDF-1	Glu	Arg

100

25 **Between residues 43 and 44 of GDF-1 lies the amino acid
sequence Gly-Gly-Pro-Pro.

As is apparent from the foregoing amino acid
sequence comparisons, significant amino acid changes
30 can be made within the generic sequences while
retaining the morphogenic activity. For example, while
the GDF-1 protein sequence depicted in Table II shares
only about 50% amino acid identity with the hOP1
sequence described therein, the GDF-1 sequence shares
35 greater than 70% amino acid sequence homology (or

- 45 -

"similarity") with the hOP1 sequence, where "homology" or "similarity" includes allowed conservative amino acid changes within the sequence as defined by Dayoff, et al., Atlas of Protein Sequence and Structure vol.5, 5 supp.3, pp.345-362, (M.O. Dayoff, ed., Nat'l BioMed. Res. Fd'n, Washington D.C. 1979.)

The currently most preferred protein sequences useful as morphogens in this invention include those 10 having greater than 60% identity, preferably greater than 65% identity, with the amino acid sequence defining the conserved six cysteine skeleton of hOP1 (e.g., residues 43-139 of Seq. ID No. 5). These most preferred sequences include both allelic and species 15 variants of the OP-1 and OP-2 proteins, including the Drosophila 60A protein. Accordingly, in still another preferred aspect, the invention includes morphogens comprising species of polypeptide chains having the generic amino acid sequence referred to herein as 20 "OPX", which defines the seven cysteine skeleton and accommodates the identities between the various identified mouse and human OP1 and OP2 proteins. OPX is presented in Seq. ID No. 29. As described therein, each Xaa at a given position independently is selected 25 from the residues occurring at the corresponding position in the C-terminal sequence of mouse or human OP1 or OP2 (see Seq. ID Nos. 5-8 and/or Seq. ID Nos. 16-23).

30 II. Formulations and Methods for Administering Therapeutic Agents

The morphogens or morphogen-stimulating agents may be provided to an individual by any suitable means, 35 preferably by oral, rectal or other direct

- 46 -

administration or, alternatively, by systemic administration.

The suitability of systemic administration is demonstrated by the detection of endogenous morphogen in milk and human serum described, for example, in international application US92/07432 (WO93/05751) and in Example 2, below. Where the morphogen is to be provided parenterally, such as by intravenous, subcutaneous, intramuscular, intraorbital, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal or vaginal administration, the morphogen preferably comprises part of an aqueous solution. The solution is physiologically acceptable so that in addition to delivery of the desired morphogen to the patient, the solution does not otherwise adversely affect the patient's electrolyte and volume balance. The aqueous medium for the morphogen thus may comprise normal physiologic saline (0.85% NaCl, 0.15M), pH 7-7.4. The aqueous solution containing the morphogen can be made, for example, by dissolving the protein in 50% ethanol containing acetonitrile in 0.1% trifluoroacetic acid (TFA) or 0.1% HCl, or equivalent solvents. One volume of the resultant solution then is added, for example, to ten volumes of phosphate buffered saline (PBS), which further may include 0.1-0.2% human serum albumin (HSA). The resultant solution preferably is vortexed extensively. If desired, a given morphogen may be made more soluble by association with a suitable molecule. For example, the pro form of the morphogenic protein comprises a species that is soluble in physiological solutions. In fact, the endogenous protein is thought to be transported (e.g., secreted and circulated) in this form. This soluble form of the protein may be

- 47 -

obtained from the culture medium of morphogen-secreting cells. Alternatively, a soluble species may be formulated by complexing the mature dimer, (or an active fragment thereof) with part or all of a pro domain as described herein below (see Section II.A.). Other components, including various serum proteins, also may be useful.

Useful solutions for parenteral administration may be prepared by any of the methods well known in the pharmaceutical art, described, for example, in Remington's Pharmaceutical Sciences (Gennaro, A., ed.), Mack Pub., 1990. Formulations may include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. Other potentially useful parenteral delivery systems for these morphogens include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for parenteral administration may also include cutric acid for vaginal administration.

Preferably, the morphogens described herein are administered directly e.g., topically, for example, by oral or rectal administration, or by directly applying the therapeutic formulation onto the desired tissue. Oral administration of proteins as therapeutics generally is not practiced as most proteins are readily degraded by digestive enzymes and acids in the mammalian digestive system before they can be absorbed into the bloodstream. However, the morphogens described herein typically are acid stable and protease-resistant (see, for example, U.S. Pat.No. 4,968,590.) In addition, at least one morphogen, OP-1,

- 48 -

has been identified in mammary gland extract, colostrum and 57-day milk. Moreover, the OP-1 purified from mammary gland extract is morphogenically active. Specifically, this protein induces endochondral bone formation in mammals when implanted subcutaneously in association with a suitable matrix material, using a standard in vivo bone assay, such as is disclosed in U.S. Pat.No. 4,968,590. Moreover, as described above, the morphogen also is detected in the bloodstream.

These findings indicate that oral administration is a viable means for administering morphogens to an individual. In addition, while the mature forms of certain morphogens described herein typically are sparingly soluble, the morphogen form found in milk (and mammary gland extract and colostrum) is readily soluble, probably by association of the mature, morphogenically active form with part or all of the pro domain of the intact sequence and/or by association with one or more milk components. Accordingly, the compounds provided herein also may be associated with molecules capable of enhancing their solubility in vitro or in vivo.

For oral mucositis treatments the morphogens or morphogen-stimulating agents (herein below referred to collectively as "therapeutic agent") may be formulated into an oral rinse similar to a mouthwash, where the liquid is swished around in the mouth so that the therapeutic agent is brought in contact with the oral mucosa to maximize treatment of lesions.

Alternatively, the therapeutic agent may be formulated as part of a slow dissolving troche or lozenge, or dispersed in a gum base suitable for a chewing gum, such that the agent is released with mastication.

35

- 49 -

Longer contact with the mucosal surface of the mouth cavity or elsewhere in the G.I. tract can be attained by direct topical administration, using a suitable vehicle which is capable of coating mucosa.

- 5 Typical examples are pectin-containing formulations or sucralfate suspensions, such as are found in Kaopectate and Milk of Magnesia. Formulations for direct administration also may include glycerol and other compositions of high viscosity. Tissue adhesives
- 10 capable of adhering to the mucosal tissue surface and maintaining the therapeutic agent at the tissue locus, also may be used. Useful adhesive compositions include hydroxypropyl-cellulose-containing solutions, such as is found in Orabase[®] (Colgate-Hoyt Laboratories,
- 15 Norwood, MA), or fibrinogen/thrombin-containing solutions. Another useful adhesive is the bio-adhesive described in US Patent No. 5,197,973. Preferably these formulations are painted onto the tissue surface or formulated as an aerosol and sprayed onto the tissue
- 20 surface. As for parenteral administration, the therapeutic agent may be associated with a molecule that enhances solubility. For example, addition of 0.2% casein increases solubility of the mature active form of OP-1 by 80%. Another useful molecule is a
- 25 morphogen pro domain.

For all treatments of the gastrointestinal tract, the therapeutic agent also may be formulated into a solid or liquid to be consumed or as an inhalant. For

30 treatments of the lower bowel, formulations for rectal administration may be preferable, and may include suppositories, creams, gels, lotions and the like.

In all applications, biocompatible, preferably

35 bior sorbabl , p lym rs, including, for example,

- 50 -

- hyaluronic acid, collagen, polybutyrate, tricalcium phosphate, glycolide, lactide and lactide/glycolide copolymers, also may be useful excipients to control the release of the morphogen in vivo. Tablets or
- 5 capsules may be prepared by employing additives such as pharmaceutically acceptable carriers (e.g., lactose, corn starch, light silicic anhydride, microcrystalline cellulose, sucrose), binders (e.g., alpha-form starch, methylcellulose, carboxymethylcellulose,
- 10 hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone), disintegrating agents (e.g., carboxymethylcellulose calcium, starch, low substituted hydroxypropylcellulose), surfactants [e.g., Tween 80 Kao-Atlas), Pluronic F68 (Asahi Denka, Japan);
- 15 polyoxyethylene-polyoxypropylene copolymer)], antioxidants (e.g., L-cysteine, sodium sulfite, sodium ascorbate), lubricants (e.g., magnesium stearate, talc), and the like.
- 20 Formulations for inhalation administration may contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in
- 25 the form of nasal drops, or as a gel to be applied intranasally. Formulations for rectal administration also may include methoxy salicylate. The formulations for rectal administration also can be a spreadable cream, gel, suppository, foam, lotion or ointment
- 30 having a pharmaceutically acceptable nontoxic vehicle or carrier. Biocompatible, preferably bioresorbable, polymers, including, for example, hyaluronic acid, collagen, polybutyrate, tricalcium phosphate, lactide and lactide/glycolide copolymers, also may be useful
- 35 excipients to control the release of the morphogen in vivo.

- 51 -

The compounds provided herein also may be associated with molecules capable of targeting the morphogen or morphogen-stimulating agent to the gastrointestinal barrier tissue. For example, an
5 antibody, antibody fragment, or other binding protein that interacts specifically with a surface molecule on basal epithelial cells, may be used. Useful targeting molecules may be designed, for example, using the single chain binding site technology disclosed, for
10 example, in U.S. Pat. No. 5,091,513.

As described above, the morphogens provided herein share significant sequence homology in the C-terminal active domains. By contrast, the sequences typically
15 diverge significantly in the sequences which define the pro domain. Accordingly, the pro domain is thought to be morphogen-specific. As described above, it is also known that the various morphogens identified to date are differentially expressed in different tissues.
20 Accordingly, without being limited to any given theory, it is likely that, under natural conditions in the body, selected morphogens typically act on a given tissue. Accordingly, part or all of the pro domains which have been identified associated with the active
25 form of the morphogen in solution, may serve as targeting molecules for the morphogens described herein. For example, the pro domains may interact specifically with one or more molecules at the target tissue to direct the morphogen associated with the pro
30 domain to that tissue. Accordingly, another useful targeting molecule for targeting a morphogen to gastrointestinal barrier tissues may include part or all of a morphogen pro domain, particularly part or all of a pro domain normally associated with an endogenous
35 morphogen known to act on GI tract tissue. As

- 52 -

described above, morphogen species comprising the pro domain may be obtained from the culture medium of morphogen-secreting mammalian cells. Alternatively, a tissue-targeting species may be formulated by

- 5 complexing the mature dimer (or an active fragment thereof) with part or all of a pro domain. Example 1 describes a protocol for identifying morphogen-expressing tissue and/or morphogen target tissue.

10

- Finally, the morphogens or morphogen-stimulating agents provided herein may be administered alone or in combination with other molecules known to be beneficial in treating gastrointestinal tract ulcers, particularly
- 15 symptom-alleviating cofactors. Useful pharmaceutical cofactors include analgesics and anesthetics such as xylocaine, benzocaine and the like; antiseptics such as chlorohexidine; anti-viral and anti-fungal agents; and antibiotics, including aminoglycosides, macrolides,
- 20 penicillins, and cephalosporins. Other potentially useful cofactors include antisecretory agents such as H₂-receptor antagonists (e.g., cimetidine, ranitidine, famotidine, roxatidine acetate), muscarine receptor antagonists (e.g., Pirenzepine), and antacids such as
- 25 aluminum hydroxide gel, magnesium hydroxide and sodium bicarbonate. Such agents may be administered either separately or as components of the therapeutic composition containing morphogens or morphogen-stimulating agents.

30

- The compositions can be formulated for parenteral or direct administration to humans or other mammals in therapeutically effective amounts, e.g., amounts which provide appropriate concentrations for a time
- 35 sufficient to protect the patient's gastrointestinal

- 53 -

luminal lining from lesion formation, including amounts which limit the proliferation of epithelial cells, particularly the basal epithelial cells of the G.I. tract, amounts which limit the inflammation associated with the ulcerative diseases and disorders described above, and amounts sufficient to stimulate lesion repair and tissue regeneration.

As will be appreciated by those skilled in the art, the concentration of the compounds described in a therapeutic composition will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, and the route of administration. The preferred dosage of drug to be administered also is likely to depend on such variables as the type and extent of progression of the ulcerative disease, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound excipients, and its route of administration. In general terms, the compounds of this invention may be provided in an aqueous physiological buffer solution containing about 0.001 to 10% w/v compound for parenteral administration. Typical dose ranges are from about 10 ng/kg to about 1 g/kg of body weight per day; a preferred dose range is from about 0.1 μ g/kg to 100 mg/kg of body weight per day. Optimally, the morphogen dosage given is between 0.1-100 μ g of protein per kilogram weight of the patient. Administration may be a single dose per day, or may include multiple doses, such as multiple rinsings with a mouthwash, e.g., a 1 minute rinse three or four times daily. No obvious induced pathological lesions are induced when mature morph gen (e.g., OP-1, 20 μ g) is administered

- 54 -

daily to normal growing rats for 21 consecutive days. Moreover, 10 μ g systemic injections of morphogen (e.g., OP-1) injected daily for 10 days into normal newborn mice does not produce any gross abnormalities.

5

In administering morphogens systemically in the methods of the present invention, preferably a large volume loading dose is used at the start of the treatment. The treatment then is continued with a maintenance dose. Further administration then can be determined by monitoring at intervals the levels of the morphogen in the blood using, for example, a morphogen-specific antibody and standard immunoassay procedures.

15 Where injury to the mucosa is induced deliberately or incidentally, as part of, for example, a chemical or radiation therapy, the morphogen preferably is provided just prior to, or concomitant with induction of the treatment. Preferably, the morphogen is administered prophylactically in a clinical setting. Optimally, the morphogen dosage given is between 0.1-100 μ g of protein per kilogram weight of the patient. Similarly, the morphogen may be administered prophylactically to individuals at risk for ulcer formation, including xerostomatic or immune-compromised individuals, regardless of etiology.

An effective amount of an agent capable of stimulating endogenous morphogen levels also may be administered by any of the routes described above. For example, an agent capable of stimulating morphogen production in and/or secretion to G.I. tract tissue cells may be provided to a mammal. A method for identifying and testing agents capable of modulating the levels of endogenous morphogens in a given tissue

- 55 -

is described generally herein in Example 10, and in detail in international application US 92/07358 (WO93/04692). In addition, Example 1 describes a protocol for determining morphogen-expressing tissue.

5 Briefly, candidate compounds can be identified and tested by incubating the compound in vitro with a test tissue or cells thereof, for a time sufficient to allow the compound to affect the production, i.e., the expression and/or secretion, of a morphogen produced by
10 the cells of that tissue. Here, suitable tissue or cultured cells of a tissue preferably would include cells of the G.I. tract barrier. For example, suitable tissue for testing may include cultured cells isolated from the basal epithelium and mucosa, and the like.

15 A currently preferred detection means for evaluating the level of the morphogen in culture upon exposure to the candidate compound comprises an immunoassay utilizing an antibody or other suitable
20 binding protein capable of reacting specifically with a morphogen and being detected as part of a complex with the morphogen. Immunoassays may be performed using standard techniques known in the art and antibodies raised against a morphogen and specific for that
25 morphogen. As described herein, morphogens may be isolated from natural-sourced material or they may be recombinantly produced. Agents capable of stimulating endogenous morphogens then may be formulated into pharmaceutical preparations and administered as
30 described herein.

II.A. Soluble Morphogen Complexes

A currently preferred form of the morphogen useful
35 in therapeutic formulations, having improved solubility

- 56 -

in aqueous solutions and consisting essentially of amino acids, is a dimeric morphogenic protein comprising at least the 100 amino acid peptide sequence having the pattern of seven or more cysteine residues
5 characteristic of the morphogen family complexed with a peptide comprising part or all of a pro region of a member of the morphogen family, or an allelic, species or other sequence variant thereof. Preferably, the dimeric morphogenic protein is complexed with two
10 peptides. Also, the dimeric morphogenic protein preferably is noncovalently complexed with the pro region peptide or peptides. The pro region peptides also preferably comprise at least the N-terminal eighteen amino acids that define a given morphogen
15 pro region. In a most preferred embodiment, peptides defining substantially the full length pro region are used.

Other soluble forms of morphogens include dimers of
20 the uncleaved pro forms of these proteins, as well as "hemi-dimers" wherein one subunit of the dimer is an uncleaved pro form of the protein, and the other subunit comprises the mature form of the protein, including truncated forms thereof, preferably
25 noncovalently associated with a cleaved pro domain peptide.

As described above, useful pro domains include the full length pro regions, as well as various truncated
30 forms hereof, particularly truncated forms cleaved at proteolytic Arg-Xaa-Xaa-Arg cleavage sites. For example; in OP-1, possible pro sequences include sequences defined by residues 30-292 (full length form); 48-292; and 158-292. Soluble OP-1 complex
35 stability is enhanced when the pro region comprises the

- 57 -

full length form rather than a truncated form, such as the 48-292 truncated form, in that residues 30-47 show sequence homology to the N-terminal portions of other morphogens, and are believed to have particular utility in enhancing complex stability for all morphogens. Accordingly, currently preferred pro sequences are those encoding the full length form of the pro region for a given morphogen. Other pro sequences contemplated to have utility include biosynthetic pro sequences, particularly those that incorporate a sequence derived from the N-terminal portion of one or more morphogen pro sequences.

As will be appreciated by those having ordinary skill in the art, useful sequences encoding the pro region may be obtained from genetic sequences encoding known morphogens. Alternatively, chimeric pro regions can be constructed from the sequences of one or more known morphogens. Still another option is to create a synthetic sequence variant of one or more known pro region sequences.

In another preferred aspect, useful pro region peptides include polypeptide chains comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a DNA or RNA sequence encoding at least the N-terminal eighteen amino acids of the pro region sequence for OP1 or OP2, e.g., nucleotides 136-192 and 152-211 of Seq. ID No. 16 and 20, respectively.

II.A1. Isolation of Soluble morphogen complex from conditioned media or body fluid

Morphogens are expressed from mammalian cells as soluble complexes. Typically, however the complex is

- 58 -

disassociated during purification, generally by exposure to denaturants often added to the purification solutions, such as detergents, alcohols, organic solvents, chaotropic agents and compounds added to

5 reduce the pH of the solution. Provided below is a currently preferred protocol for purifying the soluble proteins from conditioned media (or, optionally, a body fluid such as serum, cerebro-spinal or peritoneal fluid), under non-denaturing conditions. The method is

10 rapid, reproducible and yields isolated soluble morphogen complexes in substantially pure form.

Soluble morphogen complexes can be isolated from conditioned media using a simple, three step

15 chromatographic protocol performed in the absence of denaturants. The protocol involves running the media (or body fluid) over an affinity column, followed by ion exchange and gel filtration chromatographies. The affinity column described below is a Zn-IMAC column.

20 The present protocol has general applicability to the purification of a variety of morphogens, all of which are anticipated to be isolatable using only minor modifications of the protocol described below. An alternative protocol also envisioned to have utility an

25 immunoaffinity column, created using standard procedures and, for example, using antibody specific for a given morphogen pro domain (complexed, for example, to a protein A-conjugated Sepharose column.) Protocols for developing immunoaffinity columns are

30 well described in the art, (see, for example, Guide to Protein Purification, M. Deutscher, ed., Academic Press, San Diego, 1990, particularly sections VII and XI.)

- 59 -

In this experiment OP-1 was expressed in mammalian CHO (chinese hamster ovary) cells as described in the art (see, for example, international application US90/05903 (WO91/05802).) The CHO cell conditioned media containing 0.5% FBS was initially purified using Immobilized Metal-Ion Affinity Chromatography (IMAC). The soluble OP-1 complex from conditioned media binds very selectively to the Zn-IMAC resin and a high concentration of imidazole (50 mM imidazole, pH 8.0) is required for the effective elution of the bound complex. The Zn-IMAC step separates the soluble OP-1 from the bulk of the contaminating serum proteins that elute in the flow through and 35 mM imidazole wash fractions. The Zn-IMAC purified soluble OP-1 is next applied to an S-Sepharose cation-exchange column equilibrated in 20 mM NaPO_4 (pH 7.0) with 50 mM NaCl. This S-Sepharose step serves to further purify and concentrate the soluble OP-1 complex in preparation for the following gel filtration step. The protein was applied to a Sephacryl S-200HR column equilibrated in TBS. Using substantially the same protocol, soluble morphogens also may be isolated from one or more body fluids, including serum, cerebro-spinal fluid or peritoneal fluid.

25

IMAC was performed using Chelating-Sepharose (Pharmacia) that had been charged with three column volumes of 0.2 M ZnSO_4 . The conditioned media was titrated to pH 7.0 and applied directly to the Zn-IMAC resin equilibrated in 20 mM HEPES (pH 7.0) with 500 mM NaCl. The Zn-IMAC resin was loaded with 80 mL of starting conditioned media per mL of resin. After loading, the column was washed with equilibration buffer and most of the contaminating proteins were eluted with 35 mM imidazole (pH 7.0) in equilibration

35

- 60 -

buffer. The soluble OP-1 complex then is eluted with 50 mM imidazole (pH 8.0) in 20 mM HEPES and 500 mM NaCl.

5 The 50 mM imidazole eluate containing the soluble OP-1 complex was diluted with nine volumes of 20 mM NaPO_4 (pH 7.0) and applied to an S-Sepharose (Pharmacia) column equilibrated in 20 mM NaPO_4 (pH 7.0) with 50 mM NaCl. The S-Sepharose resin was loaded with
10 an equivalent of 800 mL of starting conditioned media per mL of resin. After loading the S-Sepharose column was washed with equilibration buffer and eluted with 100 mM NaCl followed by 300 mM and 500 mM NaCl in 20 mM NaPO_4 (pH 7.0). The 300 mM NaCl pool was further
15 purified using gel filtration chromatography. Fifty mls of the 300 mM NaCl eluate was applied to a 5.0 X 90 cm Sephacryl S-200HR (Pharmacia) equilibrated in Tris buffered saline (TBS), 50 mM Tris, 150 mM NaCl (pH 7.4). The column was eluted at a flow rate of 5
20 mL/minute collecting 10 mL fractions. The apparent molecular of the soluble OP-1 was determined by comparison to protein molecular weight standards (alcohol dehydrogenase (ADH, 150 kDa), bovine serum albumin (BSA, 68 kDa), carbonic anhydrase (CA, 30 kDa)
25 and cytochrome C (cyt C, 12.5 kDa). The purity of the S-200 column fractions was determined by separation on standard 15% polyacrylamide SDS gels stained with coomassie blue. The identity of the mature OP-1 and the pro-domain was determined by N-terminal sequence
30 analysis after separation of the mature OP-1 from the pro-domain using standard reverse phase C18 HPLC.

The soluble OP-1 complex elutes with an apparent molecular weight of 110 kDa. This agrees well with the
35 predicted composition of the soluble OP-1 complex with

- 61 -

one mature OP-1 dimer (35-36 kDa) associated with two pro-domains (39 kDa each). Purity of the final complex can be verified by running the appropriate fraction in a reduced 15% polyacrylamide gel.

5

The complex components can be verified by running the complex-containing fraction from the S-200 or S-200HR columns over a reverse phase C18 HPLC column and eluting in an acetonitrile gradient (in 0.1% TFA),
10 using standard procedures. The complex is dissociated by this step, and the pro domain and mature species elute as separate species. These separate species then can be subjected to N-terminal sequencing using standard procedures (see, for example, Guide to
15 Protein Purification, M. Deutscher, ed., Academic Press, San Diego, 1990, particularly pp. 602-613), and the identity of the isolated 36kD, 39kDa proteins confirmed as mature morphogen and isolated, cleaved pro domain, respectively. N-terminal sequencing of the
20 isolated pro domain from mammalian cell produced OP-1 revealed 2 forms of the pro region, the intact form (beginning at residue 30 of Seq. ID No. 16) and a truncated form, (beginning at residue 48 of Seq. ID No. 16.) N-terminal sequencing of the polypeptide subunit
25 of the isolated mature species reveals a range of N-termini for the mature sequence, beginning at residues 293, 300, 313, 315, 316, and 318, of Seq. ID No. 16, all of which are active as demonstrated by the standard bone induction assay.

30

II.A2. In Vitro Soluble Morphogen Complex Formation

As an alternative to purifying soluble complexes from culture media or a body fluid, soluble complexes
35 may be formulated from purified pro domains and matur

- 62 -

dimeric species. Successful complex formation apparently requires association of the components under denaturing conditions sufficient to relax the folded structure of these molecules, without affecting

5 disulfide bonds. Preferably, the denaturing conditions mimic the environment of an intracellular vesicle sufficiently such that the cleaved pro domain has an opportunity to associate with the mature dimeric species under relaxed folding conditions. The

10 concentration of denaturant in the solution then is decreased in a controlled, preferably step-wise manner, so as to allow proper refolding of the dimer and pro regions while maintaining the association of the pro domain with the dimer. Useful denaturants include 4-6M

15 urea or guanidine hydrochloride (GuHCl), in buffered solutions of pH 4-10, preferably pH 6-8. The soluble complex then is formed by controlled dialysis or dilution into a solution having a final denaturant concentration of less than 0.1-2M urea or GuHCl,

20 preferably 1-2 M urea or GuHCl, which then preferably can be diluted into a physiological buffer. Protein purification/renaturing procedures and considerations are well described in the art, and details for developing a suitable renaturing protocol readily can

25 be determined by one having ordinary skill in the art. One useful text on the subject is Guide to Protein Purification, M. Deutscher, ed.; Academic Press, San Diego, 1990, particularly section V. Complex formation also may be aided by addition of one or more chaperone

30 proteins.

II.A3. Stability of Soluble Morphogen Complexes

The stability of the highly purified soluble

35 morphogen complex in a physiological buffer, e.g.,

- 63 -

tris-buffered saline (TBS) and phosphate-buffered saline (PBS), can be enhanced by any of a number of means. Currently preferred is by means of a pro region that comprises at least the first 18 amino acids of the pro sequence (e.g., residues 30-47 of Seq. ID NO. 16 for OP-1), and preferably is the full length pro region. Residues 30-47 show sequence homology to the N-terminal portion of other morphogens and are believed to have particular utility in enhancing complex stability for all morphogens. Other useful means for enhancing the stability of soluble morphogen complexes include three classes of additives. These additives include basic amino acids (e.g., L-arginine, lysine and betaine); nonionic detergents (e.g., Tween 80 or Nonidet P-120); and carrier proteins (e.g., serum albumin and casein). Useful concentrations of these additives include 1-100 mM, preferably 10-70 mM, including 50 mM, basic amino acid; 0.01-1.0%, preferably 0.05-0.2%, including 0.1% (v/v) nonionic detergent; and 0.01-1.0%, preferably 0.05-0.2%, including 0.1% (w/v) carrier protein.

III. Examples

Example 1. Identification of Morphogen-Expressing Tissue

Determining the tissue distribution of morphogens may be used to identify different morphogens expressed in a given tissue, as well as to identify new, related morphogens. Tissue distribution also may be used to identify useful morphogen-producing tissue for use in screening and identifying candidate morphogen-stimulating agents. The morphogens (or their mRNA

- 64 -

transcripts) readily are identified in different tissues using standard methodologies and minor modifications thereof in tissues where expression may be low. For example, protein distribution may be
5 determined using standard Western blot analysis or immunofluorescent techniques, and antibodies specific to the morphogen or morphogens of interest. Similarly, the distribution of morphogen transcripts may be determined using standard Northern hybridization
10 protocols and transcript-specific oligonucleotide probes.

Any probe capable of hybridizing specifically to a transcript, and distinguishing the transcript of
15 interest from other, related transcripts may be used. Because the morphogens described herein share such high sequence homology in their active, C-terminal domains, the tissue distribution of a specific morphogen transcript may best be determined using a probe
20 specific for the pro region of the immature protein and/or the N-terminal region of the mature protein. Another useful sequence is the 3' non-coding region flanking and immediately following the stop codon. These portions of the sequence vary substantially among
25 the morphogens of this invention, and accordingly, are specific for each protein. For example, a particularly useful Vgr-1-specific probe sequence is the PvuII-SacI fragment, a 265 bp fragment encoding both a portion of the untranslated pro region and the N-terminus of the
30 mature sequence (see Lyons et al. (1989) PNAS 86:4554-4558 for a description of the cDNA sequence). Similarly, particularly useful mOP-1-specific probe sequences are the BstXI-BglI fragment, a 0.68 Kb sequence that covers approximately two-thirds of the
35 mOP-1 pro region; a StuI-StuI fragment, a 0.2 Kb

- 65 -

sequence immediately upstream of the 7-cysteine domain;
and the Earl-PstI fragment, an 0.3 Kb fragment
containing a portion of the 3'untranslated sequence
(See Seq. ID No. 18, where the pro region is defined
5 essentially by residues 30-291.) Similar approaches
may be used, for example, with hOP-1 (Seq. ID No. 16)
or human or mouse OP-2 (Seq. ID Nos. 20 and 22.)

Using these morphogen-specific probes, which may be
10 synthetically engineered or obtained from cloned
sequences, morphogen transcripts can be identified in
mammalian tissue, using standard methodologies well
known to those having ordinary skill in the art.
Briefly, total RNA is prepared from various adult
15 murine tissues (e.g., liver, kidney, testis, heart,
brain, thymus and stomach) by a standard methodology
such as by the method of Chomczyaski et al. ((1987)
Anal. Biochem 162:156-159) and described below. Poly
(A)+ RNA is prepared by using oligo (dT)-cellulose
20 chromatography (e.g., Type 7, from Pharmacia LKB
Biotechnology, Inc.). Poly (A)+ RNA (generally 15 µg)
from each tissue is fractionated on a 1%
agarose/formaldehyde gel and transferred onto a Nytran
membrane (Schleicher & Schuell). Following the
25 transfer, the membrane is baked at 80°C and the RNA is
cross-linked under UV light (generally 30 seconds at 1
mW/cm²). Prior to hybridization, the appropriate probe
is denatured by heating. The hybridization is carried
out in a lucite cylinder rotating in a roller bottle
30 apparatus at approximately 1 rev/min for approximately
15 hours at 37°C using a hybridization mix of 40%
formamide, 5 x Denhardts, 5 x SSPE, and 0.1% SDS.
Following hybridization, the non-specific counts are
washed off the filters in 0.1 x SSPE, 0.1% SDS at 50°C.

35

- 66 -

Examples demonstrating the tissue distribution of various morphogens, including Vgr-1, OP-1, BMP2, BMP3, BMP4, BMP5, GDF-1, and OP-2 in developing and adult tissue are disclosed in US92/01968 (WO92/15323), and in 5 Ozkaynak, et al., (1991) Biochem. Biophys. Res. Commun. 179:116-123, and Ozkaynak, et al. (1992) J. Biol. Chem. 267:25220-25227, the disclosures of which are incorporated herein by reference. Using the general probing methodology described herein, Northern blot 10 hybridizations using probes specific for these morphogens to probe brain, spleen, lung, heart, liver and kidney tissue indicate that kidney-related tissue appears to be the primary expression source for OP-1, with brain, heart and lung tissues being secondary 15 sources. OP-1 mRNA also was identified in salivary glands, specifically rat parotid glands, using this probing methodology. Lung tissue appears to be the primary tissue expression source for Vgr-1, BMP5, BMP4 and BMP3. Lower levels of Vgr-1 also are seen in kidney 20 and heart tissue, while the liver appears to be a secondary expression source for BMP5, and the spleen appears to be a secondary expression source for BMP4. GDF-1 appears to be expressed primarily in brain tissue. To date, OP-2 appears to be expressed 25 primarily in early embryonic tissue. Specifically, Northern blots of murine embryos and 6-day post-natal animals shows abundant OP2 expression in 8-day embryos. Expression is reduced significantly in 17-day embryos and is not detected in post-natal animals.

30

Immunolocalization studies using OP-1 specific antibodies also localize the morphogen to both the inner circular and outer longitudinal coats of smooth muscles in the tubular organs of the digestive system 35 during early embryo development (gestation: weeks 5-

- 67 -

13), suggesting the endogenous morphogen also plays a role in tissue morphogenesis of the digestive tract.

Moreover, Northern blot analysis on rat tissue
5 (probed with an mOP-1-specific labelled nucleotide fragment, as described above) identifies OP-1 mRNA in the gastrointestinal tract tissues of growing rats, including the stomach, duodenal and intestine tissues. These data demonstrate that morphogens are both
10 expressed in, and act on, tissues of the GI tract.

Example 2. Active Morphogens in Body Fluids

OP-1 expression has been identified in saliva
15 (specifically, the rat parotid gland, see Example 1), human blood serum, and various milk forms, including mammary gland extract, colostrum, and 57-day bovine milk. Moreover, and as described in international application US92/07432 (WO93/05751), the body fluid-
20 extracted protein is morphogenically active. The discovery that the morphogen naturally is present in milk and saliva, together with the known observation that mature, active OP-1 is acid-stable and protease-resistant, indicate that oral administration is a
25 useful route for therapeutic administration of morphogen to a mammal. Oral administration typically is the preferred mode of delivery for extended or prophylactic therapies. In addition, the identification of morphogen in all milk forms,
30 including colostrum, suggests that the protein may play a significant role in tissue development, including skeletal development, of juveniles.

- 68 -

2.1 Morphogen Detection in Milk

OP-1 was partially purified from rat mammary gland extract and bovine colostrum and 57 day milk by passing
5 these fluids over a series of chromatography columns:
(e.g., cation-exchange, affinity and reverse phase). At
each step the eluant was collected in fractions and
these were tested for the presence of OP-1 by standard
immunoblot. Immunoreactive fractions then were
10 combined and purified further. The final, partially
purified product then was examined for the presence of
OP-1 by Western blot analysis using OP-1-specific
antisera, and tested for in vivo and in vitro activity.

15 OP-1 purified from the different milk sources were
characterized by Western blotting using antibodies
raised against OP-1 and BMP2. Antibodies were prepared
using standard immunology protocols well known in the
art, and as described generally in Example 15, below,
20 using full-length E. coli-produced OP-1 and BMP2 as the
immunogens. In all cases, the purified OP-1 reacted
only with the anti-OP-1 antibody, and not with
anti-BMP2 antibody.

25 The morphogenic activity of OP-1 purified from
mammary gland extract was evaluated in vivo essentially
following the rat model assay described in U.S. Pat.
No. 4,968,590, hereby incorporated by reference.
Briefly, a sample was prepared from each OP-1
30 immunoreactive fraction of the mammary gland
extract-derived OP-1 final product by lyophilizing a
portion (33%) of the fraction and resuspending the
protein in 220 μ l of 50% acetonitrile/0.1% TFA. After
vortexing, 25 mg of collagen matrix was added. The
35 samples were lyophilized overnight, and implanted in

- 69 -

Long Evans rats (Charles River Laboratories, Wilmington, MA, 28-35 days old). Each fraction was implanted in duplicate. For details of the collagen matrix implantation procedure, see, for example, U.S. Pat. No. 4,968,590, hereby incorporated by reference. After 12 days, the implants were removed and evaluated for new bone formation by histological observation as described in U.S. Patent No. 4,968,590. In all cases, the immunoreactive fractions were osteogenically active.

2.2 Morphogen Detection in Serum

Morphogen may be detected in serum using morphogen-specific antibodies. The assay may be performed using any standard immunoassay, such as Western blot (immunoblot) and the like. Preferably, the assay is performed using an affinity column to which the morphogen-specific antibody is bound and through which the sample serum then is poured, to selectively extract the morphogen of interest. The morphogen then is eluted. A suitable elution buffer may be determined empirically by determining appropriate binding and elution conditions first with a control (e.g., purified, recombinantly-produced morphogen.) Fractions then are tested for the presence of the morphogen by standard immunoblot, and the results confirmed by N-terminal sequencing. Preferably, the affinity column is prepared using monoclonal antibodies. Morphogen concentrations in serum or other fluid samples then may be determined using standard protein quantification techniques, including by spectrophotometric absorbance or by quantitation of conjugated antibody.

- 70 -

Presented below is a sample protocol for identifying OP-1 in serum. Following this general methodology other morphogens may be detected in body fluids, including serum. The identification of morphogen in serum further indicates that systemic administration is a suitable means for providing therapeutic concentrations of a morphogen to an individual, and that morphogens likely behave systemically as endocrine-like factors. Finally, using this protocol, fluctuations in endogenous morphogen levels can be detected, and these altered levels may be used as an indicator of tissue dysfunction. Alternatively, fluctuations in morphogen levels may be assessed by monitoring morphogen transcription levels, either by standard Northern blot analysis as described in Example 1, or by in situ hybridization, using a labelled probe capable of hybridizing specifically to morphogen mRNA, and standard RNA hybridization protocols well described in the art and described generally in Example 1.

OP-1 was detected in human serum using the following assay. A monoclonal antibody raised against mammalian, recombinantly produced OP-1 using standard immunology techniques well described in the art and described generally in Example 15, was immobilized by passing the antibody over an agarose-activated gel (e.g., Affi-Gel™, from Bio-Rad Laboratories, Richmond, CA, prepared following manufacturer's instructions) and used to purify OP-1 from serum. Human serum then was passed over the column and eluted with 3M K-thiocyanate. K-thiocyanate fractions then were dialyzed in 6M urea, 20mM PO₄, pH 7.0, applied to a C8 HPLC column, and eluted with a 20 minute, 25-50% acetonitrile/0.1% TFA gradient. Since mature,

- 71 -

recombinantly produced OP-1 homodimers elute between 20-22 minutes, these fractions then were collected and tested for the presence of OP-1 by standard immunoblot using an OP-1 specific antibody as for Example 2.A.

5

Administered or endogenous morphogen levels may be monitored in the therapies described herein by comparing the quantity of morphogen present in a body fluid sample with a predetermined reference value, for example, to evaluate the efficiency of a therapeutic protocol, and the like. In addition, fluctuations in the level of endogenous morphogen antibodies may be detected by this method, most likely in serum, using an antibody or other binding protein capable of interacting specifically with the endogenous morphogen antibody. Detected fluctuations in the levels of the morphogen or endogenous antibody may be used, for example, as indicators of a change in tissue status. For example, as damaged tissue is regenerated and the tissue or organ's function returns to "normal" and, in the absence of additional tissue damage, lower doses of morphogen may be required, and a higher level of circulating morphogen antibody may be measured.

25 Example 3. Morphogen Treatment of Oral Mucositis

Oral mucositis involves ulcerations of the mouth as a consequence of, e.g., radiation therapy or chemotherapy. The course of ulcerative mucositis may be divided into a destructive phase and a healing phase. Since the cells of the basal layer of the oral epithelium divide at a rapid rate, they are susceptible to the antimitogenic and toxic effects of chemotherapy. As a result, atrophic changes occur which then are followed by ulceration. This constitutes the

- 72 -

destructive phase. Following ulcer formation, the lesions slowly resolve during the healing phase.

The example below demonstrates morphogen efficacy in protecting the oral mucosa from oral mucositis in a hamster model, including both inhibiting ulceration and enhancing regeneration of ulcerated tissue. Details of the protocol can be found in Sonis, et al., (1990) Oral Surg. Oral Med. Oral Pathol 69: 437-443, the disclosure of which is incorporated herein by reference. Briefly, golden syrian hamsters (6-8 wks old, Charles River Laboratories, Wilmington, MA) were divided into 3 test groups: Group 1, a placebo (e.g., saline) control, and a morphogen low dose group (100 ng) and a morphogen high dose group (1 μ g), Groups 2 and 3, respectively. Morphogen dosages were provided in 30% ethanol. Each group contained 12 animals.

Beginning on day 0 and continuing through day 5, Groups 2 and 3 received twice daily morphogen applications. On day 3, all groups began the mucositis-induction procedure. 5-fluorouracil was injected intraperitoneally on days 3 (60 mg/kg) and 5 (40 mg/kg). On day 7, the right buccal pouch mucosa was superficially irritated with a calibrated 18 gauge needle. In untreated animals, severe ulcerative mucositis was induced in at least 80% of the animals by day 10.

For each administration of the vehicle control (placebo) or morphogen, administration was performed by first gently drying the cheek pouch mucosa, then providing an even application over the mucosal surface of the vehicle or morphogen material. A hydroxypropylcellulose-based coating was used to

- 73 -

maintain contact of the morphogen with the mucosa.
This coating provided at least 4 hours of contact time.

On day 12, two animals in each group were
5 sacrificed for histological studies. The right buccal
pouch mucosa and underlying connective tissue were
dissected and fixed in 10% formalin using standard
dissection and histology procedures. The specimens
were mounted in paraffin and prepared for histologic
10 examination. Sections then were stained with
hematoxylin and eosin and were examined blindly by
three oral pathologists with expertise in hamster
histology and scored blind against a standard mucositis
panel. The extent of atrophy, cellular infiltration,
15 connective tissue breakdown, degree of ulceration and
epithelialization were assessed.

The mean mucositis score for each group was
determined daily for each experimental group for a
20 period of 21 days by photography and visual examination
of the right buccal cheek pouch. Differences between
groups were determined using the Students' 't' test.
In addition, data was evaluated between groups by
comparing the numbers of animals with severe mucositis
25 using Chi Square statistical analysis. The
significance of differences in mean daily weights also
was determined.

The experimental results are presented in Figs. 1
30 and 2. Figure 1 graphs the effect of morphogen (high
dose, squares; low dose, diamonds) and placebo
(circles) on mean mucositis scores. Both low and high
morphogen doses inhibit lesion formation significantly
in a dose-dependent manner. Fig. 2 (A and B) are
35 photomicrographs of a buccal cheek pouch on day 14,

- 74 -

pretreated with morphogen, high dose (B) or saline alone (A). Significant tissue necrosis, indicated by the dark regions in the tissue, and ulceration, indicated by the light globular areas in the tissue, is
5 evident in the untreated pouch in Fig. 2A. By contrast, the morphogen-treated tissue in Fig. 2B shows healthy tissue with no necrosis and little or no ulceration. In addition, histology results consistently showed significantly reduced amounts of
10 tissue atrophy, cellular debris, and immune effector cells, including activated macrophages and neutrophils, in the morphogen-treated animals, as compared with the untreated, control animals.

15 In a variation on this protocol, morphogen also may be administered daily for several days before mucositis-induction and/or for longer periods following 5-fluorouracil treatments.

20 Example 4. Morphogen Treatment of Duodenal Ulcer Formation

The following example provides a rat model for demonstrating morphogen efficacy in treating duodenal
25 ulcers. A detailed description of the protocol is provided in Pilan et al., (1985) Digestive Diseases and Sciences 30: 240-246, the disclosure of which is incorporated herein by reference.

30 Briefly, Sprague-Dawley female rats (e.g., Charles River Laboratories, 150-200 grams) receive the duodenal ulcerogen cysteamine-HCl at a dose of 25-28 milligrams (mg) per 100 grams (gm) of body weight orally by intragastric gavage 3 times on the same day.
35 Additionally, cortisol is administered subcutaneously

- 75 -

to each rat at a single dose of 5mg of cortisol to 100 gm of body weight to decrease the mortality resulting from the administration of the cysteamine-HCl.

5

Three days after administration of the cysteamine-HCl, rats having penetrating and perforating duodenal ulcers are identified by standard laparotomy and randomized into control and morphogen-treated groups.

10

The rats of Group 1, all of which have ulcers, receive no morphogen and are treated only with saline. The rats of Group 2 each of which also have ulcers, receive 50-100 ng of morphogen per 100 gm of body weight. Group 3 rats, all of which have ulcers, receive 200-500 ng of morphogen per 100 gm of body weight. All treatments are by gavage twice daily until autopsy on day 21, when the ulcers are measured and histologic sections taken.

20

Histology of duodenal sections from morphogen-treated animals is anticipated to show reduced tissue damage associated with duodenal ulcers and/or healed ulcers. Moreover, treatment with morphogen before or concomitantly with ulceration also is anticipated to inhibit ulcer formation and/or to reduce associated tissue damage.

25

Example 5. Gastric acid and Pepsin Secretion of Morphogen-Treated Rats

30

The following example demonstrates morphogen efficacy as determined by gastric acid and pepsin secretion. A detailed description of the protocol is

- 76 -

provided in Pihan et al., disclosed above. Briefly, 18-20 rats are divided into 2 groups, a control group (Group 1) and a morphogen treated group (Group 2).

- 5 All rats are fasted for 24 hours and given either saline vehicle alone (Group 1) or morphogen (e.g., 500 ng/ml, Group 2). The stomachs of the rats then are constricted with a pyloric ligature for one hour.
- 10 Gastric juice is collected from each rat in groups 1 and 2, centrifuged and aliquots processed for acid titration to calculate gastric acid output and pepsin determination. Gastric acid is measured by the acidity of the gastric juices, and pepsin levels are determined
- 15 according to standard protease assays well-known in the art. Since pepsin is the most abundant protease in the stomach, the total protease level is a good measurement of the pepsin level. The gastric juice aliquots are spectrophotometrically analyzed using albumin as a
- 20 substrate. (Szabo, S. et al. (1977) Res. Comm. Chem. Pathol. Pharmacol. 16: 311-323, hereby incorporated by reference).

In both control and morphogen-treated rats normal

25 levels of gastric pepsin output and gastric juice volume can be measured. Morphogen treatment of ulcers of the GI tract is anticipated not to affect significantly the normal levels of gastric acid or pepsin in the GI tract.

30

Example 6. Morphogen Treatment of Ulcerative colitis

Ulcerative colitis involves ulcers of the colon.

The example provided below demonstrates morphogen

35 efficacy in treating ulcerative colitis using a guinea

- 77 -

pig model. A detailed description of the protocol is provided in Onderdonk et al. (1979) Amer. J. Clin. Nutr. 32: 258-265, the disclosure of which is incorporated herein by reference.

5

Briefly, guinea pigs, (e.g., 500-550 gms, Charles River Laboratories) are divided into 3 experimental groups, each group containing multiple animals: a control, Group 1, which receives distilled water to
10 drink; Group 2, which receives distilled water containing 1% degraded carrageenin; and Group 3, which receives distilled water containing 5% degraded carrageenin to drink. Degraded carrageenin is a polysaccharide derived from red seaweeds, (Glaxo
15 Laboratories, Paris, France), and is a known inducer of ulcerative colitis in guinea pigs.

The development of colitis is determined using several criteria: 1) presence of loose and/or bloody
20 feces by visual inspection, 2) detection of occult blood in the feces using Coloscreen III with hemocult developer (Helena Labs, Bumont, TX), and 3) weight loss.

25 At day 25, each animal is anesthetized with Ketamine (3-5 mg/kg) administered intramuscularly and a 3 mm colorectal mucosa biopsy taken using a small nasal scope. All of the specimens are fixed in 15% formaldehyde and examined histologically using
30 hematoxylin and eosin. The pathologic diagnosis of ulcerative colitis is established by the presence of crypt abscesses, lymphocytic infiltration, capillary congestion of the lamina propria and ulceration of the colon mucosa (Onderdonk, (1985) Digestive Disease
35 Science 30:40(s), hereby incorporated by reference).

- 78 -

The severity of ulcerative colitis is graded on a scale of 0 to 3 and expressed as the pathological index according to the standard scoring system (Onderdonk et al. (1979), Amer. J. Clin. Nutrition 32:258.)

5

At day 30, 25% of the guinea pigs in which ulcerative colitis was demonstrated histologically are treated with morphogen and the remaining 25% receive distilled water as a control. Morphogen is administered both at a low dose (e.g., 100 ng/100 gm) in one half of the guinea pigs; and at a high dose (e.g., 500-1000 ng/100 gm), administered orally through a 3 mm bulbed needle, twice per day for a period of 10 days (days 28-37).

15

During treatment, the animals are evaluated clinically and improvements in body weight, stool consistency and reduction or absence of blood in stools recorded. At day 37, all animals are sacrificed with an overdose of pentobarbital (>200 mg/kg) and the entire colon removed for histological evaluation. Tissue damage associated with colon ulcers in morphogen treated animals is anticipated to be reduced and/or the ulcers to be significantly repaired and healed as compared with untreated ulcers.

25

Example 7. Morphogen Inhibition of Epithelial Cell Proliferation

This example demonstrates the ability of morphogens to inhibit epithelial cell proliferation in vitro, as determined by ³H-thymidine uptake using culture cells from a mink lung epithelial cell line (ATCC No. CCL 64, Rockville, MD), and standard mammalian cell culturing procedures. Briefly, cells were grown to confluency in Eagle's minimum essential medium (EMEM) supplemented

35

- 79 -

with 10% fetal bovine serum (FBS), 200 units/ml penicillin, and 200 μ g/ml streptomycin, and used to seed a 48-well cell culture plate at a cell density of 200,000 cells per well. When this culture became

5 confluent, the media was replaced with 0.5 ml of EMEM containing 1% FBS and penicillin/streptomycin and the culture incubated for 24 hours at 37 C. Morphogen test samples in EMEM containing 5% FBS then were added to the wells, and the cells incubated for another 18

10 hours. After incubation, 1.0 μ Ci of 3 H-thymidine in 10 μ l was added to each well, and the cells incubated for four hours at 37 C. The media then was removed and the cells washed once with ice-cold phosphate-buffer saline and DNA precipitated by adding 0.5 ml of 10% TCA to

15 each well and incubating at room temperature of 15 minutes. The cells then were washed three times with ice-cold distilled water, lysed with 0.5 ml 0.4 M NaOH, and the lysate from each well then transferred to a scintillation vial and the radioactivity recorded using

20 a scintillation counter (Smith-Kline Beckman).

The results are presented in Fig. 3A and 3B. The anti-proliferative effect of the various morphogens tested was expressed as the counts of 3 H-thymidine (x

25 1000) integrated into DNA. In this example, the biosynthetic constructs COP-5 and COP-7 were tested in duplicate: COP-7-1 (10 ng) and COP-7-2 (3 ng, Fig. 3A), and COP-5-1 (66 ng) and COP-5-2 (164 ng, Fig. 3B.) Morphogens were compared with untreated cells (negative

30 control) and TGF- β (1 ng), a local-acting factor also known to inhibit epithelial cell proliferation. COP-5 and COP-7 previously have been shown to have osteogenic activity, capable of inducing the complete cascade resulting in endochondral bone formation in a standard

35 rat b n assay (s U.S. Pat. No. 5,011,691.) As is

- 80 -

evident in the figure, the morphogens significantly inhibit cell epithelial cell proliferation. Similar experiments, performed with the morphogens COP-16 and bOP (bone-purified osteogenic protein, a dimeric protein comprising CBMP2 and OP-1) and recombinant OP-1 also inhibit cell proliferation. bOP and COP-16 also induce endochondral bone formation (see US Pat. No. 4,968,590 and 5,011,691.)

10 Example 8. Morphogen Inhibition of Cellular and Humoral Inflammatory Response

Morphogens described herein inhibit multinucleation of mononuclear phagocytic cells under conditions where these cells normally would be activated, e.g., in response to a tissue injury or the presence of a foreign substance. For example, and as described in international application US92/07358 (W093/04692) in the absence of morphogen, an implanted substrate material (e.g., implanted subcutaneously) composed of, for example, mineralized bone, a ceramic such as titanium oxide or any other substrate that provokes multinucleated giant cell formation, rapidly becomes surrounded by multinucleated giant cells, e.g., activated phagocytes stimulated to respond and destroy the foreign object. In the presence of morphogen however, the recruited cells remain in their mononuclear precursor form and the matrix material is undisturbed. Accordingly, the morphogens' effect in maintaining the integrity of the GI tract luminal lining also may include inhibiting activation of these immune effector cells.

In addition, the morphogens described herein also suppress antibody production stimulated in response to

- 81 -

a foreign antigen in a mammal. Specifically, when bovine bone collagen matrix alone was implanted in a bony site in a rat, a standard antibody response to the collagen was stimulated in the rat as determined by standard anti-bovine collagen ELISA experiments performed on blood samples taken at four week intervals following implantation (e.g., between 12 and 20 weeks.) Serum anti-collagen antibody titers, measured by ELISA essentially following the procedure described by Nagler-Anderson et al, (1986) PNAS 83:7443-7446, the disclosure of which is incorporated herein by reference, increased consistently throughout the experiment. However, when the matrix was implanted together with a morphogen (e.g., OP-1, dispersed in the matrix and adsorbed thereto, essentially as described in U.S. Pat. No. 4,968,590) anti-bovine collagen antibody production was suppressed significantly. This ability of morphogen to suppress the humoral response is further evidence of morphogen utility in alleviating tissue damage associated with GI tract ulceration.

Example 9. Morphogen Effect on Fibrogenesis and Scar Tissue Formation

The morphogens described herein induce tissue morphogenesis of damaged or lost tissue. The ability of these proteins to regenerate new tissue enhances the anti-inflammatory effect of these proteins. Provided below are a series of in vitro experiments demonstrating the ability of morphogens to induce migration and accumulation of mesenchymal cells. In addition, the experiments demonstrate that morphogens, unlike TGF- β , do not stimulate fibrogenesis or scar tissue formation. Specifically, morphogens do not stimulate production of collagen, hyaluronic acid (HA)

- 82 -

or metalloproteinases in primary fibroblasts, all of which are associated with fibrogenesis or scar tissue formation. By contrast, TGF- β , a known inducer of fibrosis, but not of tissue morphogenesis as defined
5 herein, does stimulate production of these markers of fibrosis.

Chemotaxis and migration of mesenchymal progenitor cells were measured in modified Boyden chambers
10 essentially as described by Fava, R.A. et al (1991) J. Exp. Med. 173: 1121-1132, the disclosure of which is incorporated herein by reference, using polycarbonate filters of 2, 3 and 8 micron pores to measure migration of progenitor neutrophils, monocytes and fibroblasts.
15 Chemotaxis was measured over a range of morphogen concentrations, e.g., 10^{-20} M to 10^{-12} M OP-1. For progenitor neutrophils and monocytes, 10^{-18} - 10^{-17} M OP-1 consistently induced maximal migration, and 10^{-14} to 10^{-13} M OP-1 maximally induced migration of progenitor
20 fibroblasts. In all cases the chemotactic activity could be inhibited with anti-OP-1 antibody. Similar migration activities also were measured and observed with TGF- β .

25 The effect of morphogen on fibrogenesis was determined by evaluating fibroblast production of hyaluronic acid (HA), collagen, collagenase and tissue inhibitor of metalloproteinases (TIMP).

30 Human fibroblasts were established from explants of infant foreskins and maintained in monolayer culture using standard culturing procedures. (See, for example, (1976) J. Exp. Med. 144: 1188-1203.) Briefly, fibroblasts were grown in maintenance medium consisting
35 of Eagle's MEM, supplemented with nonessential amino

- 83 -

acids, ascorbic acid (50 $\mu\text{g/ml}$), NaHCO_3 and HEPES buffers (pH 7.2), penicillin (100 U/ml), streptomycin (100 $\mu\text{g/ml}$), amphotericin B (1 $\mu\text{g/ml}$) and 9% heat inactivated FCS. Fibroblasts used as target cells to
5 measure chemotaxis were maintained in 150 mm diameter glass petri dishes. Fibroblasts used in assays to measure synthesis of collagen, hyaluronic acid, collagenase and tissue inhibitors of metalloproteinases (TIMP) were grown in 100 mm diameter plastic tissue
10 culture petri dishes.

The effects of morphogen on fibroblast production of hyaluronic acid, collagens, collagenase and TIMP were determined by standard assays (See, for example,
15 Posttethwaite et al. (1989) J. Clin. Invest. 83: 629-636, Posttethwaite (1988) J. Cell Biol. 106: 311-318 and Clark et al (1985) Arch. Bio-chem Biophys. 241: 36-44, the disclosures of which are incorporated by reference.) For these assays, fibroblasts were
20 transferred to 24-well tissue culture plates at a density of 8×10^4 cells per well. Fibroblasts were grown confluently in maintenance medium containing 9% FCS for 72 h and then grown in serum-free maintenance medium for 24 h. Medium was then removed from each
25 well and various concentrations of OP-1 (recombinantly produced mature or soluble form) or TGF- β -1 (R&D Systems, Minneapolis) in 50 μl PBS were added to triplicate wells containing the confluent fibroblast monolayers. For experiments that measured production
30 of collagenase and TIMP, maintenance medium (450 μl) containing 5% FCS was added to each well, and culture supernatants were harvested from each well 48 h later and stored at -70°C until assayed. For experiments that assessed HA production, maintenance medium (450
35 μl) containing 2.5% FCS was added to each well, and

- 84 -

cultures grown for 48 h. For experiments that measured fibroblast production of collagens, serum-free maintenance medium (450 μ l) without non-essential amino acids was added to each well and cultures grown for 72 h. Fibroblast production of HA was measured by labeling newly synthesized glycosaminoglycans (GAG) with [3 H]-acetate the last 24 h of culture and quantitating released radioactivity after incubation with hyaluronidase from Streptomyces hyalurolyticus (ICN Biochemicals, Cleveland, OH) which specifically degrades hyaluronic acid. Production of total collagen by fibroblasts was measured using a collagenase-sensitive protein assay that reflects [3 H]-proline incorporation the last 24 h of culture into newly synthesized collagens. Collagenase and TIMP protein levels in fibroblast cultures supernatants was measured by specific ELISAs.

As shown in Fig. 4, OP1 does not stimulate significant collagen or HA production, as compared with TGF- β . In the figure, panel A shows OP-1 effect on collagen production, panel B shows TGF- β effect on collagen production, and panels C and D show OP-1 (panel C) and TGF- β (panel D) effect on HA production. The morphogen results were the same whether the soluble or mature form of OP1 was used. By contrast, the latent form of TGF- β (e.g., pro domain-associated form of TGF- β) was not active.

Example 10. Screening Assay for Candidate Compounds which Alter Endogenous Morphogen Levels

Candidate compound(s) which may be administered to affect the level of a given morphogen may be found using the following screening assay, in which the level

- 85 -

of morphogen production by a cell type which produces measurable levels of the morphogen is determined with and without incubating the cell in culture with the compound, in order to assess the effects of the
5 compound on the cell. This can be accomplished by detection of the morphogen either at the protein or RNA level. A more detailed description also may be found in international application US92/07359 (WO93/05172).

10 10.1 Growth of Cells in Culture

Cell cultures of kidney, adrenals, urinary bladder, brain, or other organs, may be prepared as described widely in the literature. For example, kidneys may be
15 explanted from neonatal or new born or young or adult rodents (mouse or rat) and used in organ culture as whole or sliced (1-4 mm) tissues. Primary tissue cultures and established cell lines, also derived from kidney, adrenals, urinary, bladder, brain, mammary, or
20 other tissues may be established in multiwell plates (6 well or 24 well) according to conventional cell culture techniques, and are cultured in the absence or presence of serum for a period of time (1-7 days). Cells may be cultured, for example, in Dulbecco's Modified Eagle
25 medium (Gibco, Long Island, NY) containing serum (e.g., fetal calf serum at 1%-10%, Gibco) or in serum-deprived medium, as desired, or in defined medium (e.g., containing insulin, transferrin, glucose, albumin, or other growth factors).

30

Samples for testing the level of morphogen production includes culture supernatants or cell lysates, collected periodically and evaluated for OP-1 production by immunoblot analysis (Sambrook et al.,
35 eds., 1989, Molecular Cloning, Cold Spring Harbor

- 86 -

Press, Cold Spring Harbor, NY), or a portion of the cell culture itself, collected periodically and used to prepare polyA+ RNA for RNA analysis. To monitor de novo OP-1 synthesis, some cultures are labeled
5 according to conventional procedures with an ^{35}S -methionine/ ^{35}S -cysteine mixture for 6-24 hours and then evaluated to OP-1 synthesis by conventional immunoprecipitation methods.

10 10.2 Determination of Level of Morphogenic Protein

In order to quantitate the production of a morphogenic protein by a cell type, an immunoassay may be performed to detect the morphogen using a polyclonal
15 or monoclonal antibody specific for that protein. For example, OP-1 may be detected using a polyclonal antibody specific for OP-1 in an ELISA, as follows.

1 $\mu\text{g}/100 \mu\text{l}$ of affinity-purified polyclonal rabbit
20 IgG specific for OP-1 is added to each well of a 96-well plate and incubated at 37°C for an hour. The wells are washed four times with 0.167M sodium borate buffer with 0.15 M NaCl (BSB), pH 8.2, containing 0.1% Tween 20. To minimize non-specific binding, the wells
25 are blocked by filling completely with 1% bovine serum albumin (BSA) in BSB and incubating for 1 hour at 37°C. The wells are then washed four times with BSB containing 0.1% Tween 20. A 100 μl aliquot of an appropriate dilution of each of the test samples of
30 cell culture supernatant is added to each well in triplicate and incubated at 37°C for 30 min. After incubation, 100 μl biotinylated rabbit anti-OP-1 serum (stock solution is about 1 mg/ml and diluted 1:400 in BSB containing 1% BSA before use) is added to each well
35 and incubated at 37°C for 30 min. The wells are then

- 87 -

washed four times with BSB containing 0.1% Tween 20. 100 μ l strepavidin-alkaline phosphatase (Southern Biotechnology Associates, Inc. Birmingham, Alabama, diluted 1:2000 in BSB containing 0.1% Tween 20 before use) is added to each well and incubated at 37°C for 30 min. The plates are washed four times with 0.5M Tris buffered Saline (TBS), pH 7.2. 50 μ l substrate (ELISA Amplification System Kit, Life Technologies, Inc., Bethesda, MD) is added to each well incubated at room temperature for 15 min. Then, 50 μ l amplifier (from the same amplification system kit) is added and incubated for another 15 min at room temperature. The reaction is stopped by the addition of 50 μ l 0.3 M sulphuric acid. The OD at 490 nm of the solution in each well is recorded. To quantitate OP-1 in culture media, a OP-1 standard curve is performed in parallel with the test samples.

Polyclonal antibody may be prepared as follows.

Each rabbit is given a primary immunization of 100 μ g/500 μ l E. coli produced OP-1 monomer (amino acids 328-431 in SEQ ID NO:5) in 0.1% SDS mixed with 500 μ l Complete Freund's Adjuvant. The antigen is injected subcutaneously at multiple sites on the back and flanks of the animal. The rabbit is boosted after a month in the same manner using incomplete Freund's Adjuvant. Test bleeds are taken from the ear vein seven days later. Additional boosts and test bleeds are performed at monthly intervals until antibody against OP-1 is detected in the serum using an ELISA assay. Then, the rabbit is boosted with 100 μ g of antigen and bled (15 ml per bleed) at days seven and ten after boosting.

Monoclonal antibody specific for a given morphogen may be prepared as follows. A mouse is given tw

- 88 -

injections of E. coli produced OP-1 monomer. The first injection contains 100 μ g of OP-1 in complete Freund's adjuvant and is given subcutaneously. The second injection contains 50 μ g of OP-1 in incomplete adjuvant and is given intraperitoneally. The mouse then receives a total of 230 μ g of OP-1 (amino acids 307-431 in SEQ ID NO:5) in four intraperitoneal injections at various times over an eight month period. One week prior to fusion, the mouse is boosted intraperitoneally with 100 μ g of OP-1 (307-431) and 30 μ g of the N-terminal peptide (Ser₂₉₃-Asn₃₀₉-Cys) conjugated through the added cysteine to bovine serum albumin with SMCC crosslinking agent. This boost was repeated five days (IP), four days (IP), three days (IP) and one day (IV) prior to fusion. The mouse spleen cells are then fused to myeloma (e.g., 653) cells at a ratio of 1:1 using PEG 1500 (Boeringer Mannheim), and the cell fusion is plated and screened for OP-1-specific antibodies using OP-1 (307-431) as antigen. The cell fusion and monoclonal screening then are according to standard procedures well described in standard texts widely available in the art.

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

- 89 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: CREATIVE BIOMOLECULES, INC.
- (B) STREET: 45 SOUTH STREET
- (C) CITY: HOPKINTON
- 10 (D) STATE: MA
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 01748
- (G) TELEPHONE: 1-508-435-9001
- (H) TELEFAX: 1-508-435-0454
- 15 (I) TELEX:

(ii) TITLE OF INVENTION: MORPHOGEN TREATMENT OF GASTROINTESTINAL
ULCERS

20

(iii) NUMBER OF SEQUENCES: 33

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: CREATIVE BIOMOLECULES, INC.
- (B) STREET: 45 SOUTH STREET
- 25 (C) CITY: HOPKINTON
- (D) STATE: MA
- (E) COUNTRY: USA
- (F) ZIP: 01748

30

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- 35 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

35

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- 40 (C) CLASSIFICATION:

40

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:

45

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: KELLEY ESQ, ROBIN D.
- (B) REGISTRATION NUMBER: 34,637
- (C) REFERENCE/DOCKET NUMBER: CRP-074

50

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 617/248-7477
- (B) TELEFAX: 617/248-7100

- 90 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 97 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: protein

(ix) FEATURE:

- 15 (A) NAME/KEY: Protein
 (B) LOCATION: 1..97
 (D) OTHER INFORMATION: /label= GENERIC-SEQ1
 /note= "WHEREIN EACH XAA INDEPENDENTLY INDICATES
 ONE OF THE 20 NATURALLY-OCCURRING L-ISOMER, A-AMINO
 20 ACIDS; OR A DERIVATIVE THEREOF."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

25 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10 15
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa
 20 25 30
 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40 45
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa
 50 55 60
 35 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65 70 75 80
 40 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
 85 90 95
 Xaa

45 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 97 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

55

- 91 -

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..97

(D) OTHER INFORMATION: /label= GENERIC-SEQ2

5 /note= "WHEREIN EACH XAA INDEPENDENTLY INDICATES
ONE OF THE 20 NATURALLY OCCURRING L-ISOMER A-AMINO
ACIDS, OR A DERIVATIVE THEREOF."

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

20 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa
50 55 60

25 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75 80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
85 90 95

30 Xaa

(2) INFORMATION FOR SEQ ID NO:3:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 97 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

45 (A) NAME/KEY: Protein

(B) LOCATION: 1..97

(D) OTHER INFORMATION: /label= GENERIC-SEQ3

50 /note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED
FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS
AS DEFINED IN THE SPECIFICATION."

- 92 -

xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

5 Leu Tyr Val Xaa Phe Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa Xaa Ala
 1 5 10 15
 Pro Xaa Gly Xaa Xaa Ala Xaa Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Pro
 20 25 30
 10 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala Xaa Xaa Xaa Xaa Leu
 35 40 45
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Pro
 50 55 60
 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65 70 75 80
 Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val Xaa Xaa Cys Gly Cys
 85 90 95
 20 Xaa

(2) INFORMATION FOR SEQ ID NO:4:

25

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

35

(ix) FEATURE:

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..102
 (D) OTHER INFORMATION: /label= GENERIC-SEQ4
 40 /note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED
 FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS
 AS DEFINED IN THE SPECIFICATION."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

45

Cys Xaa Xaa Xaa Xaa Leu Tyr Val Xaa Phe Xaa Xaa Xaa Gly Trp Xaa
 1 5 10 15
 Xaa Trp Xaa Xaa Ala Pro Xaa Gly Xaa Xaa Ala Xaa Tyr Cys Xaa Gly
 50 20 25 30
 Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala
 35 40 45
 55 Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50 55 60

SUBSTITUTE SHEET

- 93 -

Xaa Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
 65 70 75 80

5 Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val
 85 90 95

Xaa Xaa Cys Gly Cys Xaa
 100

10 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 15 (A) LENGTH: 139 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
 20

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens
 (F) TISSUE TYPE: HIPPOCAMPUS

25 (ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..139
 (D) OTHER INFORMATION: /label= hOP1-MATURE

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro Lys
 1 5 10 15

35 Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser Ser
 20 25 30

40 Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg
 35 40 45

Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala
 50 55 60

45 Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn
 65 70 75 80

50 Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn Pro
 85 90 95

Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile
 100 105 110

55 Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr
 115 120 125

SUBSTITUTE SHEET

- 94 -

Arg Asn Met Val Val Arg Ala Cys Gly Cys His
130 135

5 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 139 amino acids
(B) TYPE: amino acid
10 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

15 (vi) ORIGINAL SOURCE:

- (A) ORGANISM: MURIDAE
(F) TISSUE TYPE: EMBRYO

20 (ix) FEATURE:

- (A) NAME/KEY: Protein
(B) LOCATION: 1..139
(D) OTHER INFORMATION: /label= HOP1-MATURE

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ser Thr Gly Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro Lys
1 5 10 15
Asn Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser
20 25 30
Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg
35 40 45
Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala
50 55 60
Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn
65 70 75 80
Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn Pro
85 90 95
Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile
100 105 110
Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr
115 120 125
Arg Asn Met Val Val Arg Ala Cys Gly Cys His
130 135

- 95 -

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 139 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: HOMO SAPIENS
 (F) TISSUE TYPE: HIPPOCAMPUS

15

(ix) FEATURE:

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..139
 (D) OTHER INFORMATION: /label= HOP2-MATURE

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ala Val Arg Pro Leu Arg Arg Arg Gln Pro Lys Lys Ser Asn Glu Leu
 1 5 10 15
 Pro Gln Ala Asn Arg Leu Pro Gly Ile Phe Asp Asp Val His Gly Ser
 20 25 30
 His Gly Arg Gln Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Gln
 35 40 45
 Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala
 50 55 60
 Tyr Tyr Cys Glu Gly Glu Cys Ser Phe Pro Leu Asp Ser Cys Met Asn
 65 70 75 80
 Ala Thr Asn His Ala Ile Leu Gln Ser Leu Val His Leu Met Lys Pro
 85 90 95
 Asn Ala Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr
 100 105 110
 Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His
 115 120 125
 Arg Asn Met Val Val Lys Ala Cys Gly Cys His
 130 135

(2) INFORMATION FOR SEQ ID NO:8:

50

(i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 139 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- 96 -

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

5

(A) ORGANISM: MURIDAE

(F) TISSUE TYPE: EMBRYO

(ix) FEATURE:

10

(A) NAME/KEY: Protein

(B) LOCATION: 1..139

(D) OTHER INFORMATION: /label= MOP2-MATURE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

15 Ala Ala Arg Pro Leu Lys Arg Arg Gln Pro Lys Lys Thr Asn Glu Leu
 1 5 10 15

 Pro His Pro Asn Lys Leu Pro Gly Ile Phe Asp Asp Gly His Gly Ser
 20 25 30

20 Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg
 35 40 45

 Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala
 50 55 60

25 Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys Met Asn
 65 70 75 80

30 Ala Thr Asn His Ala Ile Leu Gln Ser Leu Val His Leu Met Lys Pro
 85 90 95

 Asp Val Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr
 100 105 110

35 Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His
 115 120 125

40 Arg Asn Met Val Val Lys Ala Cys Gly Cys His
 130 135

(2) INFORMATION FOR SEQ ID NO:9:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 101 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

55

(A) ORGANISM: bovine

SUBSTITUTE SHEET

- 97 -

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..101

(D) OTHER INFORMATION: /label= CBMP-2A-FX

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Cys Lys Arg His Pro Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn
 1 5 10 15
 Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala Phe Tyr Cys His Gly
 20 25 30
 Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala
 35 40 45
 Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys Ala
 50 55 60
 Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp
 65 70 75 80
 Glu Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp Met Val Val Glu
 85 90 95
 Gly Cys Gly Cys Arg
 100

(2) INFORMATION FOR SEQ ID NO:10:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 101 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

40

(A) ORGANISM: HOMO SAPIENS

(F) TISSUE TYPE: hippocampus

(ix) FEATURE:

45

(A) NAME/KEY: Protein

(B) LOCATION: 1..101

(D) OTHER INFORMATION: /label= CBMP-2B-FX

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

50

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn
 1 5 10 15
 Asp Trp Ile Val Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gly
 20 25 30

SUBSTITUTE SHEET

- 98 -

Asp Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala
 35 40 45
 5 Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Ser Ile Pro Lys Ala
 50 55 60
 Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp
 10 65 70 75 80
 Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu Met Val Val Glu
 85 90 95
 15 Gly Cys Gly Cys Arg
 100

(2) INFORMATION FOR SEQ ID NO:11:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 25 (ii) MOLECULE TYPE: protein
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: DROSOPHILA MELANOGASTER
 30 (ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..101
 (D) OTHER INFORMATION: /label= DPP-FX
 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asp
 1 5 10 15
 40 Asp Trp Ile Val Ala Pro Leu Gly Tyr Asp Ala Tyr Tyr Cys His Gly
 20 25 30
 Lys Cys Pro Phe Pro Leu Ala Asp His Phe Asn Ser Thr Asn His Ala
 35 40 45
 45 Val Val Gln Thr Leu Val Asn Asn Asn Asn Pro Gly Lys Val Pro Lys
 50 55 60
 50 Ala Cys Cys Val Pro Thr Gln Leu Asp Ser Val Ala Met Leu Tyr Leu
 65 70 75 80
 Asn Asp Gln Ser Thr Val Val Leu Lys Asn Tyr Gln Glu Met Thr Val
 85 90 95

SUBSTITUTE SHEET

- 99 -

Val Gly Cys Gly Cys Arg
100

(2) INFORMATION FOR SEQ ID NO:12:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
 15 (A) ORGANISM: XENOPUS

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..102
 20 (D) OTHER INFORMATION: /label= VGL-FX

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

25 Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys Asp Val Gly Trp Gln
 1 5 10 15

Asn Trp Val Ile Ala Pro Gln Gly Tyr Met Ala Asn Tyr Cys Tyr Gly
 20 25 30

30 Glu Cys Pro Tyr Pro Leu Thr Glu Ile Leu Asn Gly Ser Asn His Ala
 35 40 45

Ile Leu Gln Thr Leu Val His Ser Ile Glu Pro Glu Asp Ile Pro Leu
 50 55 60

35 Pro Cys Cys Val Pro Thr Lys Met Ser Pro Ile Ser Met Leu Phe Tyr
 65 70 75 80

40 Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr Glu Asn Met Ala Val
 85 90 95

Asp Glu Cys Gly Cys Arg
 100

45 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 50 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

SUBSTITUTE SHEET

- 100 -

(vi) ORIGINAL SOURCE:

(A) ORGANISM: MURIDAE

(ix) FEATURE:

5

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /label= VGR-1-FX

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

10

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Gln Asp Val Gly Trp Gln
 1 5 10 15

15

Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly
 20 25 30

Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
 35 40 45

20

Ile Val Gln Thr Leu Val His Val Met Asn Pro Glu Tyr Val Pro Lys
 50 55 60

25

Pro Cys Cys Ala Pro Thr Lys Val Asn Ala Ile Ser Val Leu Tyr Phe
 65 70 75 80

Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
 85 90 95

30

Arg Ala Cys Gly Cys His
 100

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

35

(A) LENGTH: 106 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

45

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(F) TISSUE TYPE: brain

50

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..106

(D) OTHER INFORMATION: /note= "GDF-1 (fx)"

- 101 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

5 Cys Arg Ala Arg Arg Leu Tyr Val Ser Phe Arg Glu Val Gly Trp His
 1 5 10 15
 Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Tyr Cys Gln Gly
 20 25 30
 10 Gln Cys Ala Leu Pro Val Ala Leu Ser Gly Ser Gly Gly Pro Pro Ala
 35 40 45
 Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala Ala Ala Pro Gly
 50 55 60
 15 Ala Ala Asp Leu Pro Cys Cys Val Pro Ala Arg Leu Ser Pro Ile Ser
 65 70 75 80
 Val Leu Phe Phe Asp Asn Ser Asp Asn Val Val Leu Arg Gln Tyr Glu
 85 90 95
 Asp Met Val Val Asp Glu Cys Gly Cys Arg
 100 105

25 (2) INFORMATION FOR SEQ ID NO:15:

- (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 30 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Cys Xaa Xaa Xaa Xaa
 1 5

40 (2) INFORMATION FOR SEQ ID NO:16:

- (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1822 base pairs
 (B) TYPE: nucleic acid
 45 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

50 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

SUBSTITUTE SHEET

- 102 -

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS

(F) TISSUE TYPE: HIPPOCAMPUS

5 (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 49..1341

(C) IDENTIFICATION METHOD: experimental

10 (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
 /product= "OP1"
 /evidence= EXPERIMENTAL
 /standard_name= "OP1"

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGTGGGGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG CCGGCGCG ATG CAC GTG 57
 Met His Val
 1

20 CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA 105
 Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala
 5 10 15

25 CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC 153
 Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn
 20 25 30 35

30 GAG GTG CAC TCG AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG 201
 Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg
 40 45 50

35 CGG GAG ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG CCC CAC CGC 249
 Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg
 55 60 65

CGC CGC CCG CAC CTC CAG GGC AAG CAC AAC TCG GCA CCC ATG TTC ATG 297
 Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro Met Phe Met
 70 75 80

40 CTG GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG GGC GGC GGG CCC GGC 345
 Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly Pro Gly
 85 90 95

45 GGC CAG GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC 393
 Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly
 100 105 110 115

CCC CCT CTG GCC AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC GAC 441
 Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp
 120 125 130

50 ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA CAT GAC AAG GAA TTC TTC 489
 Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe
 135 140 145

- 103 -

5	CAC CCA CGC TAC CAC CAT CGA GAG TTC CGG TTT GAT CTT TCC AAG ATC His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile 150 155 160	537
10	CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC CGG ATC TAC AAG GAC Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp 165 170 175	585
15	TAC ATC CGG GAA CGC TTC GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile Ser Val Tyr 180 185 190 195	633
20	CAG GTG CTC CAG GAG CAC TTG GGC AGG GAA TCG GAT CTC TTC CTG CTC Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu Phe Leu Leu 200 205 210	681
25	GAC AGC CGT ACC CTC TGG GCC TCG GAG GAG GGC TGG CTG GTG TTT GAC Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp 215 220 225	729
30	ATC ACA GCC ACC AGC AAC CAC TGG GTG GTC AAT CCG CGG CAC AAC CTG Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu 230 235 240	777
35	GGC CTG CAG CTC TCG GTG GAG ACG CTG GAT GGG CAG AGC ATC AAC CCC Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile Asn Pro 245 250 255	825
40	AAG TTG GCG GGC CTG ATT GGG CGG CAC GGG CCC CAG AAC AAG CAG CCC Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys Gln Pro 260 265 270 275	873
45	TTC ATG GTG GCT TTC TTC AAG GCC ACG GAG GTC CAC TTC CGC AGC ATC Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe Arg Ser Ile 280 285 290	921
50	CGG TCC ACG GGG AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG CCC Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro 295 300 305	969
55	AAG AAC CAG GAA GCC CTG CGG ATG GCC AAC GTG GCA GAG AAC AGC AGC Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser 310 315 320	1017
60	AGC GAC CAG AGG CAG GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe 325 330 335	1065
65	CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG CCT GAA GGC TAC GCC Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala 340 345 350 355	1113
70	GCC TAC TAC TGT GAG GGG GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met 360 365 370	1161

- 104 -

AAC GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC CAC TTC ATC AAC 1209
 Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn
 375 380 385
 5 CCG GAA ACG GTG CCC AAG CCC TGC TGT GCG CCC ACG CAG CTC AAT GCC 1257
 Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala
 390 395 400
 10 ATC TCC GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC CTG AAG AAA 1305
 Ile Ser Val Leu Tyr Phe Asp Ser Ser Asn Val Ile Leu Lys Lys
 405 410 415
 15 TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC 1351
 Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
 420 425 430
 GAGAATTCAG ACCCTTTGGG GCCAAGTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG 1411
 20 GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG 1471
 TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT CAGTGGCAGC 1531
 ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAC 1591
 25 GCATAAAGAA AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA TGCACGGACT 1651
 CGTTTCCAGA GGTAATTATG AGCGCCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG 1711
 30 GCGGTGGCAA GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC CCGGAAGTTC 1771
 CTGTAATAAA TGTCACAATA AAACGAATGA ATGAAAAAAA AAAAAAAAAA A 1822

35 (2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 431 amino acids
 (B) TYPE: amino acid
 40 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

45 Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
 1 5 10 15
 50 Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
 20 25 30
 Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
 35 40 45
 55 Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
 50 55 60

SUBSTITUTE SHEET

- 105 -

Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
 65 70 75 80
 5 Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly
 85 90 95
 Gly Pro Gly Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser
 100 105 110
 10 Thr Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr
 115 120 125
 Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys
 130 135 140
 15 Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu
 145 150 155 160
 20 Ser Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile
 165 170 175
 Tyr Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile
 180 185 190
 25 Ser Val Tyr Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu
 195 200 205
 Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu
 210 215 220
 30 Val Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg
 225 230 235 240
 35 His Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser
 245 250 255
 Ile Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn
 260 265 270
 40 Lys Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe
 275 280 285
 Arg Ser Ile Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser
 290 295 300
 45 Lys Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu
 305 310 315 320
 50 Asn Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr
 325 330 335
 Val Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu
 340 345 350
 55

- 106 -

Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn
 355 360 365
 Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His
 370 375 380
 Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln
 385 390 395 400
 Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile
 405 410 415
 Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
 420 425 430

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1873 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: MURIDAE
 (F) TISSUE TYPE: EMBRYO

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 104..1393
 (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
 /product= "MOP1"
 /note= "MOP1 (CDNA)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CTGCAGCAAG TGACCTCGGG TCGTGGACCG CTGCCCTGCC CCCTCCGCTG CCACCTGGGG 60
 CGGCGCGGGC CCGGTGCCCC GGATCGCGCG TAGAGCCGGC GCG ATG CAC GTG CGC 115
 Met His Val Arg
 1
 TCG CTG CGC GCT GCG GCG CCA CAC AGC TTC GTG GCG CTC TGG GCG CCT 163
 Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro
 5 10 15 20
 CTG TTC TTG CTG CGC TCC GCC CTG GCC GAT TTC AGC CTG GAC AAC GAG 211
 Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn Glu
 25 30 35

- 107 -

5	GTG CAC TCC AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG CGG Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg Arg 40 45 50	259
10	GAG ATG CAG CGG GAG ATC CTG TCC ATC TTA GGG TTG CCC CAT CGC CCG Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg Pro 55 60 65	307
15	CGC CCG CAC CTC CAG GGA AAG CAT AAT TCG GCG CCC ATG TTC ATG TTG Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro Met Phe Met Leu 70 75 80	355
20	GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG AGC GGG CCG GAC GGA CAG Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly Pro Asp Gly Gln 85 90 95 100	403
25	GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC CCC CCT Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly Pro Pro 105 110 115	451
30	TTA GCC AGC CTG CAG GAC AGC CAT TTC CTC ACT GAC GCC GAC ATG GTC Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Met Val 120 125 130	499
35	ATG AGC TTC GTC AAC CTA GTG GAA CAT GAC AAA GAA TTC TTC CAC CCT Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe His Pro 135 140 145	547
40	CGA TAC CAC CAT CGG GAG TTC CGG TTT GAT CTT TCC AAG ATC CCC GAG Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile Pro Glu 150 155 160	595
45	GGC GAA CGG GTG ACC GCA GCC GAA TTC AGG ATC TAT AAG GAC TAC ATC Gly Glu Arg Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp Tyr Ile 165 170 175 180	643
50	CGG GAG CGA TTT GAC AAC GAG ACC TTC CAG ATC ACA GTC TAT CAG GTG Arg Glu Arg Phe Asp Asn Glu Thr Phe Gln Ile Thr Val Tyr Gln Val 185 190 195	691
55	CTC CAG GAG CAC TCA GGC AGG GAG TCG GAC CTC TTC TTG CTG GAC AGC Leu Gln Glu His Ser Gly Arg Glu Ser Asp Leu Phe Leu Leu Asp Ser 200 205 210	739
60	CGC ACC ATC TGG GCT TCT GAG GAG GGC TGG TTG GTG TTT GAT ATC ACA Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp Ile Thr 215 220 225	787
65	GCC ACC AGC AAC CAC TGG GTG GTC AAC CCT CGG CAC AAC CTG GGC TTA Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu Gly Leu 230 235 240	835
70	CAG CTC TCT GTG GAG ACC CTG GAT GGG CAG AGC ATC AAC CCC AAG TTG Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile Asn Pro Lys Leu 245 250 255 260	883

SUBSTITUTE SHEET

- 108 -

5	GCA GGC CTG ATT GGA CGG CAT GGA CCC CAG AAC AAG CAA CCC TTC ATG Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys Gln Pro Phe Met 265 270 275	931
	GTG GCC TTC TTC AAG GCC ACG GAA GTC CAT CTC CGT AGT ATC CGG TCC Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg Ser Ile Arg Ser 280 285 290	979
10	ACG GGG GGC AAG CAG CGC AGC CAG AAT CGC TCC AAG ACG CCA AAG AAC Thr Gly Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro Lys Asn 295 300 305	1027
15	CAA GAG GCC CTG AGG ATG GCC AGT GTG GCA GAA AAC AGC AGC AGT GAC Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser Asp 310 315 320	1075
20	CAG AGG CAG GCC TGC AAG AAA CAT GAG CTG TAC GTC AGC TTC CGA GAC Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp 325 330 335 340	1123
25	CTT GGC TGG CAG GAC TGG ATC ATT GCA CCT GAA GGC TAT GCT GCC TAC Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr 345 350 355	1171
30	TAC TGT GAG GGA GAG TGC GCC TTC CCT CTG AAC TCC TAC ATG AAC GCC Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala 360 365 370	1219
35	ACC AAC CAC GCC ATC GTC CAG ACA CTG GTT CAC TTC ATC AAC CCA GAC Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Asp 375 380 385	1267
40	ACA GTA CCC AAG CCC TGC TGT GCG CCC ACC CAG CTC AAC GCC ATC TCT Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser 390 395 400	1315
45	GTC CTC TAC TTC GAC GAC AGC TCT AAT GTC GAC CTG AAG AAG TAC AGA Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Asp Leu Lys Lys Tyr Arg 405 410 415 420	1363
50	AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCTTCC TGAGACCCTG Asn Met Val Val Arg Ala Cys Gly Cys His 425 430	1413
55	ACCTTTGCGG GGCCACACCT TTCCAAATCT TCGATGTCTC ACCATCTAAG TCTCTCACTG CCCACCTTGG CGAGGAGAAC AGACCAACCT CTCCTGAGCC TTCCCTCACC TCCCAACCGG AAGCATGTAA GGGTTCCAGA AACCTGAGCG TGCAGCAGCT GATGAGCGCC CTTTCCTTCT GGCACGTGAC GGACAAGATC CTACCAGCTA CCACAGCAAA CGCCTAAGAG CAGGAAAAAT GTCTGCCAGG AAAGTGTCCA GTGTCCACAT GGCCCTGGC GCTCTGAGTC TTGAGGAGT	1473 1533 1593 1653 1713

SUBSTITUTE SHEET

- 109 -

AATCGCAAGC CTCGTTGAGC TGCAGCAGAA GGAACGGCTT AGCCAGGGTG GCGCTGGCG 1773
 TCTGTGTGA AGGGAAACCA AGCAGAAGCC ACTGTAATGA TATGTCACAA TAAAACCCAT 1833
 5 GAATGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAATTC 1873

(2) INFORMATION FOR SEQ ID NO:19:

10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 430 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

20 Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
 1 5 10 15

Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
 20 25 30

25 Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
 35 40 45

Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
 50 55 60

30 Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
 65 70 75 80

35 Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly
 85 90 95

Pro Asp Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr
 100 105 110

40 Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp
 115 120 125

Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu
 130 135 140

45 Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser
 145 150 155 160

50 Lys Ile Pro Glu Gly Glu Arg Val Thr Ala Ala Glu Phe Arg Ile Tyr
 165 170 175

Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Gln Ile Thr
 180 185 190

55 Val Tyr Gln Val Leu Gln Glu His Ser Gly Arg Glu Ser Asp Leu Phe
 195 200 205

SUBSTITUTE SHEET

- 110 -

Leu Leu Asp Ser Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val
 210 215 220
 5 Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His
 225 230 235 240
 Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile
 245 250 255
 10 Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys
 260 265 270
 Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg
 15 275 280 285
 Ser Ile Arg Ser Thr Gly Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys
 290 295 300
 20 Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn
 305 310 315 320
 Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val
 325 330 335
 25 Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly
 340 345 350
 Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser
 30 355 360 365
 Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe
 370 375 380
 35 Ile Asn Pro Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu
 385 390 395 400
 Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Asp Leu
 405 410 415
 40 Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
 420 425 430

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1723 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(F) TISSUE TYPE: HIPPOCAMPUS

- 111 -

(ix) FEATURE:

- 5 (A) NAME/KEY: CDS
 (B) LOCATION: 490..1696
 (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
 /product= "hOP2-PP"
 /note= "hOP2 (cDNA)"

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GGCGCCGGCA GAGCAGGAGT GGCTGGAGGA GCTGTGGTTG GAGCAGGAGG TGGCACGGCA 60
 GGGCTGGAGG GCTCCCTATG AGTGGCGGAG ACGGCCAGG AGGCGCTGGA GCAACAGCTC 120
 15 CCACACCGCA CCAAGCGGTG GCTGCAGGAG CTCGCCATC GCCCTGCGC TGCTCGGACC 180
 GCGGCCACAG CCGGACTGGC GGGTACGGCG GCGACAGAGG CATTGGCCGA GAGTCCAGT 240
 20 CCGCAGAGTA GCGCCGGCCT CGAGGCGGTG GCGTCCCGGT CCTCTCCGTC CAGGAGCCAG 300
 GACAGGTGTC GCGCGGCGGG GCTCCAGGGA CGCGCCTGA GGCCGGCTGC CCGCCGTC 360
 CGCCCGCCC CGCCGCCGC CGCCGCCGA GCCCAGCTC CTGCGCTCG GGGCGTCCC 420
 25 AGGCCCTGGG TCGGCCGG AGCCGATGCG CGCCGCTGA GCGCCCCAGC TGAGCGCCC 480
 CGGCCTGCC ATG ACC GCG CTC CCC GGC CCG CTC TGG CTC CTG GGC CTG 528
 30 Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu
 1 5 10
 GCG CTA TGC GCG CTG GGC GGG GGC GGC CCC GGC CTG CGA CCC CCG CCC 576
 Ala Leu Cys Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro
 15 20 25
 35 GGC TGT CCC CAG CGA CGT CTG GGC GCG CGC GAG CGC CGG GAC GTG CAG 624
 Gly Cys Pro Gln Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gln
 30 35 40 45
 40 CGC GAG ATC CTG GCG GTG CTC GGG CTG CCT GGG CGG CCC CGG CCC CGC 672
 Arg Glu Ile Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg
 50 55 60
 GCG CCA CCC GCC GCC TCC CGG CTG CCC GCG TCC GCG CGG CTC TTC ATG 720
 Ala Pro Pro Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met
 65 70 75
 CTG GAC CTG TAC CAC GCC ATG GCC GGC GAC GAC GAC GAG GAC GGC GCG 768
 Leu Asp Leu Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala
 80 85 90
 50 CCC GCG GAG CGG CGC CTG GGC CGC GCC GAC CTG GTC ATG AGC TTC GTT 816
 Pro Ala Glu Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val
 95 100 105
 55

SUBSTITUTE SHEET

- 112 -

	AAC ATG GTG GAG CGA GAC CGT GCC CTG GGC CAC CAG GAG CCC CAT TGG	864
	Asn Met Val Glu Arg Asp Arg Ala Leu Gly His Gln Glu Pro His Trp	
	110 115 120 125	
5	AAG GAG TTC CGC TTT GAC CTG ACC CAG ATC CCG GCT GGG GAG GCG GTC	912
	Lys Glu Phe Arg Phe Asp Leu Thr Gln Ile Pro Ala Gly Glu Ala Val	
	130 135 140	
10	ACA GCT GCG GAG TTC CGG ATT TAC AAG GTG CCC AGC ATC CAC CTG CTC	960
	Thr Ala Ala Glu Phe Arg Ile Tyr Lys Val Pro Ser Ile His Leu Leu	
	145 150 155	
15	AAC AGG ACC CTC CAC GTC AGC ATG TTC CAG GTG GTC CAG GAG CAG TCC	1008
	Asn Arg Thr Leu His Val Ser Met Phe Gln Val Val Gln Glu Gln Ser	
	160 165 170	
20	AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG CTC CGA GCT	1056
	Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gln Thr Leu Arg Ala	
	175 180 185	
25	GGA GAC GAG GGC TGG CTG GTG CTG GAT GTC ACA GCA GCC AGT GAC TGC	1104
	Gly Asp Glu Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys	
	190 195 200 205	
30	TGG TTG CTG AAG CGT CAC AAG GAC CTG GGA CTC CGC CTC TAT GTG GAG	1152
	Trp Leu Leu Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu	
	210 215 220	
35	ACT GAG GAC GGG CAC AGC GTG GAT CCT GGC CTG GCC GGC CTG CTG GGT	1200
	Thr Glu Asp Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly	
	225 230 235	
40	CAA CGG GCC CCA CGC TCC CAA CAG CCT TTC GTG GTC ACT TTC TTC AGG	1248
	Gln Arg Ala Pro Arg Ser Gln Gln Pro Phe Val Val Thr Phe Phe Arg	
	240 245 250	
45	GCC AGT CCG AGT CCC ATC CGC ACC CCT CGG GCA GTG AGG CCA CTG AGG	1296
	Ala Ser Pro Ser Pro Ile Arg Thr Pro Arg Ala Val Arg Pro Leu Arg	
	255 260 265	
50	AGG AGG CAG CCG AAG AAA AGC AAC GAG CTG CCG CAG GCC AAC CGA CTC	1344
	Arg Arg Gln Pro Lys Lys Ser Asn Glu Leu Pro Gln Ala Asn Arg Leu	
	270 275 280 285	
55	CCA GGG ATC TTT GAT GAC GTC CAC GGC TCC CAC GGC CGG CAG GTC TGC	1392
	Pro Gly Ile Phe Asp Asp Val His Gly Ser His Gly Arg Gln Val Cys	
	290 295 300	
60	CGT CGG CAC GAG CTC TAC GTC AGC TTC CAG GAC CTC GGC TGG CTG GAC	1440
	Arg Arg His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Leu Asp	
	305 310 315	
65	TGG GTC ATC GCT CCC CAA GGC TAC TCG GCC TAT TAC TGT GAG GGG GAG	1488
	Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu	
	320 325 330	

SUBSTITUTE SHEET

- 113 -

5	TGC TCC TTC CCA CTG GAC TCC TGC ATG AAT GCC ACC AAC CAC GCC ATC Cys Ser Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala Ile 335 340 345	1536
10	CTG CAG TCC CTG GTG CAC CTG ATG AAG CCA AAC GCA GTC CCC AAG GCG Leu Gln Ser Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala 350 355 360 365	1584
15	TGC TGT GCA CCC ACC AAG CTG AGC GCC ACC TCT GTG CTC TAC TAT GAC Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp 370 375 380	1632
20	AGC AGC AAC AAC GTC ATC CTG CGC AAA GCC CGC AAC ATG GTG GTC AAG Ser Ser Asn Asn Val Ile Leu Arg Lys Ala Arg Asn Met Val Val Lys 385 390 395	1680
	GCC TGC GGC TGC CAC T GAGTCAGCCC GCCCAGCCCT ACTGCAG Ala Cys Gly Cys His 400	1723

(2) INFORMATION FOR SEQ ID NO:21:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 402 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

35	Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15
	Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro Gly Cys Pro 20 25 30
40	Gln Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gln Arg Glu Ile 35 40 45
45	Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Pro Pro 50 55 60
	Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu 65 70 75 80
50	Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala Pro Ala Glu 85 90 95
	Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val 100 105 110
55	Glu Arg Asp Arg Ala Leu Gly His Gln Glu Pr His Trp Lys Glu Phe 115 120 125

SUBSTITUTE SHEET

- 114 -

Arg Phe Asp Leu Thr Gln Ile Pro Ala Gly Glu Ala Val Thr Ala Ala
 130 135 140
 5 Glu Phe Arg Ile Tyr Lys Val Pro Ser Ile His Leu Leu Asn Arg Thr
 145 150 155 160
 Leu His Val Ser Met Phe Gln Val Val Gln Glu Gln Ser Asn Arg Glu
 165 170 175
 10 Ser Asp Leu Phe Phe Leu Asp Leu Gln Thr Leu Arg Ala Gly Asp Glu
 180 185 190
 Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys Trp Leu Leu
 195 200 205
 15 Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp
 210 215 220
 20 Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly Gln Arg Ala
 225 230 235 240
 Pro Arg Ser Gln Gln Pro Phe Val Val Thr Phe Phe Arg Ala Ser Pro
 245 250 255
 25 Ser Pro Ile Arg Thr Pro Arg Ala Val Arg Pro Leu Arg Arg Arg Gln
 260 265 270
 Pro Lys Lys Ser Asn Glu Leu Pro Gln Ala Asn Arg Leu Pro Gly Ile
 275 280 285
 30 Phe Asp Asp Val His Gly Ser His Gly Arg Gln Val Cys Arg Arg His
 290 295 300
 35 Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Leu Asp Trp Val Ile
 305 310 315 320
 Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ser Phe
 325 330 335
 40 Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala Ile Leu Gln Ser
 340 345 350
 Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala Cys Cys Ala
 355 360 365
 45 Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn
 370 375 380
 50 Asn Val Ile Leu Arg Lys Ala Arg Asn Met Val Val Lys Ala Cys Gly
 385 390 395 400
 Cys His

55

- 115 -

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1926 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(vi) ORIGINAL SOURCE:

- 10 (A) ORGANISM: MURIDAE
 (F) TISSUE TYPE: EMBRYO

(ix) FEATURE:

- 15 (A) NAME/KEY: CDS
 (B) LOCATION: 93..1289
 (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
 /product= "mOP2-PP"
 /note= "mOP2 cDNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

	GCCAGGCACA GGTGCGCCGT CTGGTCCTCC CCGTCTGGCG TCAGCCGAGC CCGACCAGCT	60
25	ACCAGTGGAT GCGCGCCGGC TGAAAGTCCG AG ATG GCT ATG CGT CCC GGG CCA Met Ala Met Arg Pro Gly Pro 1 5	113
30	CTC TGG CTA TTG GGC CTT GCT CTG TGC GCG CTG GGA GGC GGC CAC GGT Leu Trp Leu Leu Gly Leu Ala Leu Cys Ala Leu Gly Gly Gly His Gly 10 15 20	161
35	CCG CGT CCC CCG CAC ACC TGT CCC CAG CGT CGC CTG GGA GCG CGC GAG Pro Arg Pro Pro His Thr Cys Pro Gln Arg Arg Leu Gly Ala Arg Glu 25 30 35	209
40	CGC CGC GAC ATG CAG CGT GAA ATC CTG GCG GTG CTC GGG CTA CCG GGA Arg Arg Asp Met Gln Arg Glu Ile Leu Ala Val Leu Gly Leu Pro Gly 40 45 50 55	257
45	CGG CCC CGA CCC CGT GCA CAA CCC GCC GCT GCC CGG CAG CCA GCG TCC Arg Pro Arg Pro Arg Ala Gln Pro Ala Ala Arg Gln Pro Ala Ser 60 65 70	305
50	GCG CCC CTC TTC ATG TTG GAC CTA TAC CAC GCC ATG ACC GAT GAC GAC Ala Pro Leu Phe Met Leu Asp Leu Tyr His Ala Met Thr Asp Asp Asp 75 80 85	353
	GAC GGC GGG CCA CCA CAG GCT CAC TTA GGC CGT GCC GAC CTG GTC ATG Asp Gly Gly Pro Pro Gln Ala His Leu Gly Arg Ala Asp Leu Val Met 90 95 100	401
	AGC TTC GTC AAC ATG GTG GAA CGC GAC CGT ACC CTG GGC TAC CAG GAG Ser Phe Val Asn Met Val Glu Arg Asp Arg Thr Leu Gly Tyr Gln Glu 105 110 115	449

- 116 -

5	CCA CAC TGG AAG GAA TTC CAC TTT GAC CTA ACC CAG ATC CCT GCT GGG Pro His Trp Lys Glu Phe His Phe Asp Leu Thr Gln Ile Pro Ala Gly 120 125 130 135	497
10	GAG GCT GTC ACA GCT GCT GAG TTC CGG ATC TAC AAA GAA CCC AGC ACC Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Glu Pro Ser Thr 140 145 150	545
15	CAC CCG CTC AAC ACA ACC CTC CAC ATC AGC ATG TTC GAA GTG GTC CAA His Pro Leu Asn Thr Thr Leu His Ile Ser Met Phe Glu Val Gln 155 160 165	593
20	GAG CAC TCC AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG Glu His Ser Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gln Thr 170 175 180	641
25	CTC CGA TCT GGG GAC GAG GGC TGG CTG GTG CTG GAC ATC ACA GCA GCC Leu Arg Ser Gly Asp Glu Gly Trp Leu Val Leu Asp Ile Thr Ala Ala 185 190 195	689
30	AGT GAC CGA TGG CTG CTG AAC CAT CAC AAG GAC CTG GGA CTC CGC CTC Ser Asp Arg Trp Leu Leu Asn His His Lys Asp Leu Gly Leu Arg Leu 200 205 210 215	737
35	TAT GTG GAA ACC GCG GAT GGG CAC AGC ATG GAT CCT GGC CTG GCT GGT Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp Pro Gly Leu Ala Gly 220 225 230	785
40	CTG CTT GGA CGA CAA GCA CCA CGC TCC AGA CAG CCT TTC ATG GTA ACC Leu Leu Gly Arg Gln Ala Pro Arg Ser Arg Gln Pro Phe Met Val Thr 235 240 245	833
45	TTC TTC AGG GCC AGC CAG AGT CCT GTG CCG GCC CCT CCG GCA GCG AGA Phe Phe Arg Ala Ser Gln Ser Pro Val Arg Ala Pro Arg Ala Ala Arg 250 255 260	881
50	CCA CTG AAG AGG AGG CAG CCA AAG AAA ACG AAC GAG CTT CCG CAC CCC Pro Leu Lys Arg Arg Gln Pro Lys Lys Thr Asn Glu Leu Pro His Pro 265 270 275	929
55	AAC AAA CTC CCA GGG ATC TTT GAT GAT GGC CAC GGT TCC CGC GGC AGA Asn Lys Leu Pro Gly Ile Phe Asp Asp Gly His Gly Ser Arg Gly Arg 280 285 290 295	977
60	GAG GTT TGC CGC AGG CAT GAG CTC TAC GTC AGC TTC CGT GAC CTT GGC Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly 300 305 310	1025
65	TGG CTG GAC TGG GTC ATC GCC CCC CAG GGC TAC TCT GCC TAT TAC TGT Trp Leu Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys 315 320 325	1073
70	GAG GGG GAG TGT GCT TTC CCA CTG GAC TCC TGT ATG AAC GCC ACC AAC Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn 330 335 340	1121

SUBSTITUTE SHEET

- 117 -

CAT GCC ATC TTG CAG TCT CTG GTG CAC CTG ATG AAG CCA GAT GTT GTC 1169
 His Ala Ile Leu Gln Ser Leu Val His Leu Met Lys Pro Asp Val Val
 345 350 355
 5
 CCC AAG GCA TGC TGT GCA CCC ACC AAA CTG AGT GCC ACC TCT GTG CTG 1217
 Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu
 360 365 370 375
 10
 TAC TAT GAC AGC AGC AAC AAT GTC ATC CTG CGT AAA CAC CGT AAC ATG 1265
 Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His Arg Asn Met
 380 385 390
 15
 GTG GTC AAG GCC TGT GGC TGC CAC TGAGGCCCCG CCCAGCATCC TGCTTCTACT 1319
 Val Val Lys Ala Cys Gly Cys His
 395
 ACCTTACCAT CTGGCCGGGC CCCTCTCCAG AGGCAGAAAC CCTTCTATGT TATCATAGCT 1379
 20
 CAGACAGGGG CAATGGGAGG CCCTTCACTT CCCCTGGCCA CTTCCTGCTA AAATTCTGGT 1439
 CTITCCCACT TCCTCTGTCC TTCATGGGGT TTCGGGGCTA TCACCCCGCC CTCTCCATCC 1499
 25
 TCCTACCCCA AGCATAGACT GAATGCACAC AGCATCCCAG AGCTATGCTA ACTGAGAGGT 1559
 CTGGGGTCAG CACTGAAGGC CCACATGAGG AAGACTGATC CTTGGCCATC CTCAGCCAC 1619
 AATGGCAAAT TCTGGATGGT CTAAGAAGGC CCTGGAATTC TAAACTAGAT GATCTGGGCT 1679
 30
 CTCTGCACCA TTCATTGTGG CAGTTGGGAC ATTTTATAGT ATAACAGACA CATACTTA 1739
 GATCAATGCA TCGCTGTACT CCTTGAAATC AGAGCTAGCT TGTTAGAAAA AGAATCAGAG 1799
 35
 CCAGGTATAG CGGTGCATGT CATTAAATCCC AGCGCTAAAG AGACAGAGAC AGGAGAATCT 1859
 CTGTGAGTTC AAGGCCACAT AGAAAGAGCC TGCTCTGGGA GCAGGAAAAA AAAAAAAAAAC 1919
 GGAATTC 1926

40

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

45

- (A) LENGTH: 399 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Met Ala Met Arg Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys
 1 5 10 15
 55
 Ala Leu Gly Gly Gly His Gly Pro Arg Pro Pro His Thr Cys Pro Gln
 20 25 30

- 118 -

Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Met Gln Arg Glu Ile Leu
 35 40 45
 5 Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Gln Pro Ala
 50 55 60
 Ala Ala Arg Gln Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr
 65 70 75 80
 10 His Ala Met Thr Asp Asp Asp Asp Gly Gly Pro Pro Gln Ala His Leu
 85 90 95
 Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val Glu Arg Asp
 100 105 110
 Arg Thr Leu Gly Tyr Gln Glu Pro His Trp Lys Glu Phe His Phe Asp
 115 120 125
 20 Leu Thr Gln Ile Pro Ala Gly Glu Ala Val Thr Ala Ala Glu Phe Arg
 130 135 140
 Ile Tyr Lys Glu Pro Ser Thr His Pro Leu Asn Thr Thr Leu His Ile
 145 150 155 160
 25 Ser Met Phe Glu Val Val Gln Glu His Ser Asn Arg Glu Ser Asp Leu
 165 170 175
 Phe Phe Leu Asp Leu Gln Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu
 180 185 190
 Val Leu Asp Ile Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn His His
 195 200 205
 35 Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Ala Asp Gly His Ser
 210 215 220
 Met Asp Pro Gly Leu Ala Gly Leu Leu Gly Arg Gln Ala Pro Arg Ser
 225 230 235 240
 40 Arg Gln Pro Phe Met Val Thr Phe Phe Arg Ala Ser Gln Ser Pro Val
 245 250 255
 Arg Ala Pro Arg Ala Ala Arg Pro Leu Lys Arg Arg Gln Pro Lys Lys
 260 265 270
 Thr Asn Glu Leu Pro His Pro Asn Lys Leu Pro Gly Ile Phe Asp Asp
 275 280 285
 50 Gly His Gly Ser Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr
 290 295 300
 Val Ser Phe Arg Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gln
 305 310 315 320
 55

- 119 -

	Gly	Tyr	Ser	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro	Leu	Asp
					325					330					335	
5	Ser	Cys	Met	Asn	Ala	Thr	Asn	His	Ala	Ile	Leu	Gln	Ser	Leu	Val	His
				340					345					350		
	Leu	Met	Lys	Pro	Asp	Val	Val	Pro	Lys	Ala	Cys	Cys	Ala	Pro	Thr	Lys
			355					360					365			
10	Leu	Ser	Ala	Thr	Ser	Val	Leu	Tyr	Tyr	Asp	Ser	Ser	Asn	Asn	Val	Ile
	370						375					380				
	Leu	Arg	Lys	His	Arg	Asn	Met	Val	Val	Lys	Ala	Cys	Gly	Cys	His	
	385					390					395					

(2) INFORMATION FOR SEQ ID NO:24:

(1) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 1368 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..1368

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

35	ATG TCG TCG GGA CTC CGA AAC ACC TCG GAG GCC GTT GCA GTG CTC GCC TCC Met Ser Gly Leu Arg Asn Thr Ser Glu Ala Val Ala Val Leu Ala Ser 1 5 10 15	48
40	CTG GGA CTC GGA ATG GTT CTG CTC ATG TTC GTG GCG ACC ACG CCG CCG Leu Gly Leu Gly Met Val Leu Leu Met Phe Val Ala Thr Thr Pro Pro 20 25 30	96
45	GCC GTT GAG GCC ACC CAG TCG GGG ATT TAC ATA GAC AAC GGC AAG GAC Ala Val Glu Ala Thr Gln Ser Gly Ile Tyr Ile Asp Asn Gly Lys Asp 35 40 45	144
50	CAG ACG ATC ATG CAC AGA GTG CTG AGC GAG GAC GAC AAG CTG GAC GTC Gln Thr Ile Met His Arg Val Leu Ser Glu Asp Asp Lys Leu Asp Val 50 55 60	192
55	TCG TAC GAG ATC CTC GAG TTC CTG GGC ATC GCC GAA CGG CCG ACG CAC Ser Tyr Glu Ile Leu Glu Phe Leu Gly Ile Ala Glu Arg Pro Thr His 65 70 75 80	240
55	CTG AGC AGC CAC CAG TTG TCG CTG ACG AAG TCG GCT CCC AAG TTC CTG Leu Ser Ser His Gln Leu Ser Leu Arg Lys Ser Ala Pro Lys Phe Leu 85 90 95	288

- 120 -

5	CTG GAC GTC TAC CAC CGC ATC ACG GCG GAG GAG GGT CTC AGC GAT CAG Leu Asp Val Tyr His Arg Ile Thr Ala Glu Glu Gly Leu Ser Asp Gln 100 105 110	336
10	GAT GAG GAC GAC GAC TAC GAA CGC GGC CAT CGG TCC AGG AGC AGC GCC Asp Glu Asp Asp Asp Tyr Glu Arg Gly His Arg Ser Arg Arg Ser Ala 115 120 125	384
15	GAC CTC GAG GAG GAT GAG GGC GAG CAG CAG AAG AAC TTC ATC ACC GAC Asp Leu Glu Glu Asp Glu Gly Glu Gln Gln Lys Asn Phe Ile Thr Asp 130 135 140	432
20	CTG GAC AAG CGG GCC ATC GAC GAG AGC GAC ATC ATC ATG ACC TTC CTG Leu Asp Lys Arg Ala Ile Asp Glu Ser Asp Ile Ile Met Thr Phe Leu 145 150 155 160	480
25	AAC AAG CGC CAC CAC AAT GTG GAC GAA CTG CGT CAC GAG CAC GGC CGT Asn Lys Arg His His Asn Val Asp Glu Leu Arg His Glu His Gly Arg 165 170 175	528
30	CGC CTG TGG TTC GAC GTC TCC AAC GTG CCC AAC GAC AAC TAC CTG GTG Arg Leu Trp Phe Asp Val Ser Asn Val Pro Asn Asp Asn Tyr Leu Val 180 185 190	576
35	ATG GCC GAG CTG CGC ATC TAT CAG AAC GCC AAC GAG GGC AAG TGG CTG Met Ala Glu Leu Arg Ile Tyr Gln Asn Ala Asn Glu Gly Lys Trp Leu 195 200 205	624
40	ACC GCC AAC AGG GAG TTC ACC ATC ACG GTA TAC GCC ATT GGC ACC GGC Thr Ala Asn Arg Glu Phe Thr Ile Thr Val Tyr Ala Ile Gly Thr Gly 210 215 220	672
45	ACG CTG GGC CAG CAC ACC ATG GAG CCG CTG TCC TCG GTG AAC ACC ACC Thr Leu Gly Gln His Thr Met Glu Pro Leu Ser Ser Val Asn Thr Thr 225 230 235 240	720
50	GGG GAC TAC GTG GGC TGG TTG GAG CTC AAC GTG ACC GAG GGC CTG CAC Gly Asp Tyr Val Gly Trp Leu Glu Leu Asn Val Thr Glu Gly Leu His 245 250 255	768
55	GAG TGG CTG GTC AAG TCG AAG GAC AAT CAT GGC ATC TAC ATT GGA GCA Glu Trp Leu Val Lys Ser Lys Asp Asn His Gly Ile Tyr Ile Gly Ala 260 265 270	816
60	CAC GCT GTC AAC CGA CCC GAC CGC GAG GTG AAG CTG GAC GAC ATT GGA His Ala Val Asn Arg Pro Asp Arg Glu Val Lys Leu Asp Asp Ile Gly 275 280 285	864
65	CTG ATC CAC CGC AAG GTG GAC GAC GAG TTC CAG CCC TTC ATG ATC GGC Leu Ile His Arg Lys Val Asp Asp Glu Phe Gln Pro Phe Met Ile Gly 290 295 300	912
70	TTC TTC CGC GGA CCG GAG CTG ATC AAG GCG ACG GCC CAC AGC AGC CAC Phe Phe Arg Gly Pro Glu Leu Ile Lys Ala Thr Ala His Ser Ser His 305 310 315 320	960

SUBSTITUTE SHEET

- 121 -

	CAC AGG AGC AAG CGA AGC GCC AGC CAT CCA CGC AAG CGC AAG AAG TCG	1008
	His Arg Ser Lys Arg Ser Ala Ser His Pro Arg Lys Arg Lys Lys Ser	
	325 330 335	
5	GTG TCG CCC AAC AAC GTG CCG CTG CTG GAA CCG ATG GAG AGC ACG CGC	1056
	Val Ser Pro Asn Asn Val Pro Leu Leu Glu Pro Met Glu Ser Thr Arg	
	340 345 350	
10	AGC TGC CAG ATG CAG ACC CTG TAC ATA GAC TTC AAG GAT CTG GGC TGG	1104
	Ser Cys Gln Met Gln Thr Leu Tyr Ile Asp Phe Lys Asp Leu Gly Trp	
	355 360 365	
15	CAT GAC TGG ATC ATC GCA CCA GAG GGC TAT GGC GCC TTC TAC TGC AGC	1152
	His Asp Trp Ile Ile Ala Pro Glu Gly Tyr Gly Ala Phe Tyr Cys Ser	
	370 375 380	
20	GGC GAG TGC AAT TTC CCG CTC AAT GCG CAC ATG AAC GCC ACG AAC CAT	1200
	Gly Glu Cys Asn Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His	
	385 390 395 400	
25	CGC ATC GTC CAG ACC CTG GTC CAC CTG CTG GAG CCC AAG AAG GTG CCC	1248
	Ala Ile Val Gln Thr Leu Val His Leu Leu Glu Pro Lys Lys Val Pro	
	405 410 415	
30	AAG CCC TGC TGC GCT CCG ACC AGG CTG GGA GCA CTA CCC GTT CTG TAC	1296
	Lys Pro Cys Cys Ala Pro Thr Arg Leu Gly Ala Leu Pro Val Leu Tyr	
	420 425 430	
35	CAC CTG AAC GAC GAG AAT GTG AAC CTG AAA AAG TAT AGA AAC ATG ATT	1344
	His Leu Asn Asp Glu Asn Val Asn Leu Lys Lys Tyr Arg Asn Met Ile	
	435 440 445	
40	GTG AAA TCC TGC GGG TGC CAT TGA	1368
	Val Lys Ser Cys Gly Cys His	
	450 455	

(2) INFORMATION FOR SEQ ID NO:25:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 455 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

50

Met	Ser	Gly	Leu	Arg	Asn	Thr	Ser	Glu	Ala	Val	Ala	Val	Leu	Ala	Ser
1				5					10					15	

Leu	Gly	Leu	Gly	Met	Val	Leu	Leu	Met	Phe	Val	Ala	Thr	Thr	Pro	Pro
		20					25						30		

55

SUBSTITUTE SHEET

- 122 -

Ala Val Glu Ala Thr Gln Ser Gly Ile Tyr Ile Asp Asn Gly Lys Asp
 35 40 45
 5 Gln Thr Ile Met His Arg Val Leu Ser Glu Asp Asp Lys Leu Asp Val
 50 55 60
 Ser Tyr Glu Ile Leu Glu Phe Leu Gly Ile Ala Glu Arg Pro Thr His
 65 70 75 80
 10 Leu Ser Ser His Gln Leu Ser Leu Arg Lys Ser Ala Pro Lys Phe Leu
 85 90 95
 Leu Asp Val Tyr His Arg Ile Thr Ala Glu Glu Gly Leu Ser Asp Gln
 100 105 110
 15 Asp Glu Asp Asp Asp Tyr Glu Arg Gly His Arg Ser Arg Arg Ser Ala
 115 120 125
 20 Asp Leu Glu Glu Asp Glu Gly Glu Gln Gln Lys Asn Phe Ile Thr Asp
 130 135 140
 Leu Asp Lys Arg Ala Ile Asp Glu Ser Asp Ile Ile Met Thr Phe Leu
 145 150 155 160
 25 Asn Lys Arg His His Asn Val Asp Glu Leu Arg His Glu His Gly Arg
 165 170 175
 Arg Leu Trp Phe Asp Val Ser Asn Val Pro Asn Asp Asn Tyr Leu Val
 180 185 190
 30 Met Ala Glu Leu Arg Ile Tyr Gln Asn Ala Asn Glu Gly Lys Trp Leu
 195 200 205
 35 Thr Ala Asn Arg Glu Phe Thr Ile Thr Val Tyr Ala Ile Gly Thr Gly
 210 215 220
 Thr Leu Gly Gln His Thr Met Glu Pro Leu Ser Ser Val Asn Thr Thr
 225 230 235 240
 40 Gly Asp Tyr Val Gly Trp Leu Glu Leu Asn Val Thr Glu Gly Leu His
 245 250 255
 Glu Trp Leu Val Lys Ser Lys Asp Asn His Gly Ile Tyr Ile Gly Ala
 260 265 270
 45 His Ala Val Asn Arg Pro Asp Arg Glu Val Lys Leu Asp Asp Ile Gly
 275 280 285
 50 Leu Ile His Arg Lys Val Asp Asp Glu Phe Gln Pro Phe Met Ile Gly
 290 295 300
 Phe Phe Arg Gly Pro Glu Leu Ile Lys Ala Thr Ala His Ser Ser His
 305 310 315 320
 55 His Arg Ser Lys Arg Ser Ala Ser His Pro Arg Lys Arg Lys Lys Ser
 325 330 335

- 124 -

Pro Glu Pro Cys Cys Val Pro Glu Lys Met Ser Ser Leu Ser Ile Leu
 65 70 75 80

5 Phe Phe Asp Glu Asn Lys Asn Val Val Leu Lys Val Tyr Pro Asn Met
 85 90 95

Thr Val Glu Ser Cys Ala Cys Arg
 100

10 (2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 102 amino acids
 15 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
 20

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: HOMO SAPIENS

(ix) FEATURE:
 25 (A) NAME/KEY: Protein
 (B) LOCATION: 1..102
 (D) OTHER INFORMATION: /note= "BMP5"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln
 1 5 10 15

35 Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Phe Tyr Cys Asp Gly
 20 25 30

Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
 35 40 45

40 Ile Val Gln Thr Leu Val His Leu Met Phe Pro Asp His Val Pro Lys
 50 55 60

45 Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe
 65 70 75 80

Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val
 85 90 95

50 Arg Ser Cys Gly Cys His
 100

- 125 -

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS

(ix) FEATURE:

15

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..102
 (D) OTHER INFORMATION: /note= "BMP6"

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Cys Arg Lys His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Gln
 1 5 10 15

25 Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly
 20 25 30

Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
 35 40 45

30

Ile Val Gln Thr Leu Val His Leu Met Asn Pro Glu Tyr Val Pro Lys
 50 55 60

35 Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe
 65 70 75 80

Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Trp Met Val Val
 85 90 95

40

Arg Ala Cys Gly Cys His
 100

(2) INFORMATION FOR SEQ ID NO:29:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: protein

- 126 -

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /label= OPX

5 /note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED
FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS
AS DEFINED IN THE SPECIFICATION (SECTION II.B.2.)"

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Cys Xaa Xaa His Glu Leu Tyr Val Xaa Phe Xaa Asp Leu Gly Trp Xaa
1 5 10 15

15 Asp Trp Xaa Ile Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys Glu Gly
20 25 30

Glu Cys Xaa Phe Pro Leu Xaa Ser Xaa Met Asn Ala Thr Asn His Ala
35 40 45

20 Ile Xaa Gln Xaa Leu Val His Xaa Xaa Xaa Pro Xaa Xaa Val Pro Lys
50 55 60

25 Xaa Cys Cys Ala Pro Thr Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa
65 70 75 80

Asp Xaa Ser Xaa Asn Val Xaa Leu Xaa Lys Xaa Arg Asn Met Val Val
85 90 95

30 Xaa Ala Cys Gly Cys His
100

(2) INFORMATION FOR SEQ ID NO:30:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 97 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

40 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

45 (ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..97

(D) OTHER INFORMATION: /label= GENERIC-SEQ5

50 /note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED
FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS
AS DEFINED IN THE SPECIFICATION."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

55 Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa Xaa Xaa
1 5 10 15

- 127 -

Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Pro
 20 25 30
 5 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala Xaa Xaa Xaa Xaa
 35 40 45
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Pro
 50 55 60
 10 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65 70 75 80
 15 Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Met Xaa Val Xaa Xaa Cys Xaa Cys
 85 90 95
 Xaa

20 (2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30

(ix) FEATURE:

- (A) NAME/KEY: Protein
 (B) LOCATION: 1..102
 35 (D) OTHER INFORMATION: /label= GENERIC-SEQ6
 /note= "WHEREIN EACH XAA IS INDEPENDENTLY SELECTED
 FROM A GROUP OF ONE OR MORE SPECIFIED AMINO ACIDS
 AS DEFINED IN THE SPECIFICATION. "

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Cys Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa
 1 5 10 15
 45 Xaa Trp Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly
 20 25 30
 Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala
 35 40 45
 50 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50 55 60
 55 Xaa Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
 65 70 75 80

- 128 -

Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val
 85 90 95

5 Xaa Xaa Cys Xaa Cys Xaa
 100

(2) INFORMATION FOR SEQ ID NO:32:

- 10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1247 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 15 (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: HOMO SAPIENS
 20 (F) TISSUE TYPE: BRAIN
- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 84..1199
 25 (D) OTHER INFORMATION: /product= "GDF-1"
 /note= "GDF-1 CDNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

30 GGGGACACCG GCCCGGCCCT CAGCCCACTG GTCCCGGGCC GCCGCGGACC CTGCGCACTC 60
 TCTGGTCATC GCCTGGGAGG AAG ATG CCA CCG CCG CAG CAA GGT CCC TGC 110
 Met Pro Pro Pro Gln Gln Gly Pro Cys
 1 5

35 GGC CAC CAC CTC CTC CTC CTC CTG GCC CTG CTG CTG CCC TCG CTG CCC 158
 Gly His His Leu Leu Leu Leu Leu Ala Leu Leu Leu Pro Ser Leu Pro
 10 15 20 25

40 CTG ACC CGC GCC CCC GTG CCC CCA GGC CCA GCC GCC GCC CTG CTC CAG 206
 Leu Thr Arg Ala Pro Val Pro Pro Gly Pro Ala Ala Ala Leu Leu Gln
 30 35 40

45 GCT CTA GGA CTG CGC GAT GAG CCC CAG GGT GCC CCC AGG CTC CGG CCG 254
 Ala Leu Gly Leu Arg Asp Glu Pro Gln Gly Ala Pro Arg Leu Arg Pro
 45 50 55

50 GTT CCC CCG GTC ATG TGG CGC CTG TTT CGA CGC CGG GAC CCC CAG GAG 302
 Val Pro Pro Val Met Trp Arg Leu Phe Arg Arg Arg Asp Pro Gln Glu
 60 65 70

ACC AGG TCT GGC TCG CGG CGG ACG TCC CCA GGG GTC ACC CTG CAA CCG 350
 Thr Arg Ser Gly Ser Arg Arg Thr Ser Pro Gly Val Thr Leu Gln Pro
 75 80 85

SUBSTITUTE SHEET

- 129 -

5	TGC CAC GTG GAG GAG CTG GGG GTC GCC GGA AAC ATC GTG CGC CAC ATC Cys His Val Glu Glu Leu Gly Val Ala Gly Asn Ile Val Arg His Ile 90 95 100 105	398
10	CCG GAC CGC GGT GCG CCC ACC CGG GCC TCG GAG CCT GTC TCG GCC GCG Pro Asp Arg Gly Ala Pro Thr Arg Ala Ser Glu Pro Val Ser Ala Ala 110 115 120	446
15	GGG CAT TGC CCT GAG TGG ACA GTC GTC TTC GAC CTG TCG GCT GTG GAA Gly His Cys Pro Glu Trp Thr Val Phe Asp Leu Ser Ala Val Glu 125 130 135	494
20	CCC GCT GAG CGC CCG AGC CGG GCC CGC CTG GAG CTG CGT TTC GCG GCG Pro Ala Glu Arg Pro Ser Arg Ala Arg Leu Glu Leu Arg Phe Ala Ala 140 145 150	542
25	GCG GCG GCG GCA GCC CCG GAG GGC GGC TGG GAG CTG AGC GTG GCG CAA Ala Ala Ala Ala Ala Pro Glu Gly Gly Trp Glu Leu Ser Val Ala Gln 155 160 165	590
30	GCG GGC CAG GGC GCG GGC GCG GAC CCC GGG CCG GTG CTG CTC CGC CAG Ala Gly Gln Gly Ala Gly Ala Asp Pro Gly Pro Val Leu Leu Arg Gln 170 175 180 185	638
35	TTG GTG CCC GCC CTG GGG CCG CCA GTG CGC GCG GAG CTG CTG GGC GCC Leu Val Pro Ala Leu Gly Pro Pro Val Arg Ala Glu Leu Leu Ala 190 195 200	686
40	GCT TGG GCT CGC AAC GCC TCA TGG CCG CGC AGC CTC CGC CTG GCG CTG Ala Trp Ala Arg Asn Ala Ser Trp Pro Arg Ser Leu Arg Leu Ala Leu 205 210 215	734
45	GCG CTA CGC CCC CCG GCC CCT GCC GCC TGC GCG CGC CTG GCC GAG GCC Ala Leu Arg Pro Arg Ala Pro Ala Ala Cys Ala Arg Leu Ala Glu Ala 220 225 230	782
50	TCG CTG CTG CTG GTG ACC CTC GAC CCG CGC CTG TGC CAC CCC CTG GCC Ser Leu Leu Leu Val Thr Leu Asp Pro Arg Leu Cys His Pro Leu Ala 235 240 245	830
55	CGG CCG CGG CGC GAC GCC GAA CCC GTG TTG GGC GGC GGC CCC GGG GGC Arg Pro Arg Arg Asp Ala Glu Pro Val Leu Gly Gly Gly Pro Gly Gly 250 255 260 265	878
60	GCT TGT CGC GCG CCG CCG CTG TAC GTG AGC TTC CGC GAG GTG GGC TGG Ala Cys Arg Ala Arg Arg Leu Tyr Val Ser Phe Arg Glu Val Gly Trp 270 275 280	926
65	CAC CGC TGG GTC ATC GCG CCG CGC GGC TTC CTG GCC AAC TAC TGC CAG His Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Tyr Cys Gln 285 290 295	974
70	GGT CAG TGC GCG CTG CCC GTC GCG CTG TCG GGG TCC GGG GGG CCG CCG Gly Gln Cys Ala Leu Pro Val Ala Leu Ser Gly Ser Gly Gly Pr Pro 300 305 310	1022

SUBSTITUTE SHEET

- 130 -

5 GCG CTC AAC CAC GCT GTG CTG CGC GCG CTC ATG CAC GCG GCC GCC CCG 1070
 Ala Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala Ala Ala Pro
 315 320 325

10 GGA GCC GCC GAC CTG CCC TGC TGC GTG CCC GCG CGC CTG TCG CCC ATC 1118
 Gly Ala Ala Asp Leu Pro Cys Cys Val Pro Ala Arg Leu Ser Pro Ile
 330 335 340 345

15 TCC GTG CTC TTC TTT GAC AAC AGC GAC AAC GTG GTG CTG CGG CAG TAT 1166
 Ser Val Leu Phe Phe Asp Asn Ser Asp Asn Val Val Leu Arg Gln Tyr
 350 355 360

20 GAG GAC ATG GTG GTG GAC GAG TGC GGC TGC CGC TAACCCGGGG CGGGCAGGGA 1219
 Glu Asp Met Val Val Asp Glu Cys Gly Cys Arg
 365 370

25 CCCGGGCCCA ACAATAAATG CGCGTGG 1247

(2) INFORMATION FOR SEQ ID NO:33:

(1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 372 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Pro Pro Pro Gln Gln Gly Pro Cys Gly His His Leu Leu Leu Leu
 1 5 10 15

35 Leu Ala Leu Leu Leu Pro Ser Leu Pro Leu Thr Arg Ala Pro Val Pro
 20 25 30

40 Pro Gly Pro Ala Ala Ala Leu Leu Gln Ala Leu Gly Leu Arg Asp Glu
 35 40 45

45 Pro Gln Gly Ala Pro Arg Leu Arg Pro Val Pro Pro Val Met Trp Arg
 50 55 60

50 Leu Phe Arg Arg Arg Asp Pro Gln Glu Thr Arg Ser Gly Ser Arg Arg
 65 70 75 80

55 Thr Ser Pro Gly Val Thr Leu Gln Pro Cys His Val Glu Glu Leu Gly
 85 90 95

Val Ala Gly Asn Ile Val Arg His Ile Pro Asp Arg Gly Ala Pro Thr
 100 105 110

Arg Ala Ser Glu Pro Val Ser Ala Ala Gly His Cys Pro Glu Trp Thr
 115 120 125

SUBSTITUTE SHEET

- 131 -

Val Val Phe Asp Leu Ser Ala Val Glu Pro Ala Glu Arg Pro Ser Arg
 130 135 140
 Ala Arg Leu Glu Leu Arg Phe Ala Ala Ala Ala Ala Ala Pro Glu
 5 145 150 155 160
 Gly Gly Trp Glu Leu Ser Val Ala Gln Ala Gly Gln Gly Ala Gly Ala
 165 170 175
 10 Asp Pro Gly Pro Val Leu Leu Arg Gln Leu Val Pro Ala Leu Gly Pro
 180 185 190
 Pro Val Arg Ala Glu Leu Leu Gly Ala Ala Trp Ala Arg Asn Ala Ser
 195 200 205
 15 Trp Pro Arg Ser Leu Arg Leu Ala Leu Ala Leu Arg Pro Arg Ala Pro
 210 215 220
 Ala Ala Cys Ala Arg Leu Ala Glu Ala Ser Leu Leu Leu Val Thr Leu
 20 225 230 235 240
 Asp Pro Arg Leu Cys His Pro Leu Ala Arg Pro Arg Arg Asp Ala Glu
 245 250 255
 25 Pro Val Leu Gly Gly Gly Pro Gly Gly Ala Cys Arg Ala Arg Arg Leu
 260 265 270
 Tyr Val Ser Phe Arg Glu Val Gly Trp His Arg Trp Val Ile Ala Pro
 275 280 285
 30 Arg Gly Phe Leu Ala Asn Tyr Cys Gln Gly Gln Cys Ala Leu Pro Val
 290 295 300
 Ala Leu Ser Gly Ser Gly Gly Pro Pro Ala Leu Asn His Ala Val Leu
 35 305 310 315 320
 Arg Ala Leu Met His Ala Ala Ala Pro Gly Ala Ala Asp Leu Pro Cys
 325 330 335
 40 Cys Val Pro Ala Arg Leu Ser Pro Ile Ser Val Leu Phe Phe Asp Asn
 340 345 350
 Ser Asp Asn Val Val Leu Arg Gln Tyr Glu Asp Met Val Val Asp Glu
 355 360 365
 45 Cys Gly Cys Arg
 370

- 132 -

What is claimed is:

1. A method for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, the
5 method comprising the step of:

providing to the cells of the luminal lining a therapeutically effective concentration of a morphogen, said concentration being sufficient to substantially
10 inhibit lesion formation in the gastrointestinal tract luminal lining.

2. The method of claim 1 where said step of providing a therapeutically effective morphogen
15 concentration to said cells of the gastrointestinal tract luminal lining comprises the step of administering a therapeutically effective concentration of a morphogen to said mammal.

- 20 3. The method of claim 1 where said step of providing a therapeutically effective morphogen concentration to said cells of the gastrointestinal tract luminal lining comprises the step of administering to said mammal an agent that stimulates
25 in vivo a therapeutically effective concentration of an endogenous morphogen.

4. The method of claim 1 wherein said mammal is a human and said human is at risk for oral mucositis.

30

- 133 -

5. The method of claim 1 wherein said mammal is a human and said human is at risk for gastric ulcers, ulcerative colitis, proctitis, regional enteritis, or
5 necrotizing enterocolitis.

6. The method of claim 4 wherein said human is a xerostomatic individual.

10 7. The method of claim 4 or 5 wherein said morphogen is provided prophylactically.

8. The method of claim 5 wherein said gastric ulcers include peptic ulcers or duodenal ulcers.

15

9. The method of claim 2 or 3 wherein said step of administering is performed by systemic administration.

10. The method of claim 2 or 3 wherein said step of
20 administering is performed by topical administration.

11. The method of claim 2 or 3 wherein said step of administering is performed by direct administration of the morphogen or morphogen-stimulating agent to said
25 cells of the gastrointestinal tract luminal lining.

12. A method for limiting the proliferation of an epithelial cell population in a mammal, the method comprising the step of providing a therapeutically
30 effective concentration of a morphogen to a proliferating epithelial cell population in a mammal, said concentration being sufficient to inhibit the proliferation of said cells.

- 134 -

13. The method of claim 10 wherein said epithelial cells comprise part of the basal epithelium of the gastrointestinal tract.

5

14. The method of claim 13 wherein said basal epithelium comprises part of the oral mucosa.

15. The method of claim 12 wherein said epithelial
10 cells comprise hair cells.

16. The method of claim 12 wherein said epithelial cells comprise epidermal skin cells.

15 17. A method of treating a gastrointestinal tract ulcerative disease in a mammal, the method comprising the step of providing a therapeutically effective concentration of a morphogen to the ulcerated tissue of the gastrointestinal tract, said concentration being
20 sufficient to repair said tissue.

18. The method of claim 17 wherein said ulcerative disease is oral mucositis.

25 19. The method of claim 17 wherein said ulcerative disease includes gastric ulcers, ulcerative colitis, regional enteritis, proctitis, inflammatory bowel disease, or necrotizing enterocolitis.

30 20. The method of claim 12 or 17 wherein said step of providing a therapeutically effective morphogen concentration to said cells of the gastrointestinal tract luminal lining comprises the step of administering a therapeutically effective concentration
35 of a morphogen to said mammal.

- 135 -

21. The method of claim 12 or 17 wherein said step of providing a therapeutically effective morphogen concentration to said cells of the gastrointestinal tract luminal lining comprises the step of administering to said mammal an agent that stimulates in vivo a therapeutically effective concentration of an endogenous morphogen.
22. The method of claim 20 wherein said step of administering is by oral, rectal or systemic administration.
23. The method of claim 21 wherein said step of administering is by oral, rectal or systemic administration.
24. The method of claim 20 wherein said therapeutically effective morphogen concentration comprises less than about 100 µg morphogen/kg weight.
25. The method of claim 24 wherein said therapeutically effective morphogen concentration comprises less than about 30 µg morphogen/kg weight.
26. The method of claim 25 wherein said therapeutically effective morphogen concentration comprises less than about 10 µg morphogen/kg weight.

- 136 -

27. A cancer treatment method comprising the steps of:

5 (a) administering a composition comprising a therapeutic concentration of a morphogen or morphogen stimulating agent to a patient; and

(b) administering a cancer therapeutic agent to
10 said patient.

28. The method of claim 27 wherein said therapeutic concentration is sufficient to substantially inhibit in ulcer format in the oral mucosa.

15

29. The method of claim 27 wherein said therapeutic concentration is sufficient to substantially inhibit proliferation of an epithelial cell population.

20 30. The method of claim 28 or 29 wherein said morphogen or morphogen-stimulating agent is administered topically.

31. The method of claim 29 wherein said epithelial
25 cell population comprises cells of the oral mucosa or hair producing cells.

32. The method of claim 27 wherein said cancer therapeutic agent is a cytotoxic agent.

30

33. The method of claim 32 wherein said cytotoxic agent is a chemotherapeutic agent or a radiotherapeutic agent.

- 137 -

34. The method of claim 33 wherein steps (a) and (b) are performed concurrently.

5 35. The method of claim 1, 12, 17 or 27 wherein said morphogen comprises an amino acid sequence sharing at least 70% homology with one of the sequences selected from the group consisting of: OP-1, OP-2, CBMP2, BMP3(fx), Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx) and
10 60A(fx).

36. The method of claim 35 wherein said morphogen comprises an amino acid sequence sharing a last 80% homology with one of the sequences selected from the
15 group consisting of: OP-1, OP-2, CBMP2, BMP3(fx), BMP5(fx), BMP6(fx), Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx) and 60A(fx).

37. The method of claim 1, 12, 17 or 27 wherein said
20 morphogen comprises an amino acid sequence having greater than 60% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).

38. The method of claim 37 wherein said morphogen
25 comprises an amino acid sequence having greater than 65% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).

39. The method of claim 38 wherein said morphogen
30 comprises an amino acid sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1), including allelic and species variants thereof.

- 138 -

40. The method of claim 1, 12, 17 or 27 wherein said morphogen comprises an amino acid sequence defined by Generic Sequences 1, 2, 3, 4, 5 or 6 (Seq. ID Nos. 1, 2, 3, 4, 30 or 31).

41. The method of claim 1, 12, 17 or 27 wherein said morphogen comprises an amino acid sequence defined by OPX (Seq. ID No. 29).

10

42. A method for enhancing the efficacy of cancer therapeutic treatment, the method comprising the step of administering a therapeutic concentration of a morphogen or morphogen-stimulating agent to the patient.

15

43. A therapeutic composition for treating ulcerations of the gastrointestinal tract comprising a therapeutic concentration of a morphogen or morphogen-stimulating agent in admixture with a biocompatible compound capable of coating the gastrointestinal tract luminal lining.

20

44. The composition of claim 43 wherein said biocompatible compound comprises a tissue adhesive.

25

45. The composition of claim 44 wherein said compound comprises hydroxypropylcellulose.

46. A therapeutic composition for treating ulcerations of the gastrointestinal tract comprising a therapeutic concentration of a morphogen or morphogen-stimulating agent in admixture with a biocompatible symptom-alleviating cofactor.

30
35

- 139 -

47. The composition of claim 46 wherein said cofactor comprises a biocompatible analgesic, anesthetic, antiseptic, antibiotic, or antiviral or antifungal agent.

48. The composition of claim 46 wherein said cofactor comprises a biocompatible antisecretory agent.

49. A composition useful as part of a cancer therapy comprising a therapeutic concentration of a morphogen or morphogen-stimulating agent in admixture with a cancer cell cytotoxin.

50. An oral rinse for treating oral mucositis comprising a therapeutically effective concentration of a morphogen or morphogen-stimulating agent.

51. A therapeutic composition for treating ulcerations of the gastrointestinal tract comprising a therapeutically effective concentration of a morphogen dispersed in a controlled release delivery vehicle.

52. A therapeutic composition for treating ulcerations of the gastrointestinal tract comprising a therapeutically effective concentration of a morphogen dispersed in a tissue adhesive composition.

53. The composition of claim 46, 49, 50, 51 or 52 where said morphogen comprises an amino acid sequence sharing at least 70% homology with one of the sequences selected from the group consisting of: OP-1, OP-2, CBMP2, BMP3(fx), BMP5(fx), BMP6(fx), Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx) and 60A(fx).

35

- 140 -

54. The composition of claim 53, wherein said morphogen comprises an amino acid sequence sharing a last 80% homology with one of the sequences selected
5 from the group consisting of: OP-1, OP-2, CBMP2, BMP3(fx), BMP5(fx), BMP6(fx), Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx) and 60A(fx).
55. The composition of claim 46, 49, 50, 51 or 52
10 wherein said morphogen comprises an amino acid sequence having greater than 60% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
- 15 56. The composition of claim 55, wherein said morphogen comprises an amino acid sequence having greater than 65% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
- 20 57. The composition of claim 56, wherein said morphogen comprises an amino acid sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1), including allelic and species variants thereof.
- 25 58. The composition of claim 46, 49, 50, 51 or 52 wherein said morphogen comprises an amino acid sequence defined by Generic Sequences 1, 2, 3, 4, 5 or 6 (Seq. ID Nos. 1, 2, 3, 4, 30 or 31).
- 30 59. The composition of claim 46, 49, 50, 51 or 52 wherein said morphogen comprises an amino acid sequence defined by OPX (Seq. ID No. 29).

- 141 -

60. The composition of claims 46, 49, 50, 51 or 52 wherein the morphogen species provided comprises the pro form.

5

61. The composition of claim 57 wherein the morphogen species provided comprises the pro domain.

62. The composition of claim 61 wherein said
10 morphogen comprises an amino acid sequence defined by residues 30-431 of Seq. ID No. 16 (hOP-1), including allelic and species variants thereof.

63. The method of claims 1, 12, 17 or 27 wherein said
15 morphogen species provided comprises the pro form.

64. The method of claim 39 wherein said morphogen species provided comprises the pro form.

20 65. The method of claim 64 wherein said morphogen comprises an amino acid sequence defined by residues 30-431 of Seq. ID No. 16 (hOP-1), including allelic and species variants thereof.

25 66. The use of a morphogen in the manufacture of a pharmaceutical for maintaining the integrity of the intestinal tract luminal lining.

67. The use according to claim 66 wherein aid
30 pharmaceutical comprises part of a medicament to treat gastric ulcers, ulcerative colitis, proctitis, regional enteritis, necrotizing enterocolitis or inflammatory bowel disease.

- 142 -

68. The use of a morphogen in the manufacture of a pharmaceutical to treat oral mucositis.

5 69. The use according to claim 66 or 68 wherein said pharmaceutical is administered topically or systemically.

70. The use of a morphogen in the manufacture of a
10 pharmaceutical for limiting the proliferation of an epithelial cell population in a mammal.

71. The use according to claim 70 wherein said cell
population comprises epidermal skin cells, hair cells,
15 or cells of the basal epithelium, including the oral mucosa.

72. The use of a morphogen in the manufacture of a
medicament to treat a cancer.

20

73. The use of a morphogen in the manufacture of a
medicament to modulate an undesired side effect
associated with a clinical or pharmaceutical therapy.

25 74. The use according to claim 73 wherein said therapy is a cancer therapy.

75. The use according to claim 66, 68, 70, 72 or 73
wherein said morphogen comprises an amino acid sequence
30 sharing at least 70% homology with one of the sequences
selected from the group consisting of: OP-1, OP-2,
CBMP2, BMP3(fx), Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx)
and 60A(fx).

- 143 -

76. The use according to claim 75 wherein said morphogen comprises an amino acid sequence sharing a last 80% homology with one of the sequences selected from the group consisting of: OP-1, OP-2, CBMP2, BMP3(fx), BMP5(fx), BMP6(fx), Vgl(fx), Vgr(fx), DPP(fx), GDF-1(fx) and 60A(fx).
77. The use according to claim 66, 68, 70, 72 or 73 wherein said morphogen comprises an amino acid sequence having greater than 60% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
78. The use according to claim 77 wherein said morphogen comprises an amino acid sequence having greater than 65% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1).
79. The use according to claim 78 wherein said morphogen comprises an amino acid sequence defined by residues 43-139 of Seq. ID No. 5 (hOP1), including allelic and species variants thereof.
80. The use according to claim 66, 68, 70, 72 or 73 wherein said morphogen comprises an amino acid sequence defined by Generic Sequences 1, 2, 3, 4, 5 or 6 (Seq. ID Nos. 1, 2, 3, 4, 30 or 31).
81. The use according to claim 66, 68, 70, 72 or 73 wherein said morphogen comprises an amino acid sequence defined by OPX (Seq. ID No. 29).

- 144 -

82. The composition of claim 43, 46, 50, 51 or 52 wherein said morphogen comprises a polypeptide chain encoded by a nucleic acid that hybridizes under
5 stringent conditions with the DNA sequence defined by nucleotides 1036-1341 of Seq. ID No. 16 or nucleotides 1390-1695 of Seq. ID No. 20.
83. The use according to claim 66, 68, 70, 72 or 73
10 wherein said morphogen comprises a polypeptide chain encoded by a nucleic acid that hybridizes under stringent conditions with the DNA sequence defined by nucleotides 1036-1341 of Seq. ID No. 16 or nucleotides 1390-1695 of Seq. ID No. 20.
- 15 84. The composition of claim 43, 46, 50, 51 or 52 wherein said morphogen comprises a dimeric protein species complexed with a peptide comprising a pro region of a member of the morphogen family, or an
20 allelic, species or other sequence variant thereof.
85. The use according to claim 66, 68, 70, 72 or 73 wherein said morphogen comprises a dimeric protein species complexed with a peptide comprising a pro
25 region of a member of the morphogen family, or an allelic, species or other sequence variant thereof.
86. The invention of claim 84 or 85 wherein said dimeric morphogen species is noncovalently complexed
30 with said peptide.
87. The invention of claim 84 or 85 wherein said dimeric morphogen species is complexed with two said peptides.

- 145 -

88. The invention of claim 84 or 85 wherein said peptide comprises at least the first 18 amino acids of a sequence defining said pro region.

5

89. The invention of claim 88 wherein said peptides comprises the full length form of said pro region.

90. The invention of claim 84 or 85 wherein said
10 peptides comprises a nucleic acid that hybridizes under stringent hybridization conditions with a DNA defined by nucleotides 136-192 of Seq. ID No. 16, or nucleotides 157-211 of Seq. ID No. 20.

15 91. The invention of claim 84 or 85 wherein said complex is further stabilized by exposure to a basic amino acid, a detergent or a carrier protein.

1/5




Fig. 1

2/5



Fig. 2A



Fig. 2B

3/5




Fig. 3A

4/5




Fig. 3B

5/5

Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4D

